International Isotopes Inc.

0001515971-20-000065.txt : 20200520 0001515971-20-000065.hdr.sgml : 20200520 20200520125129 ACCESSION NUMBER: 0001515971-20-000065 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 60 CONFORMED PERIOD OF REPORT: 20200331 FILED AS OF DATE: 20200520 DATE AS OF CHANGE: 20200520 FILER: COMPANY DATA: COMPANY CONFORMED NAME: INTERNATIONAL ISOTOPES INC CENTRAL INDEX KEY: 0001038277 STANDARD INDUSTRIAL CLASSIFICATION: INDUSTRIAL INSTRUMENTS FOR MEASUREMENT, DISPLAY, AND CONTROL [3823] IRS NUMBER: 742763837 STATE OF INCORPORATION: TX FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-22923 FILM NUMBER: 20896996 BUSINESS ADDRESS: STREET 1: 4137 COMMERCE CIRCLE CITY: IDAHO FALLS STATE: ID ZIP: 83401 BUSINESS PHONE: 2085245300 MAIL ADDRESS: STREET 1: 4137 COMMERCE CIRCLE CITY: IDAHO FALLS STATE: ID ZIP: 83401 10-Q 1 inis10q033120.htm 10-Q International Isotopes Inc.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2020

o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _____________ to _______________

Commission file number:

0-22923

INTERNATIONAL ISOTOPES INC.

(Exact name of registrant as specified in its charter)

Texas

74-2763837

(State or other jurisdiction of

incorporation or organization)

(IRS Employer Identification No.)

4137 Commerce Circle

Idaho Falls, Idaho, 83401

(Address of principal executive offices, including zip code)

(208) 524-5300

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act: None

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. ý Yes ¨ No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). ý Yes ¨ No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ¨	Accelerated filer ¨
Non-accelerated filer ¨	Smaller reporting company ý
	Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards pursuant to Section 13(a) of the Exchange Act. ¨

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). ¨ Yes ý No

As of May 15, 2020, the number of shares of common stock, $0.01 par value, outstanding was 423,794,088.

INTERNATIONAL ISOTOPES INC.

Form 10-Q

For The Quarter Ended March 31, 2020

TABLE OF CONTENTS

		Page No.
PART I – FINANCIAL INFORMATION

Item 1.	Financial Statements
	Unaudited Condensed Consolidated Balance Sheets at March 31, 2020 and December 31, 2019	3
	Unaudited Condensed Consolidated Statements of Operations for the Three Months Ended March 31, 2020 and 2019	4
	Unaudited Condensed Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2020 and 2019	5
	Unaudited Statement of Stockholder’s Equity for the Three Months Ended March 31, 2020 and 2019	6
	Notes to Unaudited Condensed Consolidated Financial Statements	8
Item 2.	Management's Discussion and Analysis of Financial Condition and Results of Operations	18
Item 4.	Controls and Procedures	26

PART II – OTHER INFORMATION

Item 1.	Legal Proceedings	27
Item 1A.	Risk Factors	27
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	27
Item 6.	Exhibits	27
Signatures		28

Part I. Financial Information

Item I. Financial Statements

INTERNATIONAL ISOTOPES INC. AND SUBSIDIARIES

Condensed Consolidated Balance Sheets

(unaudited)

	March 31,			December 31,
	2020			2019
Assets
Current assets
Cash and cash equivalents	$	568,656		$	575,422
Accounts receivable		1,024,044			875,914
Inventories		3,379,373			3,423,420
Prepaids and other current assets		1,399,325			1,444,593
Total current assets		6,371,398			6,319,349

Long-term assets
Restricted cash		637,820			635,498
Property, plant and equipment, net		1,970,872			2,003,887
Financing lease right-of-use asset		12,625			13,302
Operating lease right-of-use asset		2,630,830			709,883
Goodwill		1,384,255			1,384,255
Patents and other intangibles, net		4,150,584			4,190,621
Total long-term assets		10,786,986			8,937,446
Total assets	$	17,158,384		$	15,256,795

Liabilities and Stockholders' Equity (Deficit)
Current liabilities
Accounts payable	$	4,292,161		$	4,229,128
Accrued liabilities		968,021			1,096,090
Unearned revenue		1,213,927			1,240,205
Current portion of operating lease right-of-use liability		87,158			100,777
Current portion of financing lease liability		2,407			2,367
Current installments of notes payable		1,738,845			1,519,496
Total current liabilities		8,302,519			8,188,063

Long-term liabilities
Obligation for lease disposal costs		556,670			546,570
Related party notes payable, net of debt discount		891,802			1,216,874
Notes payable, net of current portion		10,057			12,276
Financing lease liability, net of current portion		10,353			10,970
Operating lease right-of-use liability, net of current portion		2,549,772			609,106
Mandatorily redeemable convertible preferred stock, net of discount		4,817,170			4,785,086
Total long-term liabilities		8,835,824			7,180,882
Total liabilities		17,138,343			15,368,945

Commitments and contingencies (Note 8)

Stockholders' (deficit) equity
Common stock, $0.01 par value; 750,000,000 shares authorized; 423,709,226 and 419,842,256 shares issued and outstanding respectively		4,237,092			4,198,423
Additional paid in capital		122,151,722			121,680,163
Accumulated deficit		(128,486,879	)		(128,064,385	)
Deficit attributable to International Isotopes Inc. stockholders		(2,098,065	)		(2,185,799	)
Equity attributable to noncontrolling interest		2,118,106			2,073,649
Total equity (deficit)		20,041			(112,150	)
Total liabilities and stockholders' equity (deficit)	$	17,158,384		$	15,256,795

See accompanying notes to the unaudited condensed consolidated financial statements.

INTERNATIONAL ISOTOPES INC. AND SUBSIDIARIES

Unaudited Condensed Consolidated Statements of Operations

	Three months ended March 31,
	2020			2019

Sale of product	$	2,335,786		$	2,527,852
Cost of product		968,525			1,088,429
Gross profit		1,367,261			1,439,423

Operating costs and expenses
Salaries and contract labor		741,205			623,699
General, administrative and consulting		788,438			626,863
Research and development		46,928			46,304
Total operating expenses		1,576,571			1,296,866
Net operating (loss) income		(209,310	)		142,557

Other income (expense):
Other income		23,818			24,632
Interest income		2,335			3,422
Interest expense		(194,880	)		(114,077	)
Total other income (expense)		(168,727	)		(86,023	)
Net (loss) income		(378,037	)		56,534
Less income attributable to noncontrolling interest		44,457			108,492

Net loss attributable to International Isotopes Inc.	$	(422,494	)	$	(51,958	)

Net income (loss) per common share - basic:	$	—		$	—
Net income (loss) per common share - diluted:	$	—		$	—

Weighted average common shares outstanding - basic:		420,692,023			413,906,700
Weighted average common shares outstanding - diluted:		420,692,023			413,906,700

See accompanying notes to the unaudited condensed consolidated financial statements.

INTERNATIONAL ISOTOPES INC. AND SUBSIDIARIES

Unaudited Condensed Consolidated Statements of Cash Flows

	Three months ended March 31,
	2020			2019
Cash flows from operating activities
Net (loss) income	$	(378,037	)	$	56,534
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation and amortization		103,770			64,985
Accretion of obligation for lease disposal costs		10,100			9,387
Accretion of beneficial conversion feature and discount		92,430			38,788
Equity based compensation		51,522			63,737
Changes in operating assets and liabilities:
Accounts receivable		(148,130	)		(536,554	)
Inventories		44,047			(320,397	)
Prepaids and other current assets		45,268			27,797
Accounts payable and accrued liabilities		117,068			222,378
Unearned revenues		(26,278	)		(47,231	)
Net cash used in operating activities		(88,240	)		(420,576	)

Cash flows from investing activities:
Purchase of property, plant and equipment		(1,565	)		(5,084	)
Net cash used in investing activities		(1,565	)		(5,084	)

Cash flows from financing activities:
Proceeds from sale of stock		6,666			1,581
Payments on financing lease		(577	)		—
Proceeds from issuance of related party notes payable		325,000			—
Principal payments on notes payable		(245,728	)		(1,939	)
Net cash provided by (used in) financing activities		85,361			(358	)

Net decrease in cash, cash equivalents, and restricted cash		(4,444	)		(426,018	)
Cash, cash equivalents, and restricted cash at beginning of period		1,210,920			1,450,467
Cash, cash equivalents, and restricted cash at end of period	$	1,206,476		$	1,024,449

Supplemental disclosure of cash flow activities:
Cash paid for interest	$	60,205		$	59,127

Supplemental disclosure of noncash financing and investing transactions
Decrease in accrued interest and increase in equity for conversion of dividends to stock	$	204,480		$	205,980
Increase in operating lease right-of-use asset and right-of-use liability for new lease	$	2,649,070		$	—
Decrease in related party notes payable and increase in equity for amounts allocated to warrants and beneficial conversion feature	$	247,560		$	—

Reconciliation of cash, cash equivalents, and restricted cash as shown in the condensed consolidated statements of cash flows is presented in the table below:

	March 31,		March 31,
	2020		2019
Cash and cash equivalents	$	568,656	$	398,604
Restricted cash included in long-term assets		637,820		625,845
Total cash, cash equivalents, and restricted cash shown in statement of cash flows	$	1,206,476	$	1,024,449

See accompanying notes to the unaudited condensed consolidated financial statements.

INTERNATIONAL ISOTOPES INC AND SUBSIDIARIES

Reconciliation of Stockholders' (Deficit) Equity

Three Ended March 31, 2020

(Unaudited)

										Deficit
										Attributable			Equity
										to			Attributable
	Common stock			Additional						Internat'l			to		Total
	Shares	Common		Paid-in			Accumulated			Isotopes			Noncontrolling		(Deficit)
	Outstanding	Stock		Capital			Deficit			Shareholders			Interest		Equity
Balance, January 1, 2020	419,842,256	$	4,198,423	$	121,680,163		$	(128,064,385	)	$	(2,185,799	)	$	2,073,649	$	(112,150	)

Shares issued under employee stock purchase plan	156,845		1,568		5,098			—			6,666			—		6,666

Stock grant	302,125		3,021		(3,021	)		—			—			—		—

Stock in lieu of dividends on convertible preferred C	3,408,000		34,080		170,400			—			204,480			—		204,480

Convertible debenture beneficial conversion feature	—		—		102,584			—			102,584			—		102,584

Warrants issued with convertible debenture	—		—		144,976			—			144,976			—		144,976

Stock based compensation	—		—		51,522			—			51,522			—		51,522

Net (loss) income	—		—		—			(422,494	)		(422,494	)		44,457		(378,037	)
Balance, March 31, 2020	423,709,226	$	4,237,092	$	122,151,722		$	(128,486,879	)	$	(2,098,065	)	$	2,118,106	$	20,041

See accompanying notes to the unaudited condensed consolidated financial statements.

INTERNATIONAL ISOTOPES INC AND SUBSIDIARIES

Reconciliation of Stockholders' (Deficit) Equity

Three Ended March 31, 2019

(Unaudited)

										Deficit
										Attributable			Equity
										to			Attributable
	Common stock			Additional						Internat'l			to
	Shares	Common		Paid-in			Accumulated			Isotopes			Noncontrolling		Total
	Outstanding	Stock		Capital			Deficit			Shareholders			Interest		Equity
Balance, January 1, 2019	413,168,301	$	4,131,683	$	120,805,997		$	(126,541,421	)	$	(1,603,741	)	$	1,757,875	$	154,134

Shares issued under employee stock purchase plan	31,618		316		1,265			—			1,581			—		1,581

Stock grant	279,767		2,798		(2,798	)		—			—			—		—

Stock in lieu of dividends on convertible preferred C	3,433,000		34,330		171,650			—			205,980			—		205,980

Stock based compensation	—		—		63,737			—			63,737			—		63,737

Net (loss) income	—		—		—			(51,958	)		(51,958	)		108,492		56,534
Balance, March 31, 2019	416,912,686	$	4,169,127	$	121,039,851		$	(126,593,379	)	$	(1,384,401	)	$	1,866,367	$	481,966

See accompanying notes to the unaudited condensed consolidated financial statements.

INTERNATIONAL ISOTOPES INC. AND SUBSIDIARIES

Notes to Unaudited Condensed Consolidated Financial Statements

For the Quarter Ended March 31, 2020

(1) The Company and Basis of Presentation

International Isotopes Inc. (INIS) was incorporated in Texas in November 1995. The accompanying unaudited condensed consolidated financial statements are presented in conformity with accounting principles generally accepted in the United States of America (GAAP) and include all operations and balances of INIS and its wholly owned subsidiaries. The unaudited condensed consolidated financial statements also include the accounts of INIS’s 50% owned joint venture, TI Services, LLC (TI Services), and the accounts of INIS’s 24.5% interest in RadQual, LLC (RadQual). TI Services is headquartered in Youngstown, Ohio and was formed with RadQual in December 2010 to distribute products and services for nuclear medicine, nuclear cardiology and Positron Emission Tomography (PET) imaging. RadQual is a global supplier of molecular imaging quality control and calibration devices, and is headquartered in Idaho Falls, Idaho. In August 2017, affiliates of INIS purchased 75.5% of RadQual and at the time INIS was named as one of the two managing members of RadQual. As a result of this ownership change, INIS has significant influence in management decisions with regard to RadQual’s business operations. INIS, its wholly owned subsidiaries, TI Services, and RadQual are collectively referred to herein as the “Company,” “we,” “our” or “us.”

Nature of Operations – INIS and its subsidiaries, TI Services and RadQual, manufacture a full range of nuclear medicine calibration and reference standards, generic sodium iodide I-131 drug product, cobalt teletherapy sources, and a varied selection of radiochemicals for medical research, and clinical applications. The Company also offers contract manufacturing services for certain pharmaceutical products. The Company’s business consists of five business segments: Nuclear Medicine Standards, Cobalt Products, Radiochemical Products, Fluorine Products, and Radiological Services. The Company’s headquarters and all operations, with the exception of TI Services, are located in Idaho Falls, Idaho.

With the exception of certain unique products, the Company’s normal operating cycle is considered to be one year. Due to the time required to produce some cobalt products, the Company’s operating cycle for those products is considered to be two to three years. Accordingly, preliminary payments received on cobalt contracts, where shipment will not take place for greater than one year, have been recorded as unearned revenue and, depending upon estimated ship dates, classified under either current or long-term liabilities on the Company’s consolidated balance sheets. These unearned revenues are being recognized as revenue in the periods during which the cobalt shipments take place. All assets expected to be realized in cash or sold during the normal operating cycle of business are classified as current assets.

Principles of Consolidation – The accompanying unaudited condensed consolidated financial statements are presented in conformity with GAAP and include all operations and balances of INIS and its wholly-owned subsidiaries. The Company also consolidates the accounts of RadQual into the accompanying unaudited condensed consolidated financial statements. See Note 4 “Investment and Business Consolidation” for additional information regarding RadQual. All significant intercompany accounts and transactions have been eliminated in consolidation.

Interim Financial Information – The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with GAAP for interim financial information and pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (SEC). Accordingly, the accompanying unaudited condensed consolidated financial statements do not include all of the information and notes required by GAAP for complete financial statements. In the opinion of management, all adjustments and reclassifications considered necessary in order to make the financial statements not misleading and for a fair and comparable presentation have been included and are of a normal recurring nature. Operating results for the three-month period ended March 31, 2020 are not necessarily indicative of the results that may be expected for the year ending December 31, 2020 or any future periods. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the Company’s Annual Report on Form 10-K for the year ended December 31, 2019 filed with the SEC on March 30, 2020.

(2) Current Developments and Liquidity

Business Condition – Since inception, the Company has incurred substantial losses. During the three-months ended March 31, 2020, the Company reported a net loss of $422,494, net of non-controlling interest, and net cash used in operating activities of $88,240. During the three-months ended March 31, 2019, the Company reported net loss of $51,958, net of non-controlling interest, and net cash used in operating activities of $420,576.

During the three-months ended March 31, 2020, the Company continued its focus on its long-standing core business segments which consist of its radiochemical products, cobalt products, nuclear medicine standards, and radiological services, and in particular, the pursuit of new business opportunities within those segments. During this period the Company received approval from the U.S. Food and Drug Administration (FDA) for a generic sodium iodide I-131 drug product. This product is approved for use in treatment of hyperthyroidism and carcinoma of the thyroid and is the first generic product approved by the FDA in the US.

Additionally, the Company holds a Nuclear Regulatory Commission (NRC) construction and operating license for the depleted uranium facility in, as well as the property agreement with, Lea County, New Mexico, where the plant is intended to be constructed. The NRC license for the de-conversion facility is a forty (40) year operating license and is the first commercial license of this type issued in the United States. There are no other companies with a similar license application under review by the NRC. Therefore, the NRC license represents a significant competitive barrier and the Company considers it a valuable asset.

The Company expects that cash from operations, cash raised through equity or debt financing and its current cash balance will be sufficient to fund operations for the next twelve months. Future liquidity and capital funding requirements will depend on numerous factors, including, contract manufacturing agreements, commercial relationships, technological developments, market factors, available credit, and voluntary warrant redemption by shareholders. There is no assurance that additional capital and financing will be available on acceptable terms to the Company or at all.

(3) Net Income (Loss) Per Common Share - Basic and Diluted

For the three-months ended March 31, 2020, the Company had 23,655,000 stock options outstanding, 50,090,000 warrants outstanding, 4,213 outstanding shares of Series C redeemable convertible preferred stock (Series C Preferred Stock), and 850 outstanding shares of Series B redeemable convertible preferred stock (Series B Preferred Stock), each of which were not included in the computation of diluted income (loss) per common share because they would be anti-dilutive.

For the three-months ended March 31, 2019, the Company had 27,205,000 stock options outstanding, 20,090,000 warrants outstanding, 4,213 outstanding shares of Series C Preferred Stock, and 850 outstanding shares of Series B Preferred Stock, each of which were not included in the computation of diluted income per common share because they would be anti-dilutive.

The table below summarizes common stock equivalents outstanding at March 31, 2020:

	March 31,
	2020		2019
Stock options		23,655,000		27,205,000
Warrants		50,090,000		20,090,000
850 Shares of Series B redeemable convertible preferred stock		425,000		425,000
4,213 Shares of Series C redeemable convertible preferred stock		42,130,000		42,130,000
		116,300,000		89,850,000

(4) Investment and Business Consolidation

The Company owns a 24.5% interest in RadQual, with which the Company has an exclusive manufacturing agreement for nuclear medicine products. In August 2017, affiliates of the Company, including the Company’s Chairman of the Board and the Chief Executive Officer, acquired the remaining 75.5% interest in RadQual. The Company’s Chairman of the Board and its Chief Executive Officer also each serve as the managing members of RadQual. As a result of this change in ownership, and other factors, the Company determined that it gained the ability to exercise significant management control over the operations of RadQual. Because of this increased management control, and pursuant to GAAP, the Company has consolidated the accounts of RadQual into its financial statements.

(5) Inventories

Inventories consisted of the following at March 31, 2020 and December 31, 2019:

	March 31, 2020		December 31, 2019
Raw materials	$	40,648	$	40,648
Work in process		3,334,886		3,379,943
Finished goods		3,839		2,829
	$	3,379,373	$	3,423,420

Work in process includes cobalt-60 targets that are located in the U.S. Department of Energy’s (DOE) Advanced Test Reactor (ATR) located outside of Idaho Falls, Idaho. These targets are owned by the Company and contain cobalt-60 material at various stages of irradiation. The carrying value of the targets is based on accumulated irradiation and handling costs which have been allocated to each target based on the length of time the targets have been held and processed at the ATR. At March 31, 2020, and at December 31, 2019, this cobalt target inventory had a carrying value of $201,349.

Work in process also includes costs to irradiate cobalt-60 material under a contract with the DOE. This material has been placed in the ATR and the Company made progress payments to purchase this material. The Company has contracted with several customers for the sale of some of this product material and has collected advance payments for project management, up-front handling, and other production costs from those customers. The advance payments from customers were recorded as unearned revenue which are recognized in the Company’s consolidated financial statements as cobalt products are completed and shipped. For the three-months ended March 31, 2020 and 2019, the Company recognized approximately $11,000 and $94,000, respectively, of revenue in its consolidated statements of operations for customer orders filled during the period under these cobalt contracts.

(6) Stockholders’ Equity, Options, and Warrants

Employee Stock Purchase Plan

The Company has an employee stock purchase plan pursuant to which employees of the Company may participate to purchase shares of common stock at a discount. During the three-months ended March 31, 2020 and 2019, the Company issued 156,845 and 31,618 shares of common stock, respectively, to employees under the employee stock purchase plan for proceeds of $6,666 and $1,581, respectively. As of March 31, 2020, 318,316 shares of common stock remain available for issuance under the employee stock purchase plan.

Stock-Based Compensation Plans

2015 Incentive Plan - In April 2015, the Company’s Board of Directors approved the International Isotopes Inc. 2015 Incentive Plan (as amended, the 2015 Plan), which was subsequently approved by the Company’s shareholders in July 2015. The 2015 Plan was amended and restated in July 2018 to increase the number of shares authorized for issuance under the 2015 Plan by an additional 20,000,000 shares. The 2015 Plan provides for the grant of incentive and non-qualified stock options, stock appreciation rights, restricted stock, restricted stock units, performance shares and units, and other stock or cash-based awards. The 2015 Plan amended and restated the Company’s Amended and Restated 2006 Equity Incentive Plan (2006 Plan). The 2015 Plan authorizes the issuance of up to 80,000,000 shares of common stock, plus 11,089,967 shares authorized, but not issued under the 2006 Plan. At March 31, 2020, there were 34,135,593 shares available for issuance under the 2015 Plan.

Employee/Director Grants - The Company accounts for issuances of stock-based compensation to employees by recognizing, as compensation expense, the cost of employee services received in exchange for equity awards. The compensation expense is based on the grant date fair value of the award. Stock option compensation expense is recognized over the period during which an employee is required to provide service in exchange for the award (the vesting period).

Non-Employee Grants - The Company accounts for its issuances of stock-based compensation to non-employees by measuring the value of any awards that were vested and non-forfeitable at their date of issuance based on the grant date fair value of the award. The non-vested portion of awards that are subject to the future performance of the counterparty are adjusted at each reporting date to their fair values based upon the then current market value of the Company’s stock and other assumptions that management believes are reasonable.

Option awards outstanding as of March 31, 2020, and changes during the three-months ended March 31, 2020, were as follows:

Fixed Options	Shares		Weighted Average Exercise Price		Weighted Average Remaining Contractual Life		Aggregate Intrinsic Value
Outstanding at December 31, 2019		23,655,000	$	0.05
Granted		—	$	—
Exercised		—	$	—
Expired		—	$	—
Forfeited		—	$	—
Outstanding at March 31, 2020		23,655,000	$	0.05		6.1	$	235,000
Exerciseable at March 31, 2020		17,936,000	$	0.05		5.6	$	235,000

The intrinsic value of outstanding and exercisable shares is based on the closing price of the Company’s common stock on the OTCQB of $0.06 per share on March 31, 2020, the last trading day of the quarter.

As of March 31, 2020, there was $59,808 of unrecognized compensation expense related to stock options that will be recognized over a weighted-average period of 1.76 years.

Total stock-based compensation expense for the three-months ended March 31, 2020 and 2019 was $51,522 and $63,737 respectively.

Pursuant to an employment agreement with its Chief Executive Officer, the Company awarded 500,000 fully vested shares of common stock to its Chief Executive Officer in February 2020 under the 2015 Plan. The number of shares awarded was based on a $28,000 stock award using a price of $0.056 per share. The employment agreement provides that the number of shares issued will be based on the average closing price of common stock for the 20 trading days prior to issue date but not less than $0.05 per share. Compensation expense recorded pursuant to this stock grant was $18,128, which was determined by multiplying the number of shares awarded by the closing price of the common stock on February 28, 2020, which was $0.06 per share. The Company withheld 197,875 shares of common stock to satisfy the employee’s payroll tax obligations in connection with this issuance. The net shares issued on February 28, 2020 totaled 302,125.

Warrants

Warrants outstanding at March 31, 2020, included 17,165,000 Class M Warrants which are immediately exercisable at an exercise price of $0.12 per share and expire on February 17, 2022; 2,925,000 Class N Warrants which are immediately exercisable at an exercise price of $0.10 per share and expire on May 12, 2022; and 30,000,000 Class O Warrants which are immediately exercisable at an exercise price of $0.045 per share and expire December 30, 2024.

Warrants outstanding at March 31, 2019, included 17,165,000 Class M Warrants which are immediately exercisable at an exercise price of $0.12 per share and expire on February 17, 2022 and 2,925,000 Class N Warrants which are immediately exercisable at an exercise price of $0.10 per share and expire on May 12, 2022.

Preferred Stock

At March 31, 2020, there were 850 shares of the Series B Preferred Stock outstanding with a mandatory redemption date of May 2022 at $1,000 per share or $850,000. The shares of Series B Preferred Stock are also convertible into 425,000 shares of the Company’s common stock at a conversion price of $2.00 per share. These shares of Series B Preferred Stock do not carry any dividend preferences. Due to the mandatory redemption provision, the Series B Preferred Stock has been classified as a liability in the accompanying condensed consolidated balance sheets.

At March 31, 2020, there were 4,213 shares of the Series C Preferred Stock outstanding with a mandatory redemption date of February 2022 at $1,000 per share in either cash or shares of common stock, at the option of the holder. Holders of the Series C Preferred Stock do not have any voting rights except as required by law and in connection with certain events as set forth in the Statement of Designation of the Series C Preferred Stock. The Series C Preferred Stock accrues dividends at a rate of 6% per annum, payable annually on February 17th of each year. The Series C Preferred Stock are convertible at the option of the holders at any time into shares of the Company's common stock at an initial conversion price equal to $0.10 per share, subject to adjustment. If the volume-weighted average closing price of the Company’s common stock over a period of 90 consecutive trading days is greater than $0.25 per share, the Company may redeem all or any portion of the outstanding Series C Preferred Stock at the original purchase price per share plus any accrued and unpaid dividends, payable in shares of common stock.

During the three-months ended March 31, 2020 and 2019 dividends paid to holders of the Series C Preferred Stock totaled $251,280 and $252,780, respectively. Some holders of the Series C Preferred Stock elected to settle their dividend payments with shares of the Company’s common stock in lieu of cash. For the three-months March 31, 2020 and 2019 the Company issued 3,408,000 and 3,433,000 shares of common stock, respectively, in lieu of a dividend payment of $204,480 and $205,980, respectively. The remaining $46,800 of dividend payable was settled with cash.

(7) Debt

In December 2013, we entered into a promissory note agreement with our then Chairman of the Board and one of our major shareholders, pursuant to which we borrowed $500,000 (the 2013 Promissory Note). The 2013 Promissory Note is secured and bears interest at 6% per annum and was originally due June 30, 2014. According to the terms of the 2013 Promissory Note, at any time, the lenders may settle any or all of the principal and accrued interest with shares of our common stock. In connection with the 2013 Promissory Note, each of the two lenders was issued 5,000,000 Class L warrants to purchase shares of our common stock at an exercise price of $0.06 per share. The warrants were immediately exercisable. In June 2014, we renegotiated the terms of the 2013 Promissory Note. Pursuant to the modification, the maturity date was extended to December 31, 2017 and each lender was granted an additional 7,500,000 Class L warrants to purchases shares of our common stock at an exercise price of $0.06 per share. The warrants were immediately exercisable. In February 2017, the 2013 Promissory Note was further modified to extend the maturity date to December 31, 2020, with all remaining terms unchanged. On December 23, 2018, all 25,000,000 Class L warrants expired. In December 2019, the 2013 Promissory Note was further modified to extend the maturity date to December 31, 2021, with all remaining terms unchanged.

At March 31, 2020, the principal balance of the 2013 Promissory Note was $500,000 and accrued interest payable on the 2013 Promissory Note was $189,234. Interest expense recorded for the three-months ended March 31, 2020, was $7,500.

In April 2018, we borrowed $120,000 from our Chief Executive Officer and Chairman of the Board pursuant to a promissory note (the 2018 Promissory Note). The 2018 Promissory Note accrues interest at 6% per annum, which is payable upon maturity of the 2018 Promissory Note. The 2018 Promissory Note was originally unsecured and originally matured on August 1, 2018. At any time, the holder of the 2018 Promissory Note may elect to have any or all of the principal and accrued interest settled with shares of our common stock based on the average price of the shares over the previous 20 trading days. Pursuant to an amendment to the 2018 Promissory Note in June 2018, the maturity date was extended to March 31, 2019 with all other provisions remaining unchanged. Pursuant to a second amendment to the 2018 Promissory Note in February 2019, the maturity date was extended to July 31, 2019 with all other provisions remaining unchanged. Pursuant to a third amendment to the 2018 Promissory Note in July 2019, the maturity date was extended to January 31, 2020 with all other provisions remaining unchanged. Pursuant to a fourth amendment to the 2018 Promissory Note in December 2019, the maturity date was extended to December 31, 2021, the note was modified to become secured by company assets, with all other provisions remaining unchanged.

At March 31, 2020, accrued interest on the 2018 Promissory Note totaled $13,970.

In April 2019, one of the prepaid revenue customers requested a refund of the amounts paid. The Company entered into a note agreement to repay $2,182,142 over the next 12 months. The modification was necessary to address the delays to cobalt delivery in 2019 caused by changes to the ATR operating schedule and also to accommodate this customer’s request to reduce their cobalt purchase obligations in future years. The modifications require that the Company refund approximately $1,050,000, of payments received for prior year undelivered material, plus interest at 12% per year, payable over a one-year period on a portion of that amount. The Company has also agreed with this customer to refund approximately $1,100,000 paid for material that was to have been delivered in later years. There will be no interest charge on this refund. In December 2019, this agreement was modified further allowing the Company to delay the original payments by 3 months and refund an additional $462,258 with no interest charge.

On December 20, 2019, the Company entered into a promissory note agreement with four of the Company’s major shareholders (the 2019 Promissory Note). The 2019 Promissory Note authorizes the Company to borrow up to $1,000,000. As of December 31, 2019, the Company had borrowed $675,000 under the 2019 promissory note. In February 2020, the Company borrowed an additional $325,000. The 2019 Promissory Note bears an interest rate of 4% annually and is due December 31, 2022. According to the terms of the 2019 Promissory Note, at any time, the lenders may settle any or all of the principal and accrued interest with shares of the Company’s common stock based on the average closing price of the Company’s common stock for the 20 days preceding the payment. In connection with the 2019 Promissory Note, the lenders were issued warrants totaling 30,000,000 warrants to purchase shares of the Company’s common stock at $0.045 per share. The fair value of these warrants issued totaled $446,079 and was recorded as a debt discount and will be amortized over the life of the 2019 Promissory Note. The Company calculated a beneficial conversion feature of $315,643 which will be accreted to interest expense over the life of the 2019 Promissory Note. At March 31, 2020 accrued interest on the 2019 Promissory Note totaled $9,181.

On April 23, 2020, the Company, through its wholly-owned subsidiary entered into a Loan Agreement and Promissory Note (collectively the “SBA Loan”) with KeyBank National Association pursuant to the Paycheck Protection Program (the “PPP”) under the recently enacted Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”) administered by the U.S. Small Business Administration (the “SBA”). The Company received total proceeds of $495,500 from the SBA Loan. The SBA Loan is scheduled to mature on April 22, 2022 and has a 1.00% interest rate and is subject to the terms and conditions applicable to loans administered by the SBA under the CARES Act. The SBA Loan may be prepaid at any time prior to maturity with no prepayment penalties.

The SBA Loan contains customary events of default relating to, among other things, payment defaults and breaches of representations and warranties. Subject to certain conditions, the SBA Loan may be forgiven in whole or in part by applying for forgiveness pursuant to the CARES Act and the PPP. The amount of loan proceeds eligible for forgiveness is based on a formula based on a number of factors, including the amount of loan proceeds used by the Company during the eight-week period after the loan origination for certain purposes, including payroll costs, interest on certain mortgage obligations, rent payments on certain leases, and certain qualified utility payments, provided that, among other things, at least 75% of the loan amount is used for eligible payroll costs, the employer maintaining or rehiring employees and maintaining salaries at certain level. In accordance with the requirements of the CARES Act and the PPP, the Company intends to use the proceeds from the SBA Loan primarily for payroll costs. No assurance can be given that the Company will be granted forgiveness of the SBA Loan in whole or in part.

(8) Commitments and Contingencies

Dependence on Third Parties

The production of High Specific Activity Cobalt is dependent upon the DOE, and its prime operating contractor, which controls the ATR and laboratory operations at the ATR located outside of Idaho Falls, Idaho. In October 2014, the Company signed a ten-year contract with the DOE for the irradiation of cobalt targets for the production of cobalt-60. The Company will be able to purchase cobalt targets for a fixed price per target with an annual 5% escalation in price. The contract term is October 1, 2014, through September 30, 2024, however, the contract may be extended beyond that date. Also, the DOE may end the contract if it determines termination is necessary for the national defense, security or environmental safety of the United States. If this were to occur, all payments made by the Company, for partially irradiated undelivered cobalt material, would be refunded.

Nuclear Medicine Reference and Calibration Standard manufacturing is conducted under an exclusive contract with RadQual, which in turn has an agreement in place with several companies for distributing the products. The radiochemical product sold by the Company is supplied to the Company through agreements with several suppliers. A loss of any of these customers or suppliers could adversely affect operating results by causing a delay in production or a possible loss of sales.

(8) Contingencies

Because all the Company’s business segments involve the handling or use of radioactive material, the Company is required to have an operating license from the NRC and specially trained staff to handle these materials. The Company has amended this operating license numerous times to increase the amount of material permitted within the Company’s facility. Although this license does not currently restrict the volume of business operations performed or projected to be performed in the upcoming year, additional processing capabilities and license amendments could be implemented that would permit processing of other reactor-produced radioisotopes by the Company. The financial assurance required by the NRC to support this license has been provided for with a surety bond held with North American Specialty Insurance Company which is supported by a restricted money market account held with Merrill Lynch in the amount of $637,820.

In August 2011, the Company received land from Lea County, New Mexico, pursuant to a Project Participation Agreement (PPA), whereby the land was deeded to the Company for no monetary consideration. In return, the Company committed to construct a uranium de-conversion and Fluorine Extraction Process facility on the land. In order to retain title to the property, the Company was to begin construction of the de-conversion facility no later than December 31, 2014, and complete Phase I of the project and have hired at least 75 persons to operate the facility no later than December 31, 2015, although commercial operations need not have begun by that date. In 2015, the Company negotiated a modification to the PPA that extended the start of construction date to December 31, 2015, and the hiring milestone to December 31, 2016. Those dates were also not met. The Company is in discussion with commercial companies possibly interested in purchasing rights to this project. Should those discussions come to fruition the Company plans to negotiate a second modification to the PPA agreement to further extend the commitment dates. If the Company is not successful in reaching an amendment to extend the performance dates in the PPA. then it may, at its sole option, either purchase or re-convey the property to Lea County, New Mexico. The purchase price of the property would be $776,078, plus interest at the annual rate of 5.25% from the date of the closing to the date of payment. The Company has not recorded the value of this property as an asset and will not do so until such time that sufficient progress on the project has been made to meet the Company’s obligations under the agreements for permanent transfer of the title.

On May 3, 2019, the Company’s radiological services team was involved in a contamination event involving a breached cesium-137 source at an off-site location in the state of Washington. This work was being performed under a contract with the DOE. The Company supported the initial onsite contamination clean-up operations at that location and completed removal of the cesium source Company equipment. The Company has reviewed the results of the DOE investigation into this event and has implemented appropriate corrective actions. Since August 2019 the DOE has assumed full control of the ongoing cleanup operations and has assumed all of the financial obligations associated with the contractors hired to carry out all of the facility recovery operations. Under the terms of the contract the Company believes it should be indemnified from financial liability for this event by the DOE under the Price Anderson Act (PAA) and the Company has formally requested the DOE to provide indemnification under the PAA. While the DOE’s review of the request is still underway the Company believes that a determination of indemnification under the PAA is probable. Such indemnification would allow the Company to recoup all its costs associated with this contamination event. During 2019, the Company incurred $2,384,255 in expenses related to the contamination and its cleanup. During 2019, the Company received $964,958 in reimbursements from its insurance company for expenses related to the contamination and its cleanup, and the Company has determined that an additional $1,244,744 of its incurred expenses related to the contamination and its cleanup are probable for recovery pursuant to ASC 410-30. The Company believes additional cost recoveries beyond that which is recorded are possible but are not yet deemed probable at this time.

(9) Revenue Recognition

Revenue from Product Sales

The following tables present the Company’s revenue disaggregated by business segment and geography, based on management’s assessment of available data:

	Three Months Ended March 31, 2020									Three Months Ended March 31, 2019
	U.S.		Outside U.S.		Total Revenues		% of Total Revenues			U.S.		Outside U.S.		Total Revenues		% of Total Revenues
Radiochemical Products	$	668,591	$	86,630	$	755,221		32	%	$	459,967	$	3,265	$	463,232		18	%
Cobalt Products		305,620		—		305,620		13	%		336,089		40,000		376,089		15	%
Nuclear Medicine Products		867,604		174,520		1,042,124		45	%		1,080,472		20,450		1,100,922		44	%
Radiological Services		72,321		—		72,321		3	%		587,609		—		587,609		23	%
Fluorine Products		160,500		—		160,500		7	%		—		—		—		0	%
	$	2,074,636	$	261,150	$	2,335,786		100	%	$	2,464,137	$	63,715	$	2,527,852		100	%

The Company’s revenue consists primarily of products manufactured for use in the nuclear medicine industry, distribution of radiochemicals including sodium iodide I-131 drug product, cobalt source manufacturing, and providing contract manufacturing of drug products for customers. With the exception of certain unique products, the Company’s normal operating cycle is considered to be one year. Due to the time required to produce some cobalt products, the Company’s operating cycle for those products is considered to be two to three years. Accordingly, preliminary payments received on cobalt contracts, where shipment will not take place for greater than one year, have been recorded as unearned revenue on the Company’s consolidated balance sheets and classified under current or long-term liabilities, depending upon estimated ship dates. For the three-months ended March 31, 2020, the Company

reported current unearned cobalt products revenue of $1,213,927. For the period ended December 31, 2019, the Company reported current unearned revenue of $1,240,705. These unearned revenues will be recognized as revenue in the periods during which the cobalt shipments take place.

Contract Balances

The Company records a receivable when it has an unconditional right to receive consideration after the performance obligations are satisfied. As of March 31, 2020, and December 31, 2019, accounts receivable totaled $1,024,044 and $875,914, respectively. For the three-months ended March 31, 2020, the Company did not incur material impairment losses with respect to its receivables.

(10) Leases

The Company leases office and warehouse space under operating leases. Right-of-use assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent its obligation to make lease payments under the lease. Operating lease, right-of-use assets, and liabilities are recognized at the lease commencement date based on the present value of lease payments over the reasonably certain lease term. The implicit rates with the Company’s operating leases are generally not determinable and the Company uses its incremental borrowing rate at the lease commencement date to determine the present value of its lease payments. The determination of the Company’s incremental borrowing rate requires judgement. The company determines its incremental borrowing rate for each lease using its then-current borrowing rate. Certain of the Company’s leases include options to extend or terminate the lease. The Company establishes the number of renewal options periods used in determining the operating lease term based upon its assessment at the inception of the operating lease. The option to renew the lease may be automatic, at the option of the Company, or mutually agreed to between the landlord and the Company. Once the facility lease term has begun, the present value of the aggregate future minimum lease payments is recorded as a right-of-use asset. Lease expense is recognized on a straight-line basis over the term of the lease.

	Three Months Ended March 31,
	2020			2019
Operating lease costs	$	68,400		$	36,853
Short-term operating lease costs		8,876			1,902
Financing lease expense:
Amortization of right-of-use assets		577			—
Interest on lease liabilities		222			—
Total financing lease expense		799
Total lease expense	$	78,075		$	38,755

Right-of-use assets obtained in exchange for new operating lease liabilities	$	2,649,070		$	810,367
Right-of-use assets obtained in exchange for new financing lease liabilities	$	—		$	—

Weighted-average remaining lease term (years) - operating leases		14.8			7.0
Weighted-average remaining lease term (years) - financing leases		4.7
Weighted-average discount rate - operating leases		6.75	%		6.75	%
Weighted-average discount rate - financing leases		6.75	%

The future minimum payments under these operating lease agreements are as follows:

	Operating			Financing
2020 (excluding the three months ended March 31, 2020)	$	198,091		$	2,397
2021		257,383			3,195
2022		284,631			3,195
2023		287,108			3,195
2024		287,108			2,929
Thereafter		2,886,518			—
Total minimum operating lease obligations		4,200,839			14,911
Less-amounts representing interest		(1,563,909	)		(2,151	)
Present value of minimum operating lease obligations		2,636,930			12,760
Current maturities		(87,158	)		(2,407	)
Lease obligations, net of current maturities	$	2,549,772		$	10,353

(11) Segment Information

The Company has five reportable segments which include: Nuclear Medicine Standards, Cobalt Products, Radiochemical Products, Fluorine Products, and Radiological Services. Information regarding the operations and assets of these reportable business segments is contained in the following table:

	Three months ended March 31,
Sale of Product	2020		2019
Radiochemical Products	$	755,221	$	463,232
Cobalt Products		305,620		376,089
Nuclear Medicine Standards		1,042,124		1,100,922
Radiological Services		72,321		587,609
Fluorine Products		160,500		—
Total Segments		2,335,786		2,527,852
Corporate revenue		—		—
Total consolidated	$	2,335,786	$	2,527,852

	Three months ended March 31,
Depreciation and Amortization	2020		2019
Radiochemical Products	$	10,354	$	8,817
Cobalt Products		8,761		1,080
Nuclear Medicine Standards		15,989		15,619
Radiological Services		8,636		8,636
Fluorine Products		26,095		26,095
Total Segments		69,835		60,248
Corporate depreciation and amortization		4,782		4,737
Total Consolidated	$	74,617	$	64,985

	Three months ended March 31,
Segment Income (Loss)	2020			2019
Radiochemical Products	$	5,619		$	96,006
Cobalt Products		123,796			192,870
Nuclear Medicine Standards		185,301			216,822
Radiological Services		(14,929	)		311,279
Fluorine Products		122,870			(37,495	)
Total Segments		422,657			779,481
Corporate loss		(845,151	)		(831,439	)
Net Income (Loss)	$	(422,494	)	$	(51,958	)

	Three months ended March 31,
Expenditures for Segment Assets	2020		2019
Radiochemical Products	$	—	$	—
Cobalt Products		—		3,494
Nuclear Medicine Standards		—		—
Radiological Services		—		—
Fluorine Products		1,565		1,590
Total Segments		1,565		5,084
Corporate purchases		—		—
Total Consolidated	$	1,565	$	5,084

Segment Assets	March 31, 2020		December 31, 2019
Radiochemical Products	$	536,603	$	511,381
Cobalt Products		3,388,527		3,369,828
Nuclear Medicine Standards		2,087,295		2,111,225
Radiological Services		96,427		106,374
Fluorine Products		5,482,993		5,477,808
Total Segments		11,591,845		11,576,616
Corporate assets		5,566,539		3,680,179
Total Consolidated	$	17,158,384	$	15,256,795

(12) Subsequent Events

As described under Debt above, on April 23, 2020, the Company, through its wholly-owned subsidiary entered into a Loan Agreement and Promissory Note (collectively the “SBA Loan”) with KeyBank National Association pursuant to the Paycheck Protection Program (the “PPP”) under the recently enacted Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”) administered by the U.S. Small Business Administration (the “SBA”). The Company received total proceeds of $495,500 from the SBA Loan. The SBA Loan is scheduled to mature on April 22, 2022 and has a 1.00% interest rate and is subject to the terms and conditions applicable to loans administered by the SBA under the CARES Act. The SBA Loan may be prepaid at any time prior to maturity with no prepayment penalties.

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

This Quarterly Report on Form 10-Q (the “Quarterly Report”) contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, including statements regarding industry prospects and future results of operations or financial position, made in this Quarterly Report are forward-looking statements. Words such as “anticipates,” “believes,” “should,” “expects,” “future,” “intends” and similar expressions identify forward-looking statements. In particular, statements regarding impact of the novel coronavirus (COVID-19) outbreak on our business, financial condition, operating results and liquidity, the future prospects of our business segments, future cash flow from operations, the Company’s ability to achieve profitability, the business prospects and growth projection for our business segments, the FDA approval for certain of our products, and the status of our proposed uranium de-conversion facility, are forward-looking statements. Forward-looking statements reflect management’s current expectations, plans or projections, and are inherently uncertain. Actual results could differ materially from management's expectations, plans or projections. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this Quarterly Report. Certain risks and uncertainties that could cause our actual results to differ significantly from management’s expectations are described in the risk factors set forth in our Annual Report on Form 10-K for the fiscal year ended December 31, 2019 filed with the Securities and Exchange Commission (SEC) on March 30, 2020 and in the other reports we file with the SEC. These factors describe some but not all of the factors that could cause actual results to differ significantly from management’s expectations. We undertake no obligation to update any forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. Readers are urged, however, to review the risks and other factors set forth in the reports that we file from time to time with the SEC.

BUSINESS OVERVIEW

International Isotopes Inc., its subsidiaries and joint venture, TI Services, LLC, and RadQual, LLC (collectively, the Company, we, our, or us) manufacture a full range of nuclear medicine calibration and reference standards, a wide range of products including cobalt teletherapy sources, a varied selection of radioisotopes and radiochemicals for medical research and clinical applications, and provide contract manufacturing of radiochemical products. We also hold several patents for a fluorine extraction process that we intend to use in conjunction with a planned commercial depleted uranium de-conversion facility, and provide a host of transportation, recycling, and processing services on a contract basis for clients. We also own a 24.5% interest in, and have management control of, RadQual, LLC (RadQual), a global supplier of molecular imaging quality control and calibration devices, with which we have an exclusive manufacturing agreement.

In August 2017, affiliates of the Company, including the Company’s Chairman of the Board and the Chief Executive Officer, acquired the remaining 75.5% interest in RadQual. The Company’s Chairman of the Board and its Chief Executive Officer also serve as the managing members of RadQual. As a result of this change in ownership, and other factors, the Company determined that it had gained the ability to exercise significant management control over the operations of RadQual. Because of this increased management ability and pursuant to GAAP, the Company has consolidated the accounts of RadQual into its financial statements beginning as of August 2017. See Note 4 “Investment and Business Consolidation” to our unaudited consolidated financial statements in this report for additional information

Our business consists of the following five major business segments:

Nuclear Medicine Standards. Our Nuclear Medicine Standards segment consists of the manufacture of sources and standards associated with Single Photon Emission Computed Tomography (SPECT) and Positron Emission Tomography (PET) imaging. These sources are used for indication of patient positioning for SPECT imaging, SPECT camera operational testing, and calibration of dose measurement equipment. Revenue from nuclear medicine products includes consolidated sales from TI Services, LLC (TI Services), a 50/50 joint venture that we formed with RadQual in December 2010 to distribute our products, as well as consolidated sales from RadQual, pursuant to the change in RadQual’s ownership in August 2017, as discussed above. Our nuclear medicine standards products include a host of specially designed items used in the nuclear medicine industry. In addition to the manufacture of these products, we have developed a complete line of specialty packaging for the safe transport and handling of these products.

Cobalt Products. Our Cobalt Products segment includes the production of bulk cobalt (cobalt-60), fabrication of cobalt capsules for radiation therapy and various industrial applications, and recycling of expended cobalt sources. We are the only company in the U.S. that can provide all these unique services. There has been a significant increase in regulation by the Nuclear Regulatory Commission (NRC) in recent years that has created a significant barrier to new entrants into this market.

Radiochemical Products. Our Radiochemical Products segment includes production and distribution and FDA approved generic sodium iodide I-131 drug product for the treatment of hyperthyroidism and carcinoma of the thyroid. We are the only U.S. Company distributing this generic drug product. This segment also distribution of certain radiochemical products and contract manufacturing of radiopharmaceutical products for our customers.

Fluorine Products. We established the Fluorine Products segment in 2004 to support production and sale of the gases that we expected to produce using our Fluorine Extraction Process (FEP) in conjunction with the operation of the proposed depleted uranium de-conversion facility in Lea County, New Mexico. Near the end of 2013, due to changes in the nuclear industry, we placed further engineering work on this project on hold. We continue to hold discussions with potential future customers seeking this type of service, however, further development activity within this segment will be deferred until market and industry conditions change to justify resuming design and construction of the facility. In the meantime, the Company expects to continue to incur some costs associated with the maintenance of licenses and other necessary project investments, and to continue to keep certain agreements in place that will support resumption of project activities at the appropriate time.

Radiological Services. Our Radiological Services segment consists of a wide variety of miscellaneous services such as decommissioning disused irradiation units, performing sealed source exchanges in irradiation and therapy units, and gemstone processing. The Company has suspended all of its field service activities and is in the process of terminating gemstone processing. The Company believes that eliminating work in the Radiological Services segment will allow the Company to better focus upon our core business segments and our new products pipeline. We believe that the loss in revenue resulting from wrapping up of radiological field service work will be more than compensated for by increased revenues in our remaining business segments.

COVID-19 UPDATE

As a result of the COVID-19 pandemic, we experienced a reduction of sales within our nuclear medicine calibration standards segment during the first quarter of 2020. There was no discernable impact from COVID-19 to our other business segments during the period. Revenue from nuclear medicine products for the three months ended March 31, 2020, decreased approximately 5% compared to the same period in 2019. The decrease in sales for the period ended March 31, 2020, for our nuclear medicine calibration standards segment was the result of the closure of many imaging clinics and suspension of elective or non-essential imaging procedures. We anticipate that our nuclear medicine standards segment through RadQual will recover from the impact of the COVID-19 pandemic as the year progresses. We believe many procedures have been delayed, not canceled, and that there will be a pent-up demand for these products. The volume of order flow for nuclear medicine calibration standards has begun to increase from late March levels, and we are hopeful orders will trend back towards normal levels as the year unfolds.

To-date we have not furloughed or terminated any employees as a result of the financial impact of COVID-19. The Company has only seen a limited impact in our raw material supply chain related to the COVID-19, primarily some plastics which have been in strong demand for certain types of PPE. Alternative sources of raw materials have been obtained without any interruption to production. Travel restrictions related to COVID-19 have also delayed vendor installations of some specialized equipment in our new contract manufacturing facility, but we are still targeting the new facility to be up and running around mid-July. With the heightened concern about corporate liquidity during the COVID-19 pandemic, the Company believes that it has adequate cash to support continuing operations.

RESULTS OF OPERATIONS

Three Months Ended March 31, 2020 Compared to Three Months Ended March 31, 2019

Revenue for the three months ended March 31, 2020 was $2,335,786 as compared to $2,527,852 for the same period in 2019, an overall decrease of $192,066, or approximately 8%. This decrease in revenue was largely the result of decreased revenue in our radiological services segment offset by increased revenues in our Radiochemical segment, as discussed in detail below.

The following table presents a period-to-period comparison of total revenue by segment for the three months ended March 31, 2020 and 2019:

	For the three- months ended March 31,		For the three- months ended March 31,
Sale of Product	2020		2019		$ change			% change
Radiochemical Products	$	755,221	$	463,232	$	291,989			63	%
Cobalt Products		305,620		376,089		(70,469	)		-19	%
Nuclear Medicine Standards		1,042,124		1,100,922		(58,798	)		-5	%
Radiological Services		72,321		587,609		(515,288	)		-88	%
Fluorine Products		160,500		—		160,500			0	%
Total Consolidated	$	2,335,786	$	2,527,852	$	(192,066	)		-8	%

Cost of sales decreased to $968,525 for the three months ended March 31, 2020 from $1,088,429 for the same period in 2019. This is a decrease of $119,904, or approximately 11%. The decrease in cost of sales in the three-month comparison was primarily due to the decreased sales activity in our radiological services segment, as discussed in detail below. Gross profit for the three months ended March 31, 2020 was $1,367,261, compared to $1,439,423 for the same period in 2019. This represents a decrease in gross profit of $72,162, or approximately 5%.

The following table presents cost of sales and gross profit data for each of our business segments for the three months ended March 31, 2020 and 2019:

	For the three- months ended March 31,			% of Total Sales			For the three- months ended March 31,			% of Total Sales
	2020			2020			2019			2019
Total Sales	$	2,335,786					$	2,527,852
Cost of Sales
Radiochemical Products	$	409,595			18	%	$	279,650			11	%
Cobalt Products		64,439			3	%		120,145			5	%
Nuclear Medicine Standards		472,774			20	%		471,142			19	%
Radiological Services		21,717			1	%		217,492			9	%
Fluorine Products		—			—			—			—
Total Segments		968,525			42	%		1,088,429			42	%

Gross Profit	$	1,367,261					$	1,439,423
Gross Profit %		58	%					58	%

Operating expense increased approximately 22% to $1,576,571 for the three months ended March 31, 2020, from $1,296,866 for the same period in 2019. This increase of $279,705, is primarily due to an approximate 26% increase in General, Administrative and Consulting costs combined with an approximate 19% increase in Salaries and Contract Labor costs. The increase in General, Administrative and Consulting costs is a result of increased legal, rent, and general operating supply costs incurred during the three months ended March 31, 2020, as compared to the same period in 2019. The increase in Salaries and Contract Labor was a result of adding staff to our payroll to support contract manufacturing and new product development. Research and Development costs increased to $46,928, for the three months ended March 31, 2020, as compared to $46,304, for the same period in 2019. This is an increase of $624, or approximately 1%.

The following table presents a comparison of total operating expense for the three months ended March 31, 2020 and 2019:

	For the three- months ended March 31,		For the three- months ended March 31,
Operating Costs and Expenses:	2020		2019		% change			$ change
Salaries and Contract Labor	$	741,205	$	623,699		19	%	$	117,506
General, Administrative and Consulting		788,438		626,863		26	%		161,575
Research and Development		46,928		46,304		1	%		624
Total operating expenses	$	1,576,571	$	1,296,866		22	%	$	279,705

Other income was $23,818 for the three months ended March 31, 2020, as compared to $24,632 for the same period in 2019. This is a decrease of $814, or approximately 3%. Interest expense for the three months ended March 31, 2020 was $194,880, compared to $114,077 for the same period in 2019. This is an increase of $80,803, or approximately 71%. Interest expense includes dividends accrued on our Series C Redeemable Convertible Preferred Stock (Series C Preferred Stock). As discussed below, we issued Series C Preferred Stock in February 2017 and May 2017. For the three months ended March 31, 2020, we accrued dividends payable of $63,195, which have been recorded as interest expense. Additionally, non-cash interest expense in the amount of $32,084 was recorded for this same period for the issuance of warrants related to the preferred stock issuances. As discussed below, in December 2019, we entered into a promissory note agreement with our Chief Executive Officer, Chairman of the Board, former Chairman of the Board, and one of our major shareholders (the 2019 Promissory Note). Interest recorded for the three months ended March 31, 2020 for the 2019 Promissory Note was $8,628 whereas there was no similar interest expense for the same period in 2019. Additionally, non-cash interest expense in the amount of $60,346 for the issuance of warrants in conjunction with the 2019 Promissory Note was recorded for the three months ended March 31, 2020. See Note 7 “Debt” to our unaudited consolidated financial statements in this Quarterly Report for additional information about our indebtedness and the associated interest expense.

Our net loss for the three months ended March 31, 2020, was $422,494, compared to net loss of $51,958, for the same period in 2019. This is an increase in loss of $370,536 and is the result of the reduction in radiological services revenue, the increase in operating expense from contract manufacturing salaries, and increased interest expense for the three months ended March 31, 2020, as compared to the same period in 2019.

Radiochemical Products. Revenue from the sale of radiochemical products for the three months ended March 31, 2020 was $755,221, compared to $463,232 for the same period in 2019. This is an increase of $291,989, or approximately 63%. The increase is primarily the result of increased demand for our Iodine I-131 radiochemical products and the commencement of sales of our new generic sodium iodide I-131 drug product which was launched in March 2020.

Gross profit of radiochemical products for the three months ended March 31, 2020 was $345,626, compared to $183,582, for the same period in 2019, and gross profit percentages were approximately 46% and 40% for the three months ended March 31, 2020 and 2019, respectively. This increased gross profit percentage is a result of sales of our new generic sodium iodine I-131 drug product and continued improvements of utilization of raw materials. Cost of sales for radiochemical products increased to $409,595 for the three months ended March 31, 2020, as compared to $279,650 for the same period in 2019. This is an increase of $129,945, or approximately 46%, and was primarily the result of increased sales of product. Operating expense for this segment increased to $305,605 for the three months ended March 31, 2020, compared to $87,576 for the same period in 2019. This increase in operating expense of $218,029, or approximately 249%, is primarily due to increased costs for support labor for contract manufacturing startup operations, increased support labor related to increased radiochemical sales activity, and increased support labor related to the rollout of our new generic sodium iodine I-131 drug product. This segment reported net income of $5,619 for the three months ended March 31, 2020, as compared to net income of $96,006 for the same period in 2019. The decrease in net income of $90,387 or approximately 94%, is primarily the result of the increase in operating expenses.

Cobalt Products. Revenue from the sale of cobalt products for the three months ended March 31, 2020 was $305,620, compared to $376,089, for the same period in 2019. This represents a decrease of $70,469, or approximately 19%. Our cobalt sealed source manufacturing is largely dependent on our ability to procure cobalt material from the DOE’s Advanced Test Reactor (ATR). Although we have not been able to obtain high specific activity material from the ATR reactor since late 2013, periodically we are able to acquire recycled material or material from alternative suppliers that can be used to manufacture sealed sources for customers, and in some instances, our customers have supplied their own cobalt material for source fabrication. In addition, we have begun to supply cobalt to periodically supply material to customers who previously paid for the material under supply agreements entered into with us in 2015. As we have supplied this material to our customers, we have recognized the sales on our statement of operations.

In October 2014, we entered into a ten-year agreement with the DOE for the irradiation of cobalt targets. It takes many years to irradiate these cobalt targets to the desired level of activity and we anticipated having high specific activity cobalt available for our customers in late 2019. However, extended reactor shutdowns and lower than expected production rates of cobalt-60 in the new design cobalt targets have delayed delivery of high specific activity cobalt until much later in 2020 and start of 2021. The agreement gives us the ability to purchase the current full capacity of the DOE’s ATR throughout the ten-year period.

As of March 31, 2020, we continued to hold many in-progress, old design cobalt targets at the ATR. We believe that many of the older design targets we hold at the ATR, and that we report as inventory, still hold significant market value in excess of their current carrying values and we have concluded that no impairment existed at that time. We will periodically continue to review the residual value of this cobalt material for potential impairment and make adjustments as deemed appropriate.

During 2015, we entered into cobalt-60 supply agreements with several customers. The terms of the agreements required pre-payments to secure cobalt material in future years. Those prepayments were recorded as unearned revenue on our consolidated balance sheet.

In April 2019, because of our inability to supply high specific activity cobalt material produced by the DOE’s ATR, we were forced to modify a supply agreement with one of our cobalt customers. The modifications require that we refund approximately $1,100,000, of payments received for prior year undelivered material, plus interest at 12% per year, payable over a one-year period. We have also agreed with this customer to refund approximately $1,100,000 paid for material that was to have been delivered in later years. There will be no interest charge on this refund. In December 2019, this agreement was modified further allowing the Company to delay the original payments by 3 months and refund an additional $462,258 with no interest charge. In addition, we have identified another customer ready to purchase this material. The Company does not anticipate any significant net negative effect of this change as sales under the new agreement are expected to offset most of the refunds made under the old agreement. Accordingly, we will classify refund payments due within one year as a short-term liability and payments due beyond one year as a long-term liability, rather than as short-term deferred revenue on our consolidated balance sheets.

Cost of sales for the three months ended March 31, 2020, was $64,439, as compared to $120,145, for the same period in 2019. Gross profit for cobalt products for the three months ended March 31, 2020 was $241,181 compared to $255,944 for the same period in 2019. This is a decrease of $14,763, or approximately 6% and is primarily attributable to our decrease in source manufacturing for the three months ended March 31, 2020, as compared to the same period in 2019. Our gross profit percentages were approximately 79% and 68% for the three-month periods ended March 31, 2020 and 2019, respectively. The increase in the gross profit percentage for the three months ended March 31, 2020 is primarily due to decreased costs of raw material used in the manufacture of sealed sources. Operating expense in this segment increased to $117,385 for the three months ended March 31, 2020, from $63,074 for the same period in 2019. This is an increase of $54,311, or approximately 86%. This increase in operating expenses for the three months ended March 31, 2020 is due to increased equipment expenses and labor expenses. Our net income for cobalt products was $123,796 for the three months ended March 31, 2020, as compared to a net income of $192,870 for the same period in 2019. The decrease in net income of $69,074, or approximately 36%, was attributable to the increased operating expenses.

Nuclear Medicine Standards. Revenue from nuclear medicine products for the three months ended March 31, 2020, was $1,042,124, compared to $1,100,922 for the same period in 2019. This represents a decrease in revenue of $58,798, or approximately 5%. As discussed above, due to a change in the member ownership of RadQual, in August 2017 we began reporting our investment in RadQual on a consolidated basis. Therefore, revenue in this segment includes all sales of RadQual and TI Services with all intercompany sales for the consolidated period eliminated. The decrease in sales for the period ended March 31, 2020 was due to slowing sales activity attributed to the COVID-19 global outbreak which resulted in the closure of many imaging clinics and suspension of elective or non-essential imaging procedures.

We anticipate that our sales through RadQual will recover from the impact of the COVID-19 pandemic. We believe that many of the medical procedures have been delayed, not canceled, and there is a pent-up demand for these products. We will also continue to work towards development of several new products and to further expand our international sales. In addition, we will continue to work with TI Services on marketing strategies to boost customer service and sales of some nuclear medicine imaging and pharmacy products.

Cost of sales for our nuclear medicine standards segment for the three months ended March 31, 2020, was $472,774, as compared to $471,142 for the same period in 2019. The small increase in cost of sales in the period-to-period comparison of $1,632, or less than 1%, is due to slight increases in material purchased for flood source manufacturing for the three-month period ended March 31, 2020, as compared to the same period in 2019. Gross profit for our nuclear medicine standards segment for the three months ended March 31, 2020 was $569,350 compared to $629,780 for the same period in 2019. This is a decrease in gross profit of $60,430, or approximately 10%. The decrease in gross profit in the period-to-period comparison is primarily the result of the decreased sales.

Operating expense for this segment for the three months ended March 31, 2020 decreased to $401,303, from $422,062 for the same period in 2019. This is a decrease of $20,759, or approximately 5%, and is the result of decreased non-controlling member interest expense as compared to the same period in 2019. Operating expense includes consolidated net operating expense reported for RadQual of $164,943 and non-controlling member interest expense of $42,434, for the three months ended March 31, 2020, as compared to $139,894 of net operating expense and non-controlling member interest expense of $103,390 for the same period in 2019. Net operating expense included for TI Services was $31,162 for the three months ended March 31, 2020, and $32,725 for the same period in 2019. TI Services non-controlling interest included was $2,021 for the three-month period ended March 31, 2020, as compared to $5,102 for the same period in 2019. Net income for this segment for the three months ended March 31, 2020 was $185,301, compared to $216,822 for the same period in 2019. This is a decrease in net income of $31,521, or approximately 15% and is primarily the result of decreased revenue.

Radiological Services. Revenue from all radiological services for the three months ended March 31, 2020 was $72,321, compared to $587,609, for the same period in 2019, a decrease of $515,288 or approximately 88%. The majority of our revenue in this segment has been generated by the performance of activities in connection with contracts for the DOE and the International Atomic Energy Agency (IAEA) to support recovery of disused sources and removal of certain devices. The decrease in the revenue for the period comparison is the result of the DOE cancelling and putting on hold all contracts related to this type of work. The Company plans to suspend these activities going forward.

In January 2020, we notified our gemstone processing customer that the service contract with them was being terminated because the volume of gemstones sent for processing did not meet contract minimums. The termination activities and wrap up of this service will continue through the remainder of 2020 and the Company will see a steady decline in revenue from this service as production is wrapped up. We plan to convert the spaces in the facility that had been used to perform this contract work into expanded Nuclear Medicine product manufacturing. The loss in revenue expected from termination of the gemstone processing agreement is expected to be more than compensated for by the expansion of new nuclear medicine source products.

Cost of sales for the three months ended March 31, 2020, was $21,717, as compared to $217,492, for the same period in 2019. Gross profit for this segment for the three months ended March 31, 2020 was $50,605, compared to $370,117, reported for the same period in 2019. The decrease in gross profit of $319,512, or approximately 86%, is the result of the decrease in service contracts completed and reported in this segment for the three months ended March 31, 2020, as compared to the same period in 2019. Operating expense for the three months ended March 31, 2020 was $66,224 as compared to $58,839, reported for the same period in 2019. This increase of $7,385, or approximately 13%, is the result of increased professional fees.

Net loss for this segment for the three months ended March 31, 2020 was $14,929, compared to net income of $311,279, for the same period in 2019. This is a decrease in net income of $326,207, or approximately 105% and is the result in the decrease in revenue related to DOE contracts.

Fluorine Products. For the three months ended March 31, 2020, we had revenues related to Fluorine Products of $160,500. These revenues were related to an agreement to provide engineering and technical assistance services related to our fluorine products intellectual property. There was no revenue to report from the fluorine products segment for the three months ended March 31, 2019. During the three months ended March 31, 2020, we incurred $37,630 of expense related to items in support of future planning and design for the proposed de-conversion facility, as compared to $37,495 for the same three-month period in 2019. This is an increase of less than 1% in the period-to-period comparison.

We established the Fluorine Products segment in 2004 to support production and sale of the gases produced using our FEP. The project has been placed on hold since 2013 and we will continue to limit our expenditures to essential items such as maintenance of the NRC license, land use agreements, communication with our prospective FEP product customers, and interface with the State of New Mexico and Lea County officials until such time that we decide to resume the project.

LIQUIDITY AND CAPITAL RESOURCES

At March 31, 2020, we had cash and cash equivalents of $568,656 as compared to $575,422 at December 31, 2019. This is a decrease of $6,766 or approximately 1%. For the three months ended March 31, 2020, net cash used in operating activities was $88,240 and for the three months ended March 31, 2019, net cash used in operating activities was $420,576. The decrease in cash used in operating activities and decrease in cash and cash equivalents at period end in the period-to-period comparison is the result of decreased accounts receivable.

Inventories at March 31, 2020 totaled $3,379,373, and inventories at December 31, 2019 totaled $3,423,420. A significant amount of our inventory consists of work-in-process cobalt raw material held at the ATR located outside of Idaho Falls, Idaho. At March 31, 2020, this raw cobalt material inventory accounted for approximately 89% of our work-in-process inventory. At December 31, 2019, this in-process raw material inventory accounted for approximately 89% of our work in process inventory. We periodically evaluate the carrying value of our raw materials to determine their future market value to the Company. As of March 31, 2020, we determined that no impairment of this raw material inventory was necessary.

Cash used in investing activities was $1,565 for the three months ended March 31, 2020, and cash used in investing activities was $5,084 for the same period in 2019. The cash used for the three months ended March 31, 2020, and for the same period in 2019, was for the purchase of equipment.

Financing activities provided cash of $85,361, during the three months ended March 31, 2020, and cash used by financing activities for the same period in 2019 was $358. During the three months ended March 31, 2020, cash paid for interest was $60,205 and during the same three-month period in 2019, cash paid for interest was $59,127. Additionally, during the three months ended March 31, 2020, we received $6,666 in proceeds from the sale of our common stock through our Employee Stock Purchase Plan, as compared to $1,581 for the same period in 2019.

In February 2017, we entered into subscription agreements with certain investors, including two of our directors, for the sale of (i) an aggregate of 3,433 shares of Series C Preferred Stock, and (ii) Class M warrants to purchase an aggregate of 17,165,000 shares of our common stock (Class M Warrants), for gross proceeds of $3,433,000. The Series C Preferred Stock accrues dividends at a rate of 6% per annum, payable annually on February 17th of each year, commencing on February 17, 2018. Shares of Series C Preferred Stock are convertible at the option of the holder at any time into shares of our common stock at an initial conversion price equal to $0.10 per share, subject to adjustment. If the volume-weighted average closing price of our common stock over a period of 90 consecutive trading days is greater than $0.25 per share, we may redeem all or any portion of the outstanding Series C Preferred Stock at the original purchase price per share plus any accrued and unpaid dividends, payable in shares of common stock. All outstanding shares of Series C Preferred Stock must be redeemed by us on February 17, 2022 at the original purchase price per share, payable in cash or shares of common stock, at the option of the holder. Holders of Series C Preferred Stock do not have any voting rights, except as required by law and in connection with certain events as set forth in the Statement of Designation of the Series C Preferred Stock. The Class M Warrants are immediately exercisable at an exercise price of $0.12 per share, subject to adjustment as set forth in the warrant, and have a term of five years.

In February 2020, the Company paid its second annual dividend on the Series C Preferred Stock. Dividends payable totaled $251,280. Some holders of the Series C Preferred Stock elected to settle their dividend payments with shares of the Company’s common stock in lieu of cash. The Company issued 3,408,000 shares of common stock in lieu of a dividend payment of $204,480. The remaining $46,800 of dividend payable was settled with cash.

Total decrease in cash for the three-month period ended March 31, 2020, was $4,444 compared to a cash decrease of $426,018 for the same period in 2019.

We expect that cash from operations, cash raised via equity financing, and our current cash balance will be sufficient to fund operations for the next twelve months. Our future liquidity and capital funding requirements will depend on numerous factors, including, contract manufacturing agreements, commercial relationships, technological developments, market factors, available credit, and voluntary warrant redemption by shareholders. There is no assurance that additional capital and financing will be available on acceptable terms to the Company or at all, especially in light of the market volatility and uncertainty as a result of the COVID-19 outbreak.

At March 31, 2020, there were 50,090,000 outstanding warrants to purchase our common stock. Included in this number are 17,165,000 Class M Warrants issued February 17, 2017, with an exercise price of $0.12 per share and an expiration date of February 17, 2022; and, 2,925,000 Class N Warrants issued May 12, 2017, with an exercise price of $0.10 per share and an expiration date of May 12, 2022; and, 30,000,000 Class O Warrants issued December 30, 2019, with an exercise price of $0.045 and an expiration date of December 30, 2024.

Debt

At March 31, 2020, accrued interest payable on the 2013 Promissory Note totaled $189,234.

At March 31, 2020, accrued interest on the 2018 Promissory Note totaled $13,970.

In December 2019, we entered into a promissory note agreement with our Chief Executive Officer, Chairman of the Board, former Chairman of the Board, and one of our major shareholders (the 2019 Promissory Note). The 2019 Promissory Note authorizes us to borrow up to $1,000,000. As of December 31, 2019, we had borrowed $675,000 under the 2019 promissory note. In February 2020, we borrowed an additional $325,000. The 2019 Promissory Note is secured and bears interest at 4% per annum and has a maturity date of December 31, 2022. According to the terms of the 2019 Promissory Note, at any time, a holder of the 2019 Promissory Note may elect to have any or all of the principal and accrued interest settled with shares of our common stock based on the average price of the shares over the previous 20 trading days. In connection with the 2019 Promissory Note, we issued 30,000,000 Class O Warrants to purchase shares of our common stock at $0.045 per share (the Class O Warrants). The warrants are exercisable at an exercise price of $0.045 per share and have a term of five years. At March 31, 2020, accrued interest on the 2019 Promissory Note totaled $9,131.

OFF-BALANCE SHEET ARRANGEMENTS

As of March 31, 2020, we had no off-balance sheet arrangements or obligations.

CRITICAL ACCOUNTING POLICIES

From time-to-time, management reviews and evaluates certain accounting policies that are considered to be significant in determining our results of operations and financial position.

A description of the Company’s critical accounting policies that affect the preparation of the Company’s financial statements is set forth in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, filed with the SEC on March 30, 2020.

ITEM 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

We maintain disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the Exchange Act), that are designed to ensure that material information relating to us is made known to the officers who certify our financial reports and to other members of senior management and the Board of Directors. These disclosure controls and procedures are designed to ensure that information required to be disclosed in our reports that are filed or submitted under the Exchange Act are recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is accumulated and communicated to our management, including our principal executive and principal financial officers, or persons performing similar functions, as appropriate, to allow timely decisions regarding required disclosure.

Management, with the participation of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness, as of March 31, 2020, of our disclosure controls and procedures. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective as of March 31, 2020.

Changes in Internal Control over Financial Reporting

There have been no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the quarter ended March 31, 2020 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II – OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

We were not a party to any legal proceedings that we believe to be material and we are not aware of any pending or threatened litigation against us that we believe could have a material adverse effect on our business, operating results, financial condition, or cash flows.

ITEM 1A. RISK FACTORS

There have been no material changes or updates to the risk factors previously disclosed in Item 1A. “Risk Factors” of our Annual Report on Form 10-K for the year ended December 31, 2019.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

None.

ITEM 6. EXHIBITS

Exhibit No.	Description

3.1	Restated Certificate of Formation, as amended (incorporated by reference to Exhibit 3.1 of the Company’s Quarterly Report on Form 10-Q for quarter ended June 30, 2010).

3.2	Statement of Designation of the Series C Convertible Redeemable Preferred Stock of International Isotopes Inc. (incorporated by reference to Exhibit 3.1 of the Company’s Current Report on Form 8-K filed on February 24, 2017).

3.3	Bylaws (incorporated by reference to Exhibit 3.2 of the Company's Registration Statement on Form SB-2 filed on May 1, 1997 (Registration No. 333-26269)).

31.1	Certification by the Chief Executive Officer under Section 302 of the Sarbanes-Oxley Act of 2002.*

31.2	Certification by the Chief Financial Officer under Section 302 of the Sarbanes-Oxley Act of 2002.*

32.1	Certification by the Chief Executive Officer furnished pursuant to 18 U.S.C. Section 1350 adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.**

32.2	Certification by the Chief Financial Officer furnished pursuant to 18 U.S.C. Section 1350 adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.**

101	The following financial statements, formatted in XBRL: (i) Unaudited Condensed Consolidated Balance Sheets as of March 31, 2020 and December 31, 2019, (ii) Unaudited Condensed Consolidated Statements of Operations for the three months ended March 31, 2020 and 2019, (iii) Unaudited Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2020 and 2019 and (iv) Notes to Unaudited Condensed Consolidated Financial Statements.*

_______________

* Filed herewith.

** Furnished herewith.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date: May 20, 2020	International Isotopes Inc.


	By:	/s/ Steve T. Laflin
		Steve T. Laflin
		President and Chief Executive Officer


	By:	/s/ W. Matthew Cox
		W. Matthew Cox
		Chief Financial Officer

EX-31.1 2 exhibit311.htm EXHIBIT 31.1 Exhibit 31.1

Exhibit 31.1

CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES OXLEY ACT OF 2002

I, Steve T. Laflin, certify that:

1. I have reviewed this quarterly report on Form 10-Q of International Isotopes Inc.;

2 Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15 (e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15 (f) and 15d-15 (f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 20, 2020

/s/ Steve T. Laflin

Steve T Laflin, Chief Executive Officer

EX-31.2 3 exhibit312.htm EXHIBIT 31.2 Exhibit 31.2

Exhibit 31.2

CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES OXLEY ACT OF 2002

I, W. Matthew Cox, certify that:

1. I have reviewed this quarterly report on Form 10-Q of International Isotopes Inc.;

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 20, 2020

/s/ W. Matthew Cox

W. Matthew Cox, Chief Financial Officer

EX-32.1 4 exhibit321.htm EXHIBIT 32.1 Exhibit 32.1

Exhibit 32.1

CERTIFICATION PURSUANT TO SECTION 906 OF THE SARBANES OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of International Isotopes Inc. and subsidiaries (the “Company”) for the period ended March 31, 2020, as filed with the Securities and Exchange Commission (the “Form 10-Q”), I, Steve T. Laflin, Chief Executive Officer of the Company, in my capacity as such, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

(1)

The Form 10-Q fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended (15 U.S.C. 78m or 78o(d)); and

(2)

The information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.

May 20, 2020	/s/ Steve T. Laflin
	Steve T. Laflin
	Chief Executive Officer

EX-32.2 5 exhibit322.htm EXHIBIT 32.2 Exhibit 32.2

Exhibit 32.2

CERTIFICATION PURSUANT TO SECTION 906 OF THE SARBANES OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of International Isotopes Inc. and subsidiaries (the “Company”) for the period ended March 31, 2020, as filed with the Securities and Exchange Commission (the “Form 10-Q”), I, W. Matthew Cox, Chief Financial Officer of the Company, in my capacity as such, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

(1)

The Form 10-Q fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended (15 U.S.C. 78m or 78o(d)); and

(2)

The information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.

May 20, 2020	/s/ W. Matthew Cox
	W. Matthew Cox
	Chief Financial Officer

EX-101.INS 6 inis-20200331.xml XBRL INSTANCE FILE 0001038277 2020-01-01 2020-03-31 0001038277 2019-12-31 0001038277 2018-12-31 0001038277 2020-03-31 0001038277 2019-01-01 2019-03-31 0001038277 2019-03-31 0001038277 inis:TiServicesLlcMember 2020-03-31 0001038277 inis:RadqualLlcMember 2020-03-31 0001038277 us-gaap:SeriesBPreferredStockMember 2020-01-01 2020-03-31 0001038277 us-gaap:SeriesBPreferredStockMember 2020-03-31 0001038277 us-gaap:SeriesBPreferredStockMember 2019-01-01 2019-03-31 0001038277 us-gaap:SeriesBPreferredStockMember 2019-03-31 0001038277 us-gaap:SeriesCPreferredStockMember 2019-01-01 2019-03-31 0001038277 us-gaap:SeriesCPreferredStockMember 2019-03-31 0001038277 us-gaap:SeriesCPreferredStockMember 2020-01-01 2020-03-31 0001038277 us-gaap:SeriesCPreferredStockMember 2020-03-31 0001038277 us-gaap:StockOptionMember 2020-01-01 2020-03-31 0001038277 us-gaap:StockOptionMember 2019-01-01 2019-03-31 0001038277 us-gaap:WarrantMember 2020-01-01 2020-03-31 0001038277 us-gaap:WarrantMember 2019-01-01 2019-03-31 0001038277 inis:RadqualLlcMember srt:AffiliatedEntityMember 2017-08-31 0001038277 inis:EmployeeStockOwnershipMember 2020-01-01 2020-03-31 0001038277 inis:EmployeeStockOwnershipMember 2020-03-31 0001038277 inis:EmployeeStockOwnershipMember 2019-01-01 2019-03-31 0001038277 inis:TwoThousandFifteenIncentivePlanMember 2020-03-31 0001038277 inis:TwoThousandFifteenIncentivePlanMember srt:ChiefExecutiveOfficerMember 2020-01-01 2020-03-31 0001038277 inis:TwoThousandFifteenIncentivePlanMember srt:ChiefExecutiveOfficerMember 2020-03-31 0001038277 inis:EquityIncentivePlanMember 2020-01-01 2020-03-31 0001038277 inis:ClassmWarrantsMember 2019-01-01 2019-03-31 0001038277 inis:ClassmWarrantsMember 2019-03-31 0001038277 inis:ClassmWarrantsMember 2020-01-01 2020-03-31 0001038277 inis:ClassmWarrantsMember 2020-03-31 0001038277 inis:ClassnWarrantsMember 2019-01-01 2019-03-31 0001038277 inis:ClassnWarrantsMember 2019-03-31 0001038277 inis:ClassnWarrantsMember 2020-01-01 2020-03-31 0001038277 inis:ClassnWarrantsMember 2020-03-31 0001038277 inis:ClassoWarrantsMember 2020-01-01 2020-03-31 0001038277 inis:ClassoWarrantsMember 2020-03-31 0001038277 inis:PromissoryNote2013Member inis:FormerBoardOfDirectorsChairmanMember 2016-01-01 2016-12-31 0001038277 inis:PromissoryNote2013Member inis:FormerBoardOfDirectorsChairmanMember 2013-01-01 2013-12-31 0001038277 inis:PromissoryNote2013Member inis:FormerBoardOfDirectorsChairmanMember 2013-12-31 0001038277 inis:PromissoryNote2018Member inis:CeoAndChairmanMember 2019-01-01 2019-12-31 0001038277 inis:PromissoryNote2018Member inis:CeoAndChairmanMember 2018-01-01 2018-12-31 0001038277 inis:PromissoryNote2018Member inis:CeoAndChairmanMember 2018-12-31 0001038277 inis:ContaminationEventMember 2019-01-01 2019-12-31 0001038277 inis:ContaminationEventMember 2019-12-31 0001038277 inis:RadiochemicalProductsMember country:US 2019-01-01 2019-03-31 0001038277 inis:RadiochemicalProductsMember country:US 2020-01-01 2020-03-31 0001038277 inis:RadiochemicalProductsMember us-gaap:NonUsMember 2019-01-01 2019-03-31 0001038277 inis:RadiochemicalProductsMember us-gaap:NonUsMember 2020-01-01 2020-03-31 0001038277 inis:RadiochemicalProductsMember 2019-01-01 2019-03-31 0001038277 inis:RadiochemicalProductsMember 2020-01-01 2020-03-31 0001038277 inis:CobaltProductsMember country:US 2019-01-01 2019-03-31 0001038277 inis:CobaltProductsMember country:US 2020-01-01 2020-03-31 0001038277 inis:CobaltProductsMember us-gaap:NonUsMember 2019-01-01 2019-03-31 0001038277 inis:CobaltProductsMember us-gaap:NonUsMember 2020-01-01 2020-03-31 0001038277 inis:CobaltProductsMember 2019-01-01 2019-03-31 0001038277 inis:CobaltProductsMember 2020-01-01 2020-03-31 0001038277 inis:NuclearMedicineProductsMember country:US 2019-01-01 2019-03-31 0001038277 inis:NuclearMedicineProductsMember country:US 2020-01-01 2020-03-31 0001038277 inis:NuclearMedicineProductsMember us-gaap:NonUsMember 2019-01-01 2019-03-31 0001038277 inis:NuclearMedicineProductsMember us-gaap:NonUsMember 2020-01-01 2020-03-31 0001038277 inis:NuclearMedicineProductsMember 2019-01-01 2019-03-31 0001038277 inis:NuclearMedicineProductsMember 2020-01-01 2020-03-31 0001038277 inis:RadiologicalServicesMember country:US 2019-01-01 2019-03-31 0001038277 inis:RadiologicalServicesMember country:US 2020-01-01 2020-03-31 0001038277 inis:RadiologicalServicesMember us-gaap:NonUsMember 2019-01-01 2019-03-31 0001038277 inis:RadiologicalServicesMember us-gaap:NonUsMember 2020-01-01 2020-03-31 0001038277 inis:RadiologicalServicesMember 2019-01-01 2019-03-31 0001038277 inis:RadiologicalServicesMember 2020-01-01 2020-03-31 0001038277 inis:FluorineProductsMember country:US 2019-01-01 2019-03-31 0001038277 inis:FluorineProductsMember country:US 2020-01-01 2020-03-31 0001038277 inis:FluorineProductsMember us-gaap:NonUsMember 2019-01-01 2019-03-31 0001038277 inis:FluorineProductsMember us-gaap:NonUsMember 2020-01-01 2020-03-31 0001038277 inis:FluorineProductsMember 2019-01-01 2019-03-31 0001038277 inis:FluorineProductsMember 2020-01-01 2020-03-31 0001038277 country:US 2019-01-01 2019-03-31 0001038277 country:US 2020-01-01 2020-03-31 0001038277 us-gaap:NonUsMember 2019-01-01 2019-03-31 0001038277 us-gaap:NonUsMember 2020-01-01 2020-03-31 0001038277 inis:CobaltProductsMember 2020-03-31 0001038277 inis:CobaltProductsMember 2019-12-31 0001038277 us-gaap:OperatingSegmentsMember inis:RadiochemicalProductsMember 2019-01-01 2019-03-31 0001038277 us-gaap:OperatingSegmentsMember inis:RadiochemicalProductsMember 2020-01-01 2020-03-31 0001038277 us-gaap:OperatingSegmentsMember inis:RadiochemicalProductsMember 2020-03-31 0001038277 us-gaap:OperatingSegmentsMember inis:RadiochemicalProductsMember 2019-12-31 0001038277 us-gaap:OperatingSegmentsMember inis:CobaltProductsMember 2019-01-01 2019-03-31 0001038277 us-gaap:OperatingSegmentsMember inis:CobaltProductsMember 2020-01-01 2020-03-31 0001038277 us-gaap:OperatingSegmentsMember inis:CobaltProductsMember 2020-03-31 0001038277 us-gaap:OperatingSegmentsMember inis:CobaltProductsMember 2019-12-31 0001038277 us-gaap:OperatingSegmentsMember inis:NuclearMedicineStandardsMember 2019-01-01 2019-03-31 0001038277 us-gaap:OperatingSegmentsMember inis:NuclearMedicineStandardsMember 2020-01-01 2020-03-31 0001038277 us-gaap:OperatingSegmentsMember inis:NuclearMedicineStandardsMember 2020-03-31 0001038277 us-gaap:OperatingSegmentsMember inis:NuclearMedicineStandardsMember 2019-12-31 0001038277 us-gaap:OperatingSegmentsMember inis:RadiologicalServicesMember 2019-01-01 2019-03-31 0001038277 us-gaap:OperatingSegmentsMember inis:RadiologicalServicesMember 2020-01-01 2020-03-31 0001038277 us-gaap:OperatingSegmentsMember inis:RadiologicalServicesMember 2020-03-31 0001038277 us-gaap:OperatingSegmentsMember inis:RadiologicalServicesMember 2019-12-31 0001038277 us-gaap:OperatingSegmentsMember inis:FluorineProductsMember 2019-01-01 2019-03-31 0001038277 us-gaap:OperatingSegmentsMember inis:FluorineProductsMember 2020-01-01 2020-03-31 0001038277 us-gaap:OperatingSegmentsMember inis:FluorineProductsMember 2020-03-31 0001038277 us-gaap:OperatingSegmentsMember inis:FluorineProductsMember 2019-12-31 0001038277 us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0001038277 us-gaap:OperatingSegmentsMember 2020-01-01 2020-03-31 0001038277 us-gaap:OperatingSegmentsMember 2020-03-31 0001038277 us-gaap:OperatingSegmentsMember 2019-12-31 0001038277 us-gaap:MaterialReconcilingItemsMember 2019-01-01 2019-03-31 0001038277 us-gaap:MaterialReconcilingItemsMember 2020-01-01 2020-03-31 0001038277 us-gaap:MaterialReconcilingItemsMember 2020-03-31 0001038277 us-gaap:MaterialReconcilingItemsMember 2019-12-31 0001038277 us-gaap:CommonStockMember 2019-01-01 2019-03-31 0001038277 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0001038277 us-gaap:CommonStockMember 2018-12-31 0001038277 us-gaap:CommonStockMember 2019-03-31 0001038277 us-gaap:CommonStockMember 2019-12-31 0001038277 us-gaap:CommonStockMember 2020-03-31 0001038277 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-03-31 0001038277 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0001038277 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001038277 us-gaap:AdditionalPaidInCapitalMember 2019-03-31 0001038277 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001038277 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0001038277 us-gaap:RetainedEarningsMember 2019-01-01 2019-03-31 0001038277 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0001038277 us-gaap:RetainedEarningsMember 2018-12-31 0001038277 us-gaap:RetainedEarningsMember 2019-03-31 0001038277 us-gaap:RetainedEarningsMember 2019-12-31 0001038277 us-gaap:RetainedEarningsMember 2020-03-31 0001038277 us-gaap:ParentMember 2019-01-01 2019-03-31 0001038277 us-gaap:ParentMember 2020-01-01 2020-03-31 0001038277 us-gaap:ParentMember 2018-12-31 0001038277 us-gaap:ParentMember 2019-03-31 0001038277 us-gaap:ParentMember 2019-12-31 0001038277 us-gaap:ParentMember 2020-03-31 0001038277 us-gaap:NoncontrollingInterestMember 2019-01-01 2019-03-31 0001038277 us-gaap:NoncontrollingInterestMember 2020-01-01 2020-03-31 0001038277 us-gaap:NoncontrollingInterestMember 2018-12-31 0001038277 us-gaap:NoncontrollingInterestMember 2019-03-31 0001038277 us-gaap:NoncontrollingInterestMember 2019-12-31 0001038277 us-gaap:NoncontrollingInterestMember 2020-03-31 0001038277 inis:PromissoryNote2013Member inis:FormerBoardOfDirectorsChairmanMember 2014-01-01 2014-12-31 0001038277 inis:PromissoryNote2013Member inis:FormerBoardOfDirectorsChairmanMember 2014-12-31 0001038277 inis:PromissoryNote2013Member inis:FormerBoardOfDirectorsChairmanMember 2017-01-01 2017-12-31 0001038277 inis:PromissoryNote2013Member inis:FormerBoardOfDirectorsChairmanMember 2018-01-01 2018-12-31 0001038277 inis:PromissoryNote2013Member inis:FormerBoardOfDirectorsChairmanMember 2020-01-01 2020-03-31 0001038277 inis:PromissoryNote2013Member inis:FormerBoardOfDirectorsChairmanMember 2020-03-31 0001038277 inis:PromissoryNote2018Member inis:CeoAndChairmanMember 2020-03-31 0001038277 inis:NoteAgreementMember 2019-01-01 2019-12-31 0001038277 inis:NoteAgreementMember 2019-12-31 0001038277 inis:PromissoryNote2019Member inis:MajorShareholdersMember 2019-01-01 2019-12-31 0001038277 inis:PromissoryNote2019Member inis:MajorShareholdersMember 2019-12-31 0001038277 inis:PromissoryNote2019Member inis:MajorShareholdersMember 2020-01-01 2020-03-31 0001038277 inis:PromissoryNote2019Member inis:MajorShareholdersMember 2020-03-31 0001038277 us-gaap:SubsequentEventMember inis:SbaPaycheckProtectionProgramMember 2020-04-22 2020-04-23 0001038277 us-gaap:SubsequentEventMember inis:SbaPaycheckProtectionProgramMember 2020-04-23 0001038277 2020-05-15 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure inis:Integer 10-Q false 2020-03-31 Q1 2020 --12-31 INTERNATIONAL ISOTOPES INC 0001038277 Yes Non-accelerated Filer true false 423794088

575422

568656

398604

875914

1024044

3423420

3379373

1444593

1399325

6319349

6371398

635498

637820

625845

2003887

1970872

13302

12625

709883

2630830

1384255

4190621

4150584

8937446

10786986

15256795

17158384

536603

511381

3388527

3369828

2087295

2111225

96427

106374

5482993

5477808

11591845

11576616

5566539

3680179

4229128

4292161

1096090

968021

1240205

1213927

1240705

100777

87158

2367

2407

1519496

1738845

8188063

8302519

1216874

891802

12276

10057

10970

10353

609106

2549772

4785086

4817170

850000

7180882

8835824

15368945

17138343

4198423

4237092

121680163

122151722

-128064385

-128486879

-2185799

-2098065

2073649

2118106

-112150

154134

20041

481966

4131683

4169127

4198423

4237092

120805997

121039851

121680163

122151722

-126541421

-126593379

-128064385

-128486879

-1603741

-1384401

-2185799

-2098065

1757875

1866367

2073649

2118106

15256795

17158384

0.50

0.245

0.755

-422494

-51958

96006

5619

192870

123796

216822

185301

311279

-14929

-37495

122870

779481

422657

-831439

-845151

-88240

-420576

NRC license for the de-conversion facility for a 40 year operating license.

850

4213

425000

42130000

850

4213

23655000

27205000

50090000

20090000

000-22923 TX Yes false

0.01

750000000

419842256

423709226

419842256

423709226

40648

3379943

3334886

2829

3839

201349

11000

94000

23655000

27205000

17936000

0.05

P6Y1M

P5Y7M

235000

318316

34135593

156845

31618

156845

6666

1581

80000000

500000

28000

302125

279767

302125

0.056

0.06

197875

51522

63737

18128

50090000

20090000

17165000

2925000

30000000

0.12

0.10

0.045

0.06

0.045

2022-02-17 2022-02-17 2022-05-12 2022-05-12 2024-12-30

2022-05-31

2022-02-28

1000

2.00 0.10

252780

251280

205980

204480

46800

3433000

3408000

59808

2014-06-30

2017-12-31

2020-12-31

2021-12-31

2022-04-22

The due date of the $500,000 note was extended to December 31, 2022, with all other terms of the note remaining unchanged.

500000

189234

13970

9181

0.06

0.04

2022-12-31

2021-12-31

2019-03-31

2022-12-31

7500

2182142

120000

637820

In August 2011, the Company received land from Lea County, New Mexico, pursuant to a Project Participation Agreement (PPA), whereby the land was deeded to the Company for no monetary consideration. In return, we committed to construct a uranium de-conversion and Fluorine Extraction Process (FEP) facility on the land. In order to retain title to the property, we were to begin construction of the de-conversion facility no later than December 31, 2014, and complete Phase I of the project and have hired at least 75 persons to operate the facility no later than December 31, 2015, although commercial operations need not have begun by that date. In 2015, the Company negotiated a modification to the PPA agreement that extended the start of construction date to December 31, 2015, and the hiring milestone to December 31, 2016. Those dates were not met and the Company is currently in the process of renegotiating a second modification to the agreement to further extend those dates. If the Company is not successful in extending the performance dates in the agreement then it may, at its sole option, either purchase or re-convey the property to Lea County, New Mexico. The purchase price of the property would be $776,078, plus interest at the annual rate of 5.25% from the date of the closing to the date of payment. The Company has not recorded the value of this property as an asset and will not do so until such time that sufficient progress on the project has been made to meet our obligations under the agreements for permanent transfer of the title.

2384255

964958

1244744

2335786

2527852

459967

668591

3265

86630

463232

755221

336089

305620

40000

376089

305620

1080472

867604

20450

174520

1100922

1042124

587609

72321

587609

72321

160500

2464137

2074636

63715

261150

463232

755221

376089

305620

1100922

1042124

587609

72321

160500

2527852

2335786

1.00 1.00 0.18 0.32 0.15 0.13 0.44 0.45 0.23 0.03 0.00 0.07

68400

36853

8876

1902

2649070

810367

P14Y10M

P7Y

0.0675

74617

64985

8817

10354

1080

8761

15619

15989

8636

26095

60248

69835

4737

4782

1565

5084

3494

1590

1565

5084

1565

546570

556670

968525

1088429

1367261

1439423

741205

623699

788438

626863

46928

46304

1576571

1296866

-209310

142557

23818

24632

2335

3422

194880

114077

-168727

-86023

-378037

56534

-51958

-422494

-51958

-422494

108492

44457

108492

420692023

413906700

420692023

413906700

103770

64985

10100 9387

92430

38788

51522

63737

148130

536554

-44047

320397

-45268

-27797

117068

222378

-26278

-47231

1565

5084

-1565

-5084

6666

1581

577

325000

245728

1939

85361

-358

-4444

-426018

1210920

1450467

1206476

1024449

60205

59127

204480

205980

34330

34080

171650

170400

205980

204480

247560

1206476 1024449 2649070

413168301

416912686

419842256

423709226

6666

1581

316

1568

1265

5098

1581

6666

2798

3021

-2798

-3021

3433000

3408000

51522

63737

51522

63737

51522

102584

144976

(1)       The Company and Basis of Presentation   International Isotopes Inc. (INIS) was incorporated in Texas in November 1995. The accompanying unaudited condensed consolidated financial statements are presented in conformity with accounting principles generally accepted in the United States of America (GAAP) and include all operations and balances of INIS and its wholly owned subsidiaries. The unaudited condensed consolidated financial statements also include the accounts of INIS’s 50% owned joint venture, TI Services, LLC (TI Services), and the accounts of INIS’s 24.5% interest in RadQual, LLC (RadQual). TI Services is headquartered in Youngstown, Ohio and was formed with RadQual in December 2010 to distribute products and services for nuclear medicine, nuclear cardiology and Positron Emission Tomography (PET) imaging. RadQual is a global supplier of molecular imaging quality control and calibration devices, and is headquartered in Idaho Falls, Idaho. In August 2017, affiliates of INIS purchased 75.5% of RadQual and at the time INIS was named as one of the two managing members of RadQual. As a result of this ownership change, INIS has significant influence in management decisions with regard to RadQual’s business operations. INIS, its wholly owned subsidiaries, TI Services, and RadQual are collectively referred to herein as the “Company,” “we,” “our” or “us.”   Nature of Operations – INIS and its subsidiaries, TI Services and RadQual, manufacture a full range of nuclear medicine calibration and reference standards, generic sodium iodide I-131 drug product, cobalt teletherapy sources, and a varied selection of radiochemicals for medical research, and clinical applications. The Company also offers contract manufacturing services for certain pharmaceutical products. The Company’s business consists of five business segments: Nuclear Medicine Standards, Cobalt Products, Radiochemical Products, Fluorine Products, and Radiological Services. The Company’s headquarters and all operations, with the exception of TI Services, are located in Idaho Falls, Idaho.   With the exception of certain unique products, the Company’s normal operating cycle is considered to be one year. Due to the time required to produce some cobalt products, the Company’s operating cycle for those products is considered to be two to three years. Accordingly, preliminary payments received on cobalt contracts, where shipment will not take place for greater than one year, have been recorded as unearned revenue and, depending upon estimated ship dates, classified under either current or long-term liabilities on the Company’s consolidated balance sheets. These unearned revenues are being recognized as revenue in the periods during which the cobalt shipments take place. All assets expected to be realized in cash or sold during the normal operating cycle of business are classified as current assets.   Principles of Consolidation – The accompanying unaudited condensed consolidated financial statements are presented in conformity with GAAP and include all operations and balances of INIS and its wholly-owned subsidiaries. The Company also consolidates the accounts of RadQual into the accompanying unaudited condensed consolidated financial statements. See Note 4 “Investment and Business Consolidation” for additional information regarding RadQual. All significant intercompany accounts and transactions have been eliminated in consolidation.   Interim Financial Information – The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with GAAP for interim financial information and pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (SEC). Accordingly, the accompanying unaudited condensed consolidated financial statements do not include all of the information and notes required by GAAP for complete financial statements. In the opinion of management, all adjustments and reclassifications considered necessary in order to make the financial statements not misleading and for a fair and comparable presentation have been included and are of a normal recurring nature. Operating results for the three-month period ended March 31, 2020 are not necessarily indicative of the results that may be expected for the year ending December 31, 2020 or any future periods. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the Company’s Annual Report on Form 10-K for the year ended December 31, 2019 filed with the SEC on March 30, 2020.

(2)       Current Developments and Liquidity   Business Condition – Since inception, the Company has incurred substantial losses. During the three-months ended March 31, 2020, the Company reported a net loss of $422,494, net of non-controlling interest, and net cash used in operating activities of $88,240.   During the three-months ended March 31, 2019, the Company reported net loss of $51,958, net of non-controlling interest, and net cash used in operating activities of $420,576.   During the three-months ended March 31, 2020, the Company continued its focus on its long-standing core business segments which consist of its radiochemical products, cobalt products, nuclear medicine standards, and radiological services, and in particular, the pursuit of new business opportunities within those segments. During this period the Company received approval from the U.S. Food and Drug Administration (FDA) for a generic sodium iodide I-131 drug product. This product is approved for use in treatment of hyperthyroidism and carcinoma of the thyroid and is the first generic product approved by the FDA in the US.   Additionally, the Company holds a Nuclear Regulatory Commission (NRC) construction and operating license for the depleted uranium facility in, as well as the property agreement with, Lea County, New Mexico, where the plant is intended to be constructed. The NRC license for the de-conversion facility is a forty (40) year operating license and is the first commercial license of this type issued in the United States.  There are no other companies with a similar license application under review by the NRC. Therefore, the NRC license represents a significant competitive barrier and the Company considers it a valuable asset.   The Company expects that cash from operations, cash raised through equity or debt financing and its current cash balance will be sufficient to fund operations for the next twelve months. Future liquidity and capital funding requirements will depend on numerous factors, including, contract manufacturing agreements, commercial relationships, technological developments, market factors, available credit, and voluntary warrant redemption by shareholders. There is no assurance that additional capital and financing will be available on acceptable terms to the Company or at all.

(3)       Net Income (Loss) Per Common Share - Basic and Diluted   For the three-months ended March 31, 2020, the Company had 23,655,000 stock options outstanding, 50,090,000 warrants outstanding, 4,213 outstanding shares of Series C redeemable convertible preferred stock (Series C Preferred Stock), and 850 outstanding shares of Series B redeemable convertible preferred stock (Series B Preferred Stock), each of which were not included in the computation of diluted income (loss) per common share because they would be anti-dilutive.   For the three-months ended March 31, 2019, the Company had 27,205,000 stock options outstanding, 20,090,000 warrants outstanding, 4,213 outstanding shares of Series C Preferred Stock, and 850 outstanding shares of Series B Preferred Stock, each of which were not included in the computation of diluted income per common share because they would be anti-dilutive.   The table below summarizes common stock equivalents outstanding at March 31, 2020:   <table cellspacing="0" cellpadding="0" style="font: 9pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: right; font-size: 10pt"> </td> <td style="padding-bottom: 1pt; font-size: 8.5pt; font-weight: bold"> </td> <td colspan="6" style="border-bottom: black 1pt solid; text-align: center; font-size: 8.5pt; font-weight: bold">March 31,</td> <td style="padding-bottom: 1pt; font-size: 8.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: right; font-size: 10pt"> </td> <td style="padding-bottom: 1pt; font-size: 8.5pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-size: 8.5pt; font-weight: bold">2020</td> <td style="padding-bottom: 1pt; font-size: 8.5pt; font-weight: bold"> </td> <td style="padding-bottom: 1pt; font-size: 8.5pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-size: 8.5pt; font-weight: bold">2019</td> <td style="padding-bottom: 1pt; font-size: 8.5pt; font-weight: bold"> </td></tr> <tr style="background-color: rgb(235,235,255); vertical-align: bottom"> <td style="text-align: left; width: 72%">Stock options</td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%"> </td> <td style="text-align: right; width: 11%">23,655,000</td> <td style="text-align: left; width: 1%"> </td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%"> </td> <td style="text-align: right; width: 11%">27,205,000</td> <td style="text-align: left; width: 1%"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td>Warrants</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">50,090,000</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">20,090,000</td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(235,235,255); vertical-align: bottom"> <td style="text-align: left">850 Shares of Series B redeemable convertible preferred stock</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">425,000</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">425,000</td> <td style="text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left; padding-bottom: 1pt">4,213 Shares of Series C redeemable convertible preferred stock</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">42,130,000</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">42,130,000</td> <td style="text-align: left; padding-bottom: 1pt"> </td></tr> <tr style="background-color: rgb(235,235,255); vertical-align: bottom"> <td style="text-align: right; padding-bottom: 2.5pt; font-size: 12pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left"> </td> <td style="border-bottom: black 2.5pt double; text-align: right">116,300,000</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left"> </td> <td style="border-bottom: black 2.5pt double; text-align: right">89,850,000</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td></tr> </table>

(4)       Investment and Business Consolidation   The Company owns a 24.5% interest in RadQual, with which the Company has an exclusive manufacturing agreement for nuclear medicine products. In August 2017, affiliates of the Company, including the Company’s Chairman of the Board and the Chief Executive Officer, acquired the remaining 75.5% interest in RadQual. The Company’s Chairman of the Board and its Chief Executive Officer also each serve as the managing members of RadQual. As a result of this change in ownership, and other factors, the Company determined that it gained the ability to exercise significant management control over the operations of RadQual. Because of this increased management control, and pursuant to GAAP, the Company has consolidated the accounts of RadQual into its financial statements.

(5)       Inventories   Inventories consisted of the following at March 31, 2020 and December 31, 2019:   <table cellspacing="0" cellpadding="0" style="font: 9pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: right; font-size: 12pt"> </td> <td style="padding-bottom: 1pt; font-size: 8.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-size: 8.5pt"> March 31, 2020</td> <td style="padding-bottom: 1pt; font-size: 8.5pt"> </td> <td style="padding-bottom: 1pt; font-size: 8.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-size: 8.5pt"> December 31, 2019</td> <td style="padding-bottom: 1pt; font-size: 8.5pt"> </td></tr> <tr style="background-color: rgb(235,235,255); vertical-align: bottom"> <td style="text-align: left; width: 72%">Raw materials</td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%">$</td> <td style="text-align: right; width: 11%">40,648</td> <td style="text-align: left; width: 1%"> </td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%">$</td> <td style="text-align: right; width: 11%">40,648</td> <td style="text-align: left; width: 1%"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left">Work in process</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">3,334,886</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">3,379,943</td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(235,235,255); vertical-align: bottom"> <td style="text-align: left; padding-bottom: 1pt">Finished goods</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">3,839</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">2,829</td> <td style="text-align: left; padding-bottom: 1pt"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: right; padding-bottom: 2.5pt; font-size: 12pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">3,379,373</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">3,423,420</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td></tr> </table>   Work in process includes cobalt-60 targets that are located in the U.S. Department of Energy’s (DOE) Advanced Test Reactor (ATR) located outside of Idaho Falls, Idaho. These targets are owned by the Company and contain cobalt-60 material at various stages of irradiation. The carrying value of the targets is based on accumulated irradiation and handling costs which have been allocated to each target based on the length of time the targets have been held and processed at the ATR. At March 31, 2020, and at December 31, 2019, this cobalt target inventory had a carrying value of $201,349.   Work in process also includes costs to irradiate cobalt-60 material under a contract with the DOE. This material has been placed in the ATR and the Company made progress payments to purchase this material. The Company has contracted with several customers for the sale of some of this product material and has collected advance payments for project management, up-front handling, and other production costs from those customers. The advance payments from customers were recorded as unearned revenue which are recognized in the Company’s consolidated financial statements as cobalt products are completed and shipped. For the three-months ended March 31, 2020 and 2019, the Company recognized approximately $11,000 and $94,000, respectively, of revenue in its consolidated statements of operations for customer orders filled during the period under these cobalt contracts.

(6)       Stockholders’ Equity, Options, and Warrants   Employee Stock Purchase Plan   The Company has an employee stock purchase plan pursuant to which employees of the Company may participate to purchase shares of common stock at a discount. During the three-months ended March 31, 2020 and 2019, the Company issued 156,845 and 31,618 shares of common stock, respectively, to employees under the employee stock purchase plan for proceeds of $6,666 and $1,581, respectively. As of March 31, 2020, 318,316 shares of common stock remain available for issuance under the employee stock purchase plan.   Stock-Based Compensation Plans   2015 Incentive Plan - In April 2015, the Company’s Board of Directors approved the International Isotopes Inc. 2015 Incentive Plan (as amended, the 2015 Plan), which was subsequently approved by the Company’s shareholders in July 2015. The 2015 Plan was amended and restated in July 2018 to increase the number of shares authorized for issuance under the 2015 Plan by an additional 20,000,000 shares. The 2015 Plan provides for the grant of incentive and non-qualified stock options, stock appreciation rights, restricted stock, restricted stock units, performance shares and units, and other stock or cash-based awards.  The 2015 Plan amended and restated the Company’s Amended and Restated 2006 Equity Incentive Plan (2006 Plan). The 2015 Plan authorizes the issuance of up to 80,000,000 shares of common stock, plus 11,089,967 shares authorized, but not issued under the 2006 Plan. At March 31, 2020, there were 34,135,593 shares available for issuance under the 2015 Plan.   Employee/Director Grants - The Company accounts for issuances of stock-based compensation to employees by recognizing, as compensation expense, the cost of employee services received in exchange for equity awards. The compensation expense is based on the grant date fair value of the award. Stock option compensation expense is recognized over the period during which an employee is required to provide service in exchange for the award (the vesting period).   Non-Employee Grants - The Company accounts for its issuances of stock-based compensation to non-employees by measuring the value of any awards that were vested and non-forfeitable at their date of issuance based on the grant date fair value of the award. The non-vested portion of awards that are subject to the future performance of the counterparty are adjusted at each reporting date to their fair values based upon the then current market value of the Company’s stock and other assumptions that management believes are reasonable.   Option awards outstanding as of March 31, 2020, and changes during the three-months ended March 31, 2020, were as follows:   <table cellspacing="0" cellpadding="0" style="font: 9pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1pt solid; font-size: 8.5pt; font-weight: bold">Fixed Options</td> <td style="padding-bottom: 1pt; font-size: 8.5pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-size: 8.5pt; font-weight: bold">Shares</td> <td style="padding-bottom: 1pt; font-size: 8.5pt; font-weight: bold"> </td> <td style="padding-bottom: 1pt; font-size: 8.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-size: 8.5pt"> Weighted Average Exercise Price</td> <td style="padding-bottom: 1pt; font-size: 8.5pt"> </td> <td style="padding-bottom: 1pt; font-size: 8.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-size: 8.5pt"> Weighted Average Remaining Contractual Life</td> <td style="padding-bottom: 1pt; font-size: 8.5pt"> </td> <td style="padding-bottom: 1pt; font-size: 8.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-size: 8.5pt"> Aggregate Intrinsic Value</td> <td style="padding-bottom: 1pt; font-size: 8.5pt"> </td></tr> <tr style="background-color: rgb(235,235,255); vertical-align: bottom"> <td style="width: 44%">Outstanding at December 31, 2019</td> <td style="width: 2%"> </td> <td style="text-align: left; width: 1%"> </td> <td style="text-align: right; width: 10%">23,655,000</td> <td style="text-align: left; width: 1%"> </td> <td style="width: 2%"> </td> <td style="text-align: left; width: 1%">$</td> <td style="text-align: right; width: 10%">0.05</td> <td style="text-align: left; width: 1%"> </td> <td style="width: 2%"> </td> <td style="text-align: left; width: 1%"> </td> <td style="text-align: right; width: 10%"> </td> <td style="text-align: left; width: 1%"> </td> <td style="width: 2%"> </td> <td style="text-align: left; width: 1%"> </td> <td style="text-align: right; width: 10%"> </td> <td style="text-align: left; width: 1%"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td>Granted</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">—  </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">—  </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(235,235,255); vertical-align: bottom"> <td>Exercised</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">—  </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">—  </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td>Expired</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">—  </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">—  </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(235,235,255); vertical-align: bottom"> <td style="padding-bottom: 1pt">Forfeited</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">—  </td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left">$</td> <td style="border-bottom: black 1pt solid; text-align: right">—  </td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right"> </td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right"> </td> <td style="text-align: left; padding-bottom: 1pt"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="padding-bottom: 2.5pt">Outstanding at March 31, 2020</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left"> </td> <td style="border-bottom: black 2.5pt double; text-align: right">23,655,000</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">0.05</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left"> </td> <td style="border-bottom: black 2.5pt double; text-align: right">6.1</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">235,000</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td></tr> <tr style="background-color: rgb(235,235,255); vertical-align: bottom"> <td style="padding-bottom: 2.5pt">Exerciseable at March 31, 2020</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left"> </td> <td style="border-bottom: black 2.5pt double; text-align: right">17,936,000</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">0.05</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left"> </td> <td style="border-bottom: black 2.5pt double; text-align: right">5.6</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">235,000</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td></tr> </table>     The intrinsic value of outstanding and exercisable shares is based on the closing price of the Company’s common stock on the OTCQB of $0.06 per share on March 31, 2020, the last trading day of the quarter.   As of March 31, 2020, there was $59,808 of unrecognized compensation expense related to stock options that will be recognized over a weighted-average period of 1.76 years.   Total stock-based compensation expense for the three-months ended March 31, 2020 and 2019 was $51,522 and $63,737 respectively.   Pursuant to an employment agreement with its Chief Executive Officer, the Company awarded 500,000 fully vested shares of common stock to its Chief Executive Officer in February 2020 under the 2015 Plan. The number of shares awarded was based on a $28,000 stock award using a price of $0.056 per share. The employment agreement provides that the number of shares issued will be based on the average closing price of common stock for the 20 trading days prior to issue date but not less than $0.05 per share. Compensation expense recorded pursuant to this stock grant was $18,128, which was determined by multiplying the number of shares awarded by the closing price of the common stock on February 28, 2020, which was $0.06 per share. The Company withheld 197,875 shares of common stock to satisfy the employee’s payroll tax obligations in connection with this issuance. The net shares issued on February 28, 2020 totaled 302,125.   Warrants   Warrants outstanding at March 31, 2020, included 17,165,000 Class M Warrants which are immediately exercisable at an exercise price of $0.12 per share and expire on February 17, 2022; 2,925,000 Class N Warrants which are immediately exercisable at an exercise price of $0.10 per share and expire on May 12, 2022; and 30,000,000 Class O Warrants which are immediately exercisable at an exercise price of $0.045 per share and expire December 30, 2024.   Warrants outstanding at March 31, 2019, included 17,165,000 Class M Warrants which are immediately exercisable at an exercise price of $0.12 per share and expire on February 17, 2022 and 2,925,000 Class N Warrants which are immediately exercisable at an exercise price of $0.10 per share and expire on May 12, 2022.   Preferred Stock   At March 31, 2020, there were 850 shares of the Series B Preferred Stock outstanding with a mandatory redemption date of May 2022 at $1,000 per share or $850,000. The shares of Series B Preferred Stock are also convertible into 425,000 shares of the Company’s common stock at a conversion price of $2.00 per share. These shares of Series B Preferred Stock do not carry any dividend preferences. Due to the mandatory redemption provision, the Series B Preferred Stock has been classified as a liability in the accompanying condensed consolidated balance sheets.   At March 31, 2020, there were 4,213 shares of the Series C Preferred Stock outstanding with a mandatory redemption date of February 2022 at $1,000 per share in either cash or shares of common stock, at the option of the holder. Holders of the Series C Preferred Stock do not have any voting rights except as required by law and in connection with certain events as set forth in the Statement of Designation of the Series C Preferred Stock. The Series C Preferred Stock accrues dividends at a rate of 6% per annum, payable annually on February 17th of each year. The Series C Preferred Stock are convertible at the option of the holders at any time into shares of the Company's common stock at an initial conversion price equal to $0.10 per share, subject to adjustment. If the volume-weighted average closing price of the Company’s common stock over a period of 90 consecutive trading days is greater than $0.25 per share, the Company may redeem all or any portion of the outstanding Series C Preferred Stock at the original purchase price per share plus any accrued and unpaid dividends, payable in shares of common stock.   During the three-months ended March 31, 2020 and 2019 dividends paid to holders of the Series C Preferred Stock totaled $251,280 and $252,780, respectively. Some holders of the Series C Preferred Stock elected to settle their dividend payments with shares of the Company’s common stock in lieu of cash. For the three-months March 31, 2020 and 2019 the Company issued 3,408,000 and 3,433,000 shares of common stock, respectively, in lieu of a dividend payment of $204,480 and $205,980, respectively. The remaining $46,800 of dividend payable was settled with cash.

(7)         Debt   In December 2013, we entered into a promissory note agreement with our then Chairman of the Board and one of our major shareholders, pursuant to which we borrowed $500,000 (the 2013 Promissory Note). The 2013 Promissory Note is secured and bears interest at 6% per annum and was originally due June 30, 2014. According to the terms of the 2013 Promissory Note, at any time, the lenders may settle any or all of the principal and accrued interest with shares of our common stock. In connection with the 2013 Promissory Note, each of the two lenders was issued 5,000,000 Class L warrants to purchase shares of our common stock at an exercise price of $0.06 per share. The warrants were immediately exercisable. In June 2014, we renegotiated the terms of the 2013 Promissory Note. Pursuant to the modification, the maturity date was extended to December 31, 2017 and each lender was granted an additional 7,500,000 Class L warrants to purchases shares of our common stock at an exercise price of $0.06 per share. The warrants were immediately exercisable. In February 2017, the 2013 Promissory Note was further modified to extend the maturity date to December 31, 2020, with all remaining terms unchanged. On December 23, 2018, all 25,000,000 Class L warrants expired. In December 2019, the 2013 Promissory Note was further modified to extend the maturity date to December 31, 2021, with all remaining terms unchanged.   At March 31, 2020, the principal balance of the 2013 Promissory Note was $500,000 and accrued interest payable on the 2013 Promissory Note was $189,234. Interest expense recorded for the three-months ended March 31, 2020, was $7,500.   In April 2018, we borrowed $120,000 from our Chief Executive Officer and Chairman of the Board pursuant to a promissory note (the 2018 Promissory Note). The 2018 Promissory Note accrues interest at 6% per annum, which is payable upon maturity of the 2018 Promissory Note. The 2018 Promissory Note was originally unsecured and originally matured on August 1, 2018. At any time, the holder of the 2018 Promissory Note may elect to have any or all of the principal and accrued interest settled with shares of our common stock based on the average price of the shares over the previous 20 trading days. Pursuant to an amendment to the 2018 Promissory Note in June 2018, the maturity date was extended to March 31, 2019 with all other provisions remaining unchanged. Pursuant to a second amendment to the 2018 Promissory Note in February 2019, the maturity date was extended to July 31, 2019 with all other provisions remaining unchanged. Pursuant to a third amendment to the 2018 Promissory Note in July 2019, the maturity date was extended to January 31, 2020 with all other provisions remaining unchanged. Pursuant to a fourth amendment to the 2018 Promissory Note in December 2019, the maturity date was extended to December 31, 2021, the note was modified to become secured by company assets, with all other provisions remaining unchanged.   At March 31, 2020, accrued interest on the 2018 Promissory Note totaled $13,970.   In April 2019, one of the prepaid revenue customers requested a refund of the amounts paid. The Company entered into a note agreement to repay $2,182,142 over the next 12 months. The modification was necessary to address the delays to cobalt delivery in 2019 caused by changes to the ATR operating schedule and also to accommodate this customer’s request to reduce their cobalt purchase obligations in future years. The modifications require that the Company refund approximately $1,050,000, of payments received for prior year undelivered material, plus interest at 12% per year, payable over a one-year period on a portion of that amount. The Company has also agreed with this customer to refund approximately $1,100,000 paid for material that was to have been delivered in later years. There will be no interest charge on this refund. In December 2019, this agreement was modified further allowing the Company to delay the original payments by 3 months and refund an additional $462,258 with no interest charge.   On December 20, 2019, the Company entered into a promissory note agreement with four of the Company’s major shareholders (the 2019 Promissory Note). The 2019 Promissory Note authorizes the Company to borrow up to $1,000,000. As of December 31, 2019, the Company had borrowed $675,000 under the 2019 promissory note. In February 2020, the Company borrowed an additional $325,000. The 2019 Promissory Note bears an interest rate of 4% annually and is due December 31, 2022. According to the terms of the 2019 Promissory Note, at any time, the lenders may settle any or all of the principal and accrued interest with shares of the Company’s common stock based on the average closing price of the Company’s common stock for the 20 days preceding the payment. In connection with the 2019 Promissory Note, the lenders were issued warrants totaling 30,000,000 warrants to purchase shares of the Company’s common stock at $0.045 per share. The fair value of these warrants issued totaled $446,079 and was recorded as a debt discount and will be amortized over the life of the 2019 Promissory Note. The Company calculated a beneficial conversion feature of $315,643 which will be accreted to interest expense over the life of the 2019 Promissory Note. At March 31, 2020 accrued interest on the 2019 Promissory Note totaled $9,181.   On April 23, 2020, the Company, through its wholly-owned subsidiary entered into a Loan Agreement and Promissory Note (collectively the “SBA Loan”) with KeyBank National Association pursuant to the Paycheck Protection Program (the “PPP”) under the recently enacted Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”) administered by the U.S. Small Business Administration (the “SBA”). The Company received total proceeds of $495,500 from the SBA Loan. The SBA Loan is scheduled to mature on April 22, 2022 and has a 1.00% interest rate and is subject to the terms and conditions applicable to loans administered by the SBA under the CARES Act. The SBA Loan may be prepaid at any time prior to maturity with no prepayment penalties.   The SBA Loan contains customary events of default relating to, among other things, payment defaults and breaches of representations and warranties. Subject to certain conditions, the SBA Loan may be forgiven in whole or in part by applying for forgiveness pursuant to the CARES Act and the PPP. The amount of loan proceeds eligible for forgiveness is based on a formula based on a number of factors, including the amount of loan proceeds used by the Company during the eight-week period after the loan origination for certain purposes, including payroll costs, interest on certain mortgage obligations, rent payments on certain leases, and certain qualified utility payments, provided that, among other things, at least 75% of the loan amount is used for eligible payroll costs, the employer maintaining or rehiring employees and maintaining salaries at certain level. In accordance with the requirements of the CARES Act and the PPP, the Company intends to use the proceeds from the SBA Loan primarily for payroll costs. No assurance can be given that the Company will be granted forgiveness of the SBA Loan in whole or in part.

(8)       Commitments and Contingencies   Dependence on Third Parties   The production of High Specific Activity Cobalt is dependent upon the DOE, and its prime operating contractor, which controls the ATR and laboratory operations at the ATR located outside of Idaho Falls, Idaho. In October 2014, the Company signed a ten-year contract with the DOE for the irradiation of cobalt targets for the production of cobalt-60. The Company will be able to purchase cobalt targets for a fixed price per target with an annual 5% escalation in price. The contract term is October 1, 2014, through September 30, 2024, however, the contract may be extended beyond that date. Also, the DOE may end the contract if it determines termination is necessary for the national defense, security or environmental safety of the United States. If this were to occur, all payments made by the Company, for partially irradiated undelivered cobalt material, would be refunded.   Nuclear Medicine Reference and Calibration Standard manufacturing is conducted under an exclusive contract with RadQual, which in turn has an agreement in place with several companies for distributing the products. The radiochemical product sold by the Company is supplied to the Company through agreements with several suppliers. A loss of any of these customers or suppliers could adversely affect operating results by causing a delay in production or a possible loss of sales.   (8) Contingencies   Because all the Company’s business segments involve the handling or use of radioactive material, the Company is required to have an operating license from the NRC and specially trained staff to handle these materials. The Company has amended this operating license numerous times to increase the amount of material permitted within the Company’s facility. Although this license does not currently restrict the volume of business operations performed or projected to be performed in the upcoming year, additional processing capabilities and license amendments could be implemented that would permit processing of other reactor-produced radioisotopes by the Company. The financial assurance required by the NRC to support this license has been provided for with a surety bond held with North American Specialty Insurance Company which is supported by a restricted money market account held with Merrill Lynch in the amount of $637,820.   In August 2011, the Company received land from Lea County, New Mexico, pursuant to a Project Participation Agreement (PPA), whereby the land was deeded to the Company for no monetary consideration. In return, the Company committed to construct a uranium de-conversion and Fluorine Extraction Process facility on the land.  In order to retain title to the property, the Company was to begin construction of the de-conversion facility no later than December 31, 2014, and complete Phase I of the project and have hired at least 75 persons to operate the facility no later than December 31, 2015, although commercial operations need not have begun by that date. In 2015, the Company negotiated a modification to the PPA that extended the start of construction date to December 31, 2015, and the hiring milestone to December 31, 2016. Those dates were also not met. The Company is in discussion with commercial companies possibly interested in purchasing rights to this project. Should those discussions come to fruition the Company plans to negotiate a second modification to the PPA agreement to further extend the commitment dates. If the Company is not successful in reaching an amendment to extend the performance dates in the PPA. then it may, at its sole option, either purchase or re-convey the property to Lea County, New Mexico.  The purchase price of the property would be $776,078, plus interest at the annual rate of 5.25% from the date of the closing to the date of payment.  The Company has not recorded the value of this property as an asset and will not do so until such time that sufficient progress on the project has been made to meet the Company’s obligations under the agreements for permanent transfer of the title.   On May 3, 2019, the Company’s radiological services team was involved in a contamination event involving a breached cesium-137 source at an off-site location in the state of Washington. This work was being performed under a contract with the DOE. The Company supported the initial onsite contamination clean-up operations at that location and completed removal of the cesium source Company equipment. The Company has reviewed the results of the DOE investigation into this event and has implemented appropriate corrective actions. Since August 2019 the DOE has assumed full control of the ongoing cleanup operations and has assumed all of the financial obligations associated with the contractors hired to carry out all of the facility recovery operations. Under the terms of the contract the Company believes it should be indemnified from financial liability for this event by the DOE under the Price Anderson Act (PAA) and the Company has formally requested the DOE to provide indemnification under the PAA. While the DOE’s review of the request is still underway the Company believes that a determination of indemnification under the PAA is probable. Such indemnification would allow the Company to recoup all its costs associated with this contamination event. During 2019, the Company incurred $2,384,255 in expenses related to the contamination and its cleanup. During 2019, the Company received $964,958 in reimbursements from its insurance company for expenses related to the contamination and its cleanup, and the Company has determined that an additional $1,244,744 of its incurred expenses related to the contamination and its cleanup are probable for recovery pursuant to ASC 410-30. The Company believes additional cost recoveries beyond that which is recorded are possible but are not yet deemed probable at this time.

(9)        Revenue Recognition   Revenue from Product Sales   The following tables present the Company’s revenue disaggregated by business segment and geography, based on management’s assessment of available data:   <table cellspacing="0" cellpadding="0" style="font: 9pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1pt; font-size: 8.5pt; font-weight: bold"> </td> <td colspan="14" style="border-bottom: black 1pt solid; text-align: center; font-size: 8.5pt; font-weight: bold">Three Months Ended March 31, 2020</td> <td style="padding-bottom: 1pt; font-size: 8.5pt; font-weight: bold"> </td> <td style="padding-bottom: 1pt; font-size: 8.5pt; font-weight: bold"> </td> <td colspan="14" style="border-bottom: black 1pt solid; text-align: center; font-size: 8.5pt; font-weight: bold">Three Months Ended March 31, 2019</td> <td style="padding-bottom: 1pt; font-size: 8.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1pt; font-size: 8.5pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-size: 8.5pt; font-weight: bold">U.S.</td> <td style="padding-bottom: 1pt; font-size: 8.5pt; font-weight: bold"> </td> <td style="padding-bottom: 1pt; font-size: 8.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-size: 8.5pt"> Outside U.S.</td> <td style="padding-bottom: 1pt; font-size: 8.5pt"> </td> <td style="padding-bottom: 1pt; font-size: 8.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-size: 8.5pt"> Total Revenues</td> <td style="padding-bottom: 1pt; font-size: 8.5pt"> </td> <td style="padding-bottom: 1pt; font-size: 8.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-size: 8.5pt"> % of Total Revenues</td> <td style="padding-bottom: 1pt; font-size: 8.5pt"> </td> <td style="padding-bottom: 1pt; font-size: 8.5pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-size: 8.5pt; font-weight: bold">U.S.</td> <td style="padding-bottom: 1pt; font-size: 8.5pt; font-weight: bold"> </td> <td style="padding-bottom: 1pt; font-size: 8.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-size: 8.5pt"> Outside U.S.</td> <td style="padding-bottom: 1pt; font-size: 8.5pt"> </td> <td style="padding-bottom: 1pt; font-size: 8.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-size: 8.5pt"> Total Revenues</td> <td style="padding-bottom: 1pt; font-size: 8.5pt"> </td> <td style="padding-bottom: 1pt; font-size: 8.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-size: 8.5pt"> % of Total Revenues</td> <td style="padding-bottom: 1pt; font-size: 8.5pt"> </td></tr> <tr style="background-color: rgb(235,235,255); vertical-align: bottom"> <td style="text-align: left; width: 36%">Radiochemical Products</td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%">$</td> <td style="text-align: right; width: 5%">668,591</td> <td style="text-align: left; width: 1%"> </td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%">$</td> <td style="text-align: right; width: 5%">86,630</td> <td style="text-align: left; width: 1%"> </td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%">$</td> <td style="text-align: right; width: 5%">755,221</td> <td style="text-align: left; width: 1%"> </td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%"> </td> <td style="text-align: right; width: 5%">32</td> <td style="text-align: left; width: 1%">%</td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%">$</td> <td style="text-align: right; width: 5%">459,967</td> <td style="text-align: left; width: 1%"> </td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%">$</td> <td style="text-align: right; width: 5%">3,265</td> <td style="text-align: left; width: 1%"> </td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%">$</td> <td style="text-align: right; width: 5%">463,232</td> <td style="text-align: left; width: 1%"> </td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%"> </td> <td style="text-align: right; width: 5%">18</td> <td style="text-align: left; width: 1%">%</td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left">Cobalt Products</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">305,620</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">—  </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">305,620</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">13</td> <td style="text-align: left">%</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">336,089</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">40,000</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">376,089</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">15</td> <td style="text-align: left">%</td></tr> <tr style="background-color: rgb(235,235,255); vertical-align: bottom"> <td style="text-align: left">Nuclear Medicine Products</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">867,604</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">174,520</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">1,042,124</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">45</td> <td style="text-align: left">%</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">1,080,472</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">20,450</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">1,100,922</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">44</td> <td style="text-align: left">%</td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left">Radiological Services</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">72,321</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">—  </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">72,321</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">3</td> <td style="text-align: left">%</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">587,609</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">—  </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">587,609</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">23</td> <td style="text-align: left">%</td></tr> <tr style="background-color: rgb(235,235,255); vertical-align: bottom"> <td style="text-align: left; padding-bottom: 1pt">Fluorine Products</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">160,500</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">—  </td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">160,500</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">7</td> <td style="text-align: left; padding-bottom: 1pt">%</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">—  </td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">—  </td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">—  </td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">0</td> <td style="text-align: left; padding-bottom: 1pt">%</td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">2,074,636</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">261,150</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">2,335,786</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left"> </td> <td style="border-bottom: black 2.5pt double; text-align: right">100</td> <td style="text-align: left; padding-bottom: 2.5pt">%</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">2,464,137</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">63,715</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">2,527,852</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left"> </td> <td style="border-bottom: black 2.5pt double; text-align: right">100</td> <td style="text-align: left; padding-bottom: 2.5pt">%</td></tr> </table>   The Company’s revenue consists primarily of products manufactured for use in the nuclear medicine industry, distribution of radiochemicals including sodium iodide I-131 drug product, cobalt source manufacturing, and providing contract manufacturing of drug products for customers. With the exception of certain unique products, the Company’s normal operating cycle is considered to be one year. Due to the time required to produce some cobalt products, the Company’s operating cycle for those products is considered to be two to three years. Accordingly, preliminary payments received on cobalt contracts, where shipment will not take place for greater than one year, have been recorded as unearned revenue on the Company’s consolidated balance sheets and classified under current or long-term liabilities, depending upon estimated ship dates. For the three-months ended March 31, 2020, the Company reported current unearned cobalt products revenue of $1,213,927. For the period ended December 31, 2019, the Company reported current unearned revenue of $1,240,705. These unearned revenues will be recognized as revenue in the periods during which the cobalt shipments take place.   Contract Balances   The Company records a receivable when it has an unconditional right to receive consideration after the performance obligations are satisfied.  As of March 31, 2020, and December 31, 2019, accounts receivable totaled $1,024,044 and $875,914, respectively.  For the three-months ended March 31, 2020, the Company did not incur material impairment losses with respect to its receivables.

(10)        Leases   The Company leases office and warehouse space under operating leases. Right-of-use assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent its obligation to make lease payments under the lease. Operating lease, right-of-use assets, and liabilities are recognized at the lease commencement date based on the present value of lease payments over the reasonably certain lease term. The implicit rates with the Company’s operating leases are generally not determinable and the Company uses its incremental borrowing rate at the lease commencement date to determine the present value of its lease payments. The determination of the Company’s incremental borrowing rate requires judgement. The company determines its incremental borrowing rate for each lease using its then-current borrowing rate. Certain of the Company’s leases include options to extend or terminate the lease. The Company establishes the number of renewal options periods used in determining the operating lease term based upon its assessment at the inception of the operating lease. The option to renew the lease may be automatic, at the option of the Company, or mutually agreed to between the landlord and the Company. Once the facility lease term has begun, the present value of the aggregate future minimum lease payments is recorded as a right-of-use asset. Lease expense is recognized on a straight-line basis over the term of the lease.   <table cellspacing="0" cellpadding="0" style="font: 9pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td> <td style="font-size: 8.5pt; font-weight: bold"> </td> <td colspan="6" style="text-align: center; font-size: 8.5pt; font-weight: bold">Three Months Ended March 31,</td> <td style="font-size: 8.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1pt; font-size: 8.5pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-size: 8.5pt; font-weight: bold">2020</td> <td style="padding-bottom: 1pt; font-size: 8.5pt; font-weight: bold"> </td> <td style="padding-bottom: 1pt; font-size: 8.5pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-size: 8.5pt; font-weight: bold">2019</td> <td style="padding-bottom: 1pt; font-size: 8.5pt; font-weight: bold"> </td></tr> <tr style="background-color: rgb(235,235,255); vertical-align: bottom"> <td style="text-align: left; width: 72%">Operating lease costs</td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%">$</td> <td style="text-align: right; width: 11%">68,400</td> <td style="text-align: left; width: 1%"> </td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%">$</td> <td style="text-align: right; width: 11%">36,853</td> <td style="text-align: left; width: 1%"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left">Short-term operating lease costs</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">8,876</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">1,902</td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(235,235,255); vertical-align: bottom"> <td style="text-align: left">Financing lease expense:</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left; text-indent: 9pt">Amortization of right-of-use assets</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">577</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">—  </td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(235,235,255); vertical-align: bottom"> <td style="text-align: left; padding-bottom: 1pt; text-indent: 9pt">Interest on lease liabilities</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">222</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">—  </td> <td style="text-align: left; padding-bottom: 1pt"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left; padding-bottom: 1pt; text-indent: 0.25in">Total financing lease expense</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">799</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right"> </td> <td style="text-align: left; padding-bottom: 1pt"> </td></tr> <tr style="background-color: rgb(235,235,255); vertical-align: bottom"> <td style="text-align: left; text-indent: 0.25in">Total lease expense</td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">78,075</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">38,755</td> <td style="text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(235,235,255); vertical-align: bottom"> <td style="text-align: left">Right-of-use assets obtained in exchange for new operating lease liabilities</td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">2,649,070</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">810,367</td> <td style="text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left">Right-of-use assets obtained in exchange for new financing lease liabilities</td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">—  </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">—  </td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(235,235,255); vertical-align: bottom"> <td> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left">Weighted-average remaining lease term (years) - operating leases</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">14.8</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">7.0</td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(235,235,255); vertical-align: bottom"> <td style="text-align: left">Weighted-average remaining lease term (years) - financing leases</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">4.7</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left">Weighted-average discount rate - operating leases</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">6.75</td> <td style="text-align: left">%</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">6.75</td> <td style="text-align: left">%</td></tr> <tr style="background-color: rgb(235,235,255); vertical-align: bottom"> <td style="text-align: left">Weighted-average discount rate - financing leases</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">6.75</td> <td style="text-align: left">%</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> </table>   The future minimum payments under these operating lease agreements are as follows:   <table cellspacing="0" cellpadding="0" style="font: 9pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt"> </td> <td style="padding-bottom: 1pt; font-size: 8.5pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-size: 8.5pt; font-weight: bold">Operating</td> <td style="padding-bottom: 1pt; font-size: 8.5pt; font-weight: bold"> </td> <td style="padding-bottom: 1pt; font-size: 8.5pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-size: 8.5pt; font-weight: bold">Financing</td> <td style="padding-bottom: 1pt; font-size: 8.5pt; font-weight: bold"> </td></tr> <tr style="background-color: rgb(235,235,255); vertical-align: bottom"> <td style="width: 72%">2020 (excluding the three months ended March 31, 2020)</td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%">$</td> <td style="text-align: right; width: 11%">198,091</td> <td style="text-align: left; width: 1%"> </td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%">$</td> <td style="text-align: right; width: 11%">2,397</td> <td style="text-align: left; width: 1%"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left; vertical-align: middle">2021</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">257,383</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">3,195</td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(235,235,255); vertical-align: bottom"> <td style="text-align: left; vertical-align: middle">2022</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">284,631</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">3,195</td> <td style="text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left; vertical-align: middle">2023</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">287,108</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">3,195</td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(235,235,255); vertical-align: bottom"> <td style="text-align: left; vertical-align: middle">2024</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">287,108</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">2,929</td> <td style="text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="padding-bottom: 1pt">Thereafter</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">2,886,518</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">—  </td> <td style="text-align: left; padding-bottom: 1pt"> </td></tr> <tr style="background-color: rgb(235,235,255); vertical-align: bottom"> <td style="text-align: left; text-indent: 4.5pt">Total minimum operating lease obligations</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">4,200,839</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">14,911</td> <td style="text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left; padding-bottom: 1pt">Less-amounts representing interest</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(1,563,909</td> <td style="text-align: left; padding-bottom: 1pt">)</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(2,151</td> <td style="text-align: left; padding-bottom: 1pt">)</td></tr> <tr style="background-color: rgb(235,235,255); vertical-align: bottom"> <td style="text-align: left; text-indent: 4.5pt">Present value of minimum operating lease obligations</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">2,636,930</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">12,760</td> <td style="text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left; padding-bottom: 1pt">Current maturities</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(87,158</td> <td style="text-align: left; padding-bottom: 1pt">)</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(2,407</td> <td style="text-align: left; padding-bottom: 1pt">)</td></tr> <tr style="background-color: rgb(235,235,255); vertical-align: bottom"> <td style="text-align: left; padding-bottom: 2.5pt">Lease obligations, net of current maturities</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">2,549,772</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">10,353</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td></tr> </table>

(11)        Segment Information   The Company has five reportable segments which include: Nuclear Medicine Standards, Cobalt Products, Radiochemical Products, Fluorine Products, and Radiological Services. Information regarding the operations and assets of these reportable business segments is contained in the following table:     <table cellspacing="0" cellpadding="0" style="font: 8.5pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="6" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold">Three months ended March 31,</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1pt solid">Sale of Product</td> <td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-size: 8pt; font-weight: bold">2020</td> <td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td> <td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-size: 8pt; font-weight: bold">2019</td> <td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td></tr> <tr style="background-color: rgb(235,235,255); vertical-align: bottom"> <td style="text-align: left; width: 65%">Radiochemical Products</td> <td style="width: 8%"> </td> <td style="text-align: left; width: 1%">$</td> <td style="text-align: right; width: 11%">755,221</td> <td style="text-align: left; width: 1%"> </td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%">$</td> <td style="text-align: right; width: 11%">463,232</td> <td style="text-align: left; width: 1%"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left">Cobalt Products</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">305,620</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">376,089</td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(235,235,255); vertical-align: bottom"> <td style="text-align: left">Nuclear Medicine Standards</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">1,042,124</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">1,100,922</td> <td style="text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left">Radiological Services</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">72,321</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">587,609</td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(235,235,255); vertical-align: bottom"> <td style="text-align: left; padding-bottom: 1pt">Fluorine Products</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">160,500</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">—  </td> <td style="text-align: left; padding-bottom: 1pt"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left; text-indent: 9pt">Total Segments</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">2,335,786</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">2,527,852</td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(235,235,255); vertical-align: bottom"> <td style="text-align: left; padding-bottom: 1pt">Corporate revenue</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">—  </td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">—  </td> <td style="text-align: left; padding-bottom: 1pt"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left; padding-bottom: 2.5pt; text-indent: 9pt">Total consolidated</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">2,335,786</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">2,527,852</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td></tr> </table>     <table cellspacing="0" cellpadding="0" style="font: 8.5pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="6" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold">Three months ended March 31,</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1pt solid">Depreciation and Amortization</td> <td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-size: 8pt; font-weight: bold">2020</td> <td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td> <td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-size: 8pt; font-weight: bold">2019</td> <td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td></tr> <tr style="background-color: rgb(235,235,255); vertical-align: bottom"> <td style="text-align: left; width: 65%">Radiochemical Products</td> <td style="width: 8%"> </td> <td style="text-align: left; width: 1%">$</td> <td style="text-align: right; width: 11%">10,354</td> <td style="text-align: left; width: 1%"> </td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%">$</td> <td style="text-align: right; width: 11%">8,817</td> <td style="text-align: left; width: 1%"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left">Cobalt Products</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">8,761</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">1,080</td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(235,235,255); vertical-align: bottom"> <td style="text-align: left">Nuclear Medicine Standards</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">15,989</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">15,619</td> <td style="text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left">Radiological Services</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">8,636</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">8,636</td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(235,235,255); vertical-align: bottom"> <td style="text-align: left; padding-bottom: 1pt">Fluorine Products</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">26,095</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">26,095</td> <td style="text-align: left; padding-bottom: 1pt"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left; text-indent: 9pt">Total Segments</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">69,835</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">60,248</td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(235,235,255); vertical-align: bottom"> <td style="text-align: left; padding-bottom: 1pt">Corporate depreciation and amortization</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">4,782</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">4,737</td> <td style="text-align: left; padding-bottom: 1pt"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left; padding-bottom: 2.5pt; text-indent: 9pt">Total Consolidated</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">74,617</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">64,985</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td></tr> </table>     <table cellspacing="0" cellpadding="0" style="font: 8.5pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="6" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold">Three months ended March 31,</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1pt solid">Segment Income (Loss)</td> <td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-size: 8pt; font-weight: bold">2020</td> <td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td> <td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-size: 8pt; font-weight: bold">2019</td> <td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td></tr> <tr style="background-color: rgb(235,235,255); vertical-align: bottom"> <td style="text-align: left; width: 65%">Radiochemical Products</td> <td style="width: 8%"> </td> <td style="text-align: left; width: 1%">$</td> <td style="text-align: right; width: 11%">5,619</td> <td style="text-align: left; width: 1%"> </td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%">$</td> <td style="text-align: right; width: 11%">96,006</td> <td style="text-align: left; width: 1%"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left">Cobalt Products</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">123,796</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">192,870</td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(235,235,255); vertical-align: bottom"> <td style="text-align: left">Nuclear Medicine Standards</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">185,301</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">216,822</td> <td style="text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left">Radiological Services</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(14,929</td> <td style="text-align: left">)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">311,279</td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(235,235,255); vertical-align: bottom"> <td style="text-align: left; padding-bottom: 1pt">Fluorine Products</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">122,870</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(37,495</td> <td style="text-align: left; padding-bottom: 1pt">)</td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left; text-indent: 9pt">Total Segments</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">422,657</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">779,481</td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(235,235,255); vertical-align: bottom"> <td style="text-align: left; padding-bottom: 1pt">Corporate loss</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(845,151</td> <td style="text-align: left; padding-bottom: 1pt">)</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(831,439</td> <td style="text-align: left; padding-bottom: 1pt">)</td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left; padding-bottom: 2.5pt; text-indent: 9pt">Net Income (Loss)</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">(422,494</td> <td style="text-align: left; padding-bottom: 2.5pt">)</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">(51,958</td> <td style="text-align: left; padding-bottom: 2.5pt">)</td></tr> </table>     <table cellspacing="0" cellpadding="0" style="font: 8.5pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="6" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold">Three months ended March 31,</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1pt solid">Expenditures for Segment Assets</td> <td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-size: 8pt; font-weight: bold">2020</td> <td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td> <td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-size: 8pt; font-weight: bold">2019</td> <td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td></tr> <tr style="background-color: rgb(235,235,255); vertical-align: bottom"> <td style="text-align: left">Radiochemical Products</td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">—  </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">—  </td> <td style="text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left; width: 65%">Cobalt Products</td> <td style="width: 8%"> </td> <td style="text-align: left; width: 1%"> </td> <td style="text-align: right; width: 11%">—  </td> <td style="text-align: left; width: 1%"> </td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%"> </td> <td style="text-align: right; width: 11%">3,494</td> <td style="text-align: left; width: 1%"> </td></tr> <tr style="background-color: rgb(235,235,255); vertical-align: bottom"> <td style="text-align: left">Nuclear Medicine Standards</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">—  </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">—  </td> <td style="text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left">Radiological Services</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">—  </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">—  </td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(235,235,255); vertical-align: bottom"> <td style="text-align: left; padding-bottom: 1pt">Fluorine Products</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">1,565</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">1,590</td> <td style="text-align: left; padding-bottom: 1pt"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left; text-indent: 9pt">Total Segments</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">1,565</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">5,084</td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(235,235,255); vertical-align: bottom"> <td style="text-align: left; padding-bottom: 1pt">Corporate purchases</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">—  </td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">—  </td> <td style="text-align: left; padding-bottom: 1pt"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left; padding-bottom: 2.5pt; text-indent: 9pt">Total Consolidated</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">1,565</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">5,084</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td></tr> </table>      <table cellspacing="0" cellpadding="0" style="font: 8.5pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1pt solid">Segment Assets</td> <td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-size: 8pt; font-weight: bold"> March 31, 2020</td> <td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td> <td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-size: 8pt; font-weight: bold"> December 31, 2019</td> <td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td></tr> <tr style="background-color: rgb(235,235,255); vertical-align: bottom"> <td style="text-align: left; width: 65%">Radiochemical Products</td> <td style="width: 8%"> </td> <td style="text-align: left; width: 1%">$</td> <td style="text-align: right; width: 11%">536,603</td> <td style="text-align: left; width: 1%"> </td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%">$</td> <td style="text-align: right; width: 11%">511,381</td> <td style="text-align: left; width: 1%"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left">Cobalt Products</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">3,388,527</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">3,369,828</td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(235,235,255); vertical-align: bottom"> <td style="text-align: left">Nuclear Medicine Standards</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">2,087,295</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">2,111,225</td> <td style="text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left">Radiological Services</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">96,427</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">106,374</td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(235,235,255); vertical-align: bottom"> <td style="text-align: left; padding-bottom: 1pt">Fluorine Products</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">5,482,993</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">5,477,808</td> <td style="text-align: left; padding-bottom: 1pt"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left; text-indent: 9pt">Total Segments</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">11,591,845</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">11,576,616</td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(235,235,255); vertical-align: bottom"> <td style="text-align: left; padding-bottom: 1pt">Corporate assets</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">5,566,539</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">3,680,179</td> <td style="text-align: left; padding-bottom: 1pt"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left; padding-bottom: 2.5pt; text-indent: 9pt">Total Consolidated</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">17,158,384</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">15,256,795</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td></tr> </table>

(12)        Subsequent Events   As described under Debt above, on April 23, 2020, the Company, through its wholly-owned subsidiary entered into a Loan Agreement and Promissory Note (collectively the “SBA Loan”) with KeyBank National Association pursuant to the Paycheck Protection Program (the “PPP”) under the recently enacted Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”) administered by the U.S. Small Business Administration (the “SBA”). The Company received total proceeds of $495,500 from the SBA Loan. The SBA Loan is scheduled to mature on April 22, 2022 and has a 1.00% interest rate and is subject to the terms and conditions applicable to loans administered by the SBA under the CARES Act. The SBA Loan may be prepaid at any time prior to maturity with no prepayment penalties.

Principles of Consolidation – The accompanying unaudited condensed consolidated financial statements are presented in conformity with GAAP and include all operations and balances of INIS and its wholly-owned subsidiaries. The Company also consolidates the accounts of RadQual into the accompanying unaudited condensed consolidated financial statements. See Note 4 “Investment and Business Consolidation” for additional information regarding RadQual. All significant intercompany accounts and transactions have been eliminated in consolidation.

Interim Financial Information – The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with GAAP for interim financial information and pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (SEC). Accordingly, the accompanying unaudited condensed consolidated financial statements do not include all of the information and notes required by GAAP for complete financial statements. In the opinion of management, all adjustments and reclassifications considered necessary in order to make the financial statements not misleading and for a fair and comparable presentation have been included and are of a normal recurring nature. Operating results for the three-month period ended March 31, 2020 are not necessarily indicative of the results that may be expected for the year ending December 31, 2020 or any future periods. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the Company’s Annual Report on Form 10-K for the year ended December 31, 2019 filed with the SEC on March 30, 2020.

<table cellspacing="0" cellpadding="0" style="font: 9pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: right; font-size: 10pt"> </td> <td style="padding-bottom: 1pt; font-size: 8.5pt; font-weight: bold"> </td> <td colspan="6" style="border-bottom: black 1pt solid; text-align: center; font-size: 8.5pt; font-weight: bold">March 31,</td> <td style="padding-bottom: 1pt; font-size: 8.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: right; font-size: 10pt"> </td> <td style="padding-bottom: 1pt; font-size: 8.5pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-size: 8.5pt; font-weight: bold">2020</td> <td style="padding-bottom: 1pt; font-size: 8.5pt; font-weight: bold"> </td> <td style="padding-bottom: 1pt; font-size: 8.5pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-size: 8.5pt; font-weight: bold">2019</td> <td style="padding-bottom: 1pt; font-size: 8.5pt; font-weight: bold"> </td></tr> <tr style="background-color: rgb(235,235,255); vertical-align: bottom"> <td style="text-align: left; width: 72%">Stock options</td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%"> </td> <td style="text-align: right; width: 11%">23,655,000</td> <td style="text-align: left; width: 1%"> </td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%"> </td> <td style="text-align: right; width: 11%">27,205,000</td> <td style="text-align: left; width: 1%"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td>Warrants</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">50,090,000</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">20,090,000</td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(235,235,255); vertical-align: bottom"> <td style="text-align: left">850 Shares of Series B redeemable convertible preferred stock</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">425,000</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">425,000</td> <td style="text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left; padding-bottom: 1pt">4,213 Shares of Series C redeemable convertible preferred stock</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">42,130,000</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">42,130,000</td> <td style="text-align: left; padding-bottom: 1pt"> </td></tr> <tr style="background-color: rgb(235,235,255); vertical-align: bottom"> <td style="text-align: right; padding-bottom: 2.5pt; font-size: 12pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left"> </td> <td style="border-bottom: black 2.5pt double; text-align: right">116,300,000</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left"> </td> <td style="border-bottom: black 2.5pt double; text-align: right">89,850,000</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td></tr> </table>

<table cellspacing="0" cellpadding="0" style="font: 9pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: right; font-size: 12pt"> </td> <td style="padding-bottom: 1pt; font-size: 8.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-size: 8.5pt"> March 31, 2020</td> <td style="padding-bottom: 1pt; font-size: 8.5pt"> </td> <td style="padding-bottom: 1pt; font-size: 8.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-size: 8.5pt"> December 31, 2019</td> <td style="padding-bottom: 1pt; font-size: 8.5pt"> </td></tr> <tr style="background-color: rgb(235,235,255); vertical-align: bottom"> <td style="text-align: left; width: 72%">Raw materials</td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%">$</td> <td style="text-align: right; width: 11%">40,648</td> <td style="text-align: left; width: 1%"> </td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%">$</td> <td style="text-align: right; width: 11%">40,648</td> <td style="text-align: left; width: 1%"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left">Work in process</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">3,334,886</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">3,379,943</td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(235,235,255); vertical-align: bottom"> <td style="text-align: left; padding-bottom: 1pt">Finished goods</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">3,839</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">2,829</td> <td style="text-align: left; padding-bottom: 1pt"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: right; padding-bottom: 2.5pt; font-size: 12pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">3,379,373</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">3,423,420</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td></tr> </table>

<table cellspacing="0" cellpadding="0" style="font: 9pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1pt solid; font-size: 8.5pt; font-weight: bold">Fixed Options</td> <td style="padding-bottom: 1pt; font-size: 8.5pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-size: 8.5pt; font-weight: bold">Shares</td> <td style="padding-bottom: 1pt; font-size: 8.5pt; font-weight: bold"> </td> <td style="padding-bottom: 1pt; font-size: 8.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-size: 8.5pt"> Weighted Average Exercise Price</td> <td style="padding-bottom: 1pt; font-size: 8.5pt"> </td> <td style="padding-bottom: 1pt; font-size: 8.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-size: 8.5pt"> Weighted Average Remaining Contractual Life</td> <td style="padding-bottom: 1pt; font-size: 8.5pt"> </td> <td style="padding-bottom: 1pt; font-size: 8.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-size: 8.5pt"> Aggregate Intrinsic Value</td> <td style="padding-bottom: 1pt; font-size: 8.5pt"> </td></tr> <tr style="background-color: rgb(235,235,255); vertical-align: bottom"> <td style="width: 44%">Outstanding at December 31, 2019</td> <td style="width: 2%"> </td> <td style="text-align: left; width: 1%"> </td> <td style="text-align: right; width: 10%">23,655,000</td> <td style="text-align: left; width: 1%"> </td> <td style="width: 2%"> </td> <td style="text-align: left; width: 1%">$</td> <td style="text-align: right; width: 10%">0.05</td> <td style="text-align: left; width: 1%"> </td> <td style="width: 2%"> </td> <td style="text-align: left; width: 1%"> </td> <td style="text-align: right; width: 10%"> </td> <td style="text-align: left; width: 1%"> </td> <td style="width: 2%"> </td> <td style="text-align: left; width: 1%"> </td> <td style="text-align: right; width: 10%"> </td> <td style="text-align: left; width: 1%"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td>Granted</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">—  </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">—  </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(235,235,255); vertical-align: bottom"> <td>Exercised</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">—  </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">—  </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td>Expired</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">—  </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">—  </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(235,235,255); vertical-align: bottom"> <td style="padding-bottom: 1pt">Forfeited</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">—  </td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left">$</td> <td style="border-bottom: black 1pt solid; text-align: right">—  </td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right"> </td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right"> </td> <td style="text-align: left; padding-bottom: 1pt"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="padding-bottom: 2.5pt">Outstanding at March 31, 2020</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left"> </td> <td style="border-bottom: black 2.5pt double; text-align: right">23,655,000</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">0.05</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left"> </td> <td style="border-bottom: black 2.5pt double; text-align: right">6.1</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">235,000</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td></tr> <tr style="background-color: rgb(235,235,255); vertical-align: bottom"> <td style="padding-bottom: 2.5pt">Exerciseable at March 31, 2020</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left"> </td> <td style="border-bottom: black 2.5pt double; text-align: right">17,936,000</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">0.05</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left"> </td> <td style="border-bottom: black 2.5pt double; text-align: right">5.6</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">235,000</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td></tr> </table>

<table cellspacing="0" cellpadding="0" style="font: 9pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1pt; font-size: 8.5pt; font-weight: bold"> </td> <td colspan="14" style="border-bottom: black 1pt solid; text-align: center; font-size: 8.5pt; font-weight: bold">Three Months Ended March 31, 2020</td> <td style="padding-bottom: 1pt; font-size: 8.5pt; font-weight: bold"> </td> <td style="padding-bottom: 1pt; font-size: 8.5pt; font-weight: bold"> </td> <td colspan="14" style="border-bottom: black 1pt solid; text-align: center; font-size: 8.5pt; font-weight: bold">Three Months Ended March 31, 2019</td> <td style="padding-bottom: 1pt; font-size: 8.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1pt; font-size: 8.5pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-size: 8.5pt; font-weight: bold">U.S.</td> <td style="padding-bottom: 1pt; font-size: 8.5pt; font-weight: bold"> </td> <td style="padding-bottom: 1pt; font-size: 8.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-size: 8.5pt"> Outside U.S.</td> <td style="padding-bottom: 1pt; font-size: 8.5pt"> </td> <td style="padding-bottom: 1pt; font-size: 8.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-size: 8.5pt"> Total Revenues</td> <td style="padding-bottom: 1pt; font-size: 8.5pt"> </td> <td style="padding-bottom: 1pt; font-size: 8.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-size: 8.5pt"> % of Total Revenues</td> <td style="padding-bottom: 1pt; font-size: 8.5pt"> </td> <td style="padding-bottom: 1pt; font-size: 8.5pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-size: 8.5pt; font-weight: bold">U.S.</td> <td style="padding-bottom: 1pt; font-size: 8.5pt; font-weight: bold"> </td> <td style="padding-bottom: 1pt; font-size: 8.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-size: 8.5pt"> Outside U.S.</td> <td style="padding-bottom: 1pt; font-size: 8.5pt"> </td> <td style="padding-bottom: 1pt; font-size: 8.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-size: 8.5pt"> Total Revenues</td> <td style="padding-bottom: 1pt; font-size: 8.5pt"> </td> <td style="padding-bottom: 1pt; font-size: 8.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-size: 8.5pt"> % of Total Revenues</td> <td style="padding-bottom: 1pt; font-size: 8.5pt"> </td></tr> <tr style="background-color: rgb(235,235,255); vertical-align: bottom"> <td style="text-align: left; width: 36%">Radiochemical Products</td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%">$</td> <td style="text-align: right; width: 5%">668,591</td> <td style="text-align: left; width: 1%"> </td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%">$</td> <td style="text-align: right; width: 5%">86,630</td> <td style="text-align: left; width: 1%"> </td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%">$</td> <td style="text-align: right; width: 5%">755,221</td> <td style="text-align: left; width: 1%"> </td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%"> </td> <td style="text-align: right; width: 5%">32</td> <td style="text-align: left; width: 1%">%</td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%">$</td> <td style="text-align: right; width: 5%">459,967</td> <td style="text-align: left; width: 1%"> </td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%">$</td> <td style="text-align: right; width: 5%">3,265</td> <td style="text-align: left; width: 1%"> </td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%">$</td> <td style="text-align: right; width: 5%">463,232</td> <td style="text-align: left; width: 1%"> </td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%"> </td> <td style="text-align: right; width: 5%">18</td> <td style="text-align: left; width: 1%">%</td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left">Cobalt Products</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">305,620</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">—  </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">305,620</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">13</td> <td style="text-align: left">%</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">336,089</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">40,000</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">376,089</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">15</td> <td style="text-align: left">%</td></tr> <tr style="background-color: rgb(235,235,255); vertical-align: bottom"> <td style="text-align: left">Nuclear Medicine Products</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">867,604</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">174,520</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">1,042,124</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">45</td> <td style="text-align: left">%</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">1,080,472</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">20,450</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">1,100,922</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">44</td> <td style="text-align: left">%</td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left">Radiological Services</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">72,321</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">—  </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">72,321</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">3</td> <td style="text-align: left">%</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">587,609</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">—  </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">587,609</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">23</td> <td style="text-align: left">%</td></tr> <tr style="background-color: rgb(235,235,255); vertical-align: bottom"> <td style="text-align: left; padding-bottom: 1pt">Fluorine Products</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">160,500</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">—  </td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">160,500</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">7</td> <td style="text-align: left; padding-bottom: 1pt">%</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">—  </td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">—  </td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">—  </td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">0</td> <td style="text-align: left; padding-bottom: 1pt">%</td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">2,074,636</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">261,150</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">2,335,786</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left"> </td> <td style="border-bottom: black 2.5pt double; text-align: right">100</td> <td style="text-align: left; padding-bottom: 2.5pt">%</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">2,464,137</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">63,715</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">2,527,852</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left"> </td> <td style="border-bottom: black 2.5pt double; text-align: right">100</td> <td style="text-align: left; padding-bottom: 2.5pt">%</td></tr> </table>

<table cellspacing="0" cellpadding="0" style="font: 9pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td> <td style="font-size: 8.5pt; font-weight: bold"> </td> <td colspan="6" style="text-align: center; font-size: 8.5pt; font-weight: bold">Three Months Ended March 31,</td> <td style="font-size: 8.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1pt; font-size: 8.5pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-size: 8.5pt; font-weight: bold">2020</td> <td style="padding-bottom: 1pt; font-size: 8.5pt; font-weight: bold"> </td> <td style="padding-bottom: 1pt; font-size: 8.5pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-size: 8.5pt; font-weight: bold">2019</td> <td style="padding-bottom: 1pt; font-size: 8.5pt; font-weight: bold"> </td></tr> <tr style="background-color: rgb(235,235,255); vertical-align: bottom"> <td style="text-align: left; width: 72%">Operating lease costs</td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%">$</td> <td style="text-align: right; width: 11%">68,400</td> <td style="text-align: left; width: 1%"> </td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%">$</td> <td style="text-align: right; width: 11%">36,853</td> <td style="text-align: left; width: 1%"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left">Short-term operating lease costs</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">8,876</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">1,902</td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(235,235,255); vertical-align: bottom"> <td style="text-align: left">Financing lease expense:</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left; text-indent: 9pt">Amortization of right-of-use assets</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">577</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">—  </td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(235,235,255); vertical-align: bottom"> <td style="text-align: left; padding-bottom: 1pt; text-indent: 9pt">Interest on lease liabilities</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">222</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">—  </td> <td style="text-align: left; padding-bottom: 1pt"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left; padding-bottom: 1pt; text-indent: 0.25in">Total financing lease expense</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">799</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right"> </td> <td style="text-align: left; padding-bottom: 1pt"> </td></tr> <tr style="background-color: rgb(235,235,255); vertical-align: bottom"> <td style="text-align: left; text-indent: 0.25in">Total lease expense</td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">78,075</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">38,755</td> <td style="text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(235,235,255); vertical-align: bottom"> <td style="text-align: left">Right-of-use assets obtained in exchange for new operating lease liabilities</td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">2,649,070</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">810,367</td> <td style="text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left">Right-of-use assets obtained in exchange for new financing lease liabilities</td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">—  </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">—  </td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(235,235,255); vertical-align: bottom"> <td> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left">Weighted-average remaining lease term (years) - operating leases</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">14.8</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">7.0</td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(235,235,255); vertical-align: bottom"> <td style="text-align: left">Weighted-average remaining lease term (years) - financing leases</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">4.7</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left">Weighted-average discount rate - operating leases</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">6.75</td> <td style="text-align: left">%</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">6.75</td> <td style="text-align: left">%</td></tr> <tr style="background-color: rgb(235,235,255); vertical-align: bottom"> <td style="text-align: left">Weighted-average discount rate - financing leases</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">6.75</td> <td style="text-align: left">%</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> </table>

<table cellspacing="0" cellpadding="0" style="font: 8.5pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="6" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold">Three months ended March 31,</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1pt solid">Sale of Product</td> <td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-size: 8pt; font-weight: bold">2020</td> <td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td> <td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-size: 8pt; font-weight: bold">2019</td> <td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td></tr> <tr style="background-color: rgb(235,235,255); vertical-align: bottom"> <td style="text-align: left; width: 65%">Radiochemical Products</td> <td style="width: 8%"> </td> <td style="text-align: left; width: 1%">$</td> <td style="text-align: right; width: 11%">755,221</td> <td style="text-align: left; width: 1%"> </td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%">$</td> <td style="text-align: right; width: 11%">463,232</td> <td style="text-align: left; width: 1%"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left">Cobalt Products</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">305,620</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">376,089</td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(235,235,255); vertical-align: bottom"> <td style="text-align: left">Nuclear Medicine Standards</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">1,042,124</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">1,100,922</td> <td style="text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left">Radiological Services</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">72,321</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">587,609</td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(235,235,255); vertical-align: bottom"> <td style="text-align: left; padding-bottom: 1pt">Fluorine Products</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">160,500</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">—  </td> <td style="text-align: left; padding-bottom: 1pt"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left; text-indent: 9pt">Total Segments</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">2,335,786</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">2,527,852</td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(235,235,255); vertical-align: bottom"> <td style="text-align: left; padding-bottom: 1pt">Corporate revenue</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">—  </td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">—  </td> <td style="text-align: left; padding-bottom: 1pt"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left; padding-bottom: 2.5pt; text-indent: 9pt">Total consolidated</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">2,335,786</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">2,527,852</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td></tr> </table>     <table cellspacing="0" cellpadding="0" style="font: 8.5pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="6" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold">Three months ended March 31,</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1pt solid">Depreciation and Amortization</td> <td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-size: 8pt; font-weight: bold">2020</td> <td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td> <td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-size: 8pt; font-weight: bold">2019</td> <td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td></tr> <tr style="background-color: rgb(235,235,255); vertical-align: bottom"> <td style="text-align: left; width: 65%">Radiochemical Products</td> <td style="width: 8%"> </td> <td style="text-align: left; width: 1%">$</td> <td style="text-align: right; width: 11%">10,354</td> <td style="text-align: left; width: 1%"> </td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%">$</td> <td style="text-align: right; width: 11%">8,817</td> <td style="text-align: left; width: 1%"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left">Cobalt Products</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">8,761</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">1,080</td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(235,235,255); vertical-align: bottom"> <td style="text-align: left">Nuclear Medicine Standards</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">15,989</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">15,619</td> <td style="text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left">Radiological Services</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">8,636</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">8,636</td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(235,235,255); vertical-align: bottom"> <td style="text-align: left; padding-bottom: 1pt">Fluorine Products</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">26,095</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">26,095</td> <td style="text-align: left; padding-bottom: 1pt"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left; text-indent: 9pt">Total Segments</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">69,835</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">60,248</td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(235,235,255); vertical-align: bottom"> <td style="text-align: left; padding-bottom: 1pt">Corporate depreciation and amortization</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">4,782</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">4,737</td> <td style="text-align: left; padding-bottom: 1pt"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left; padding-bottom: 2.5pt; text-indent: 9pt">Total Consolidated</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">74,617</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">64,985</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td></tr> </table>     <table cellspacing="0" cellpadding="0" style="font: 8.5pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="6" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold">Three months ended March 31,</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1pt solid">Segment Income (Loss)</td> <td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-size: 8pt; font-weight: bold">2020</td> <td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td> <td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-size: 8pt; font-weight: bold">2019</td> <td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td></tr> <tr style="background-color: rgb(235,235,255); vertical-align: bottom"> <td style="text-align: left; width: 65%">Radiochemical Products</td> <td style="width: 8%"> </td> <td style="text-align: left; width: 1%">$</td> <td style="text-align: right; width: 11%">5,619</td> <td style="text-align: left; width: 1%"> </td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%">$</td> <td style="text-align: right; width: 11%">96,006</td> <td style="text-align: left; width: 1%"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left">Cobalt Products</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">123,796</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">192,870</td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(235,235,255); vertical-align: bottom"> <td style="text-align: left">Nuclear Medicine Standards</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">185,301</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">216,822</td> <td style="text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left">Radiological Services</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(14,929</td> <td style="text-align: left">)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">311,279</td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(235,235,255); vertical-align: bottom"> <td style="text-align: left; padding-bottom: 1pt">Fluorine Products</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">122,870</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(37,495</td> <td style="text-align: left; padding-bottom: 1pt">)</td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left; text-indent: 9pt">Total Segments</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">422,657</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">779,481</td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(235,235,255); vertical-align: bottom"> <td style="text-align: left; padding-bottom: 1pt">Corporate loss</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(845,151</td> <td style="text-align: left; padding-bottom: 1pt">)</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(831,439</td> <td style="text-align: left; padding-bottom: 1pt">)</td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left; padding-bottom: 2.5pt; text-indent: 9pt">Net Income (Loss)</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">(422,494</td> <td style="text-align: left; padding-bottom: 2.5pt">)</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">(51,958</td> <td style="text-align: left; padding-bottom: 2.5pt">)</td></tr> </table>     <table cellspacing="0" cellpadding="0" style="font: 8.5pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="6" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold">Three months ended March 31,</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1pt solid">Expenditures for Segment Assets</td> <td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-size: 8pt; font-weight: bold">2020</td> <td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td> <td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-size: 8pt; font-weight: bold">2019</td> <td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td></tr> <tr style="background-color: rgb(235,235,255); vertical-align: bottom"> <td style="text-align: left">Radiochemical Products</td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">—  </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">—  </td> <td style="text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left; width: 65%">Cobalt Products</td> <td style="width: 8%"> </td> <td style="text-align: left; width: 1%"> </td> <td style="text-align: right; width: 11%">—  </td> <td style="text-align: left; width: 1%"> </td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%"> </td> <td style="text-align: right; width: 11%">3,494</td> <td style="text-align: left; width: 1%"> </td></tr> <tr style="background-color: rgb(235,235,255); vertical-align: bottom"> <td style="text-align: left">Nuclear Medicine Standards</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">—  </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">—  </td> <td style="text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left">Radiological Services</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">—  </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">—  </td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(235,235,255); vertical-align: bottom"> <td style="text-align: left; padding-bottom: 1pt">Fluorine Products</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">1,565</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">1,590</td> <td style="text-align: left; padding-bottom: 1pt"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left; text-indent: 9pt">Total Segments</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">1,565</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">5,084</td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(235,235,255); vertical-align: bottom"> <td style="text-align: left; padding-bottom: 1pt">Corporate purchases</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">—  </td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">—  </td> <td style="text-align: left; padding-bottom: 1pt"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left; padding-bottom: 2.5pt; text-indent: 9pt">Total Consolidated</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">1,565</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">5,084</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td></tr> </table>      <table cellspacing="0" cellpadding="0" style="font: 8.5pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1pt solid">Segment Assets</td> <td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-size: 8pt; font-weight: bold"> March 31, 2020</td> <td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td> <td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-size: 8pt; font-weight: bold"> December 31, 2019</td> <td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td></tr> <tr style="background-color: rgb(235,235,255); vertical-align: bottom"> <td style="text-align: left; width: 65%">Radiochemical Products</td> <td style="width: 8%"> </td> <td style="text-align: left; width: 1%">$</td> <td style="text-align: right; width: 11%">536,603</td> <td style="text-align: left; width: 1%"> </td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%">$</td> <td style="text-align: right; width: 11%">511,381</td> <td style="text-align: left; width: 1%"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left">Cobalt Products</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">3,388,527</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">3,369,828</td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(235,235,255); vertical-align: bottom"> <td style="text-align: left">Nuclear Medicine Standards</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">2,087,295</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">2,111,225</td> <td style="text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left">Radiological Services</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">96,427</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">106,374</td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(235,235,255); vertical-align: bottom"> <td style="text-align: left; padding-bottom: 1pt">Fluorine Products</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">5,482,993</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">5,477,808</td> <td style="text-align: left; padding-bottom: 1pt"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left; text-indent: 9pt">Total Segments</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">11,591,845</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">11,576,616</td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(235,235,255); vertical-align: bottom"> <td style="text-align: left; padding-bottom: 1pt">Corporate assets</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">5,566,539</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">3,680,179</td> <td style="text-align: left; padding-bottom: 1pt"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left; padding-bottom: 2.5pt; text-indent: 9pt">Total Consolidated</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">17,158,384</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">15,256,795</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td></tr> </table>

11089967

425000

0.06

P1Y9M

10000000

15000000

30000000

25000000

In April 2019, one of the prepaid revenue customers requested a refund of the amounts paid. The modification was necessary to address the delays to cobalt delivery in 2019 caused by changes to the ATR operating schedule and also to accommodate this customer’s request to reduce their cobalt purchase obligations in future years. The modifications require that the Company refund approximately $1,050,000, of payments received for prior year undelivered material, plus interest at 12% per year, payable over a one-year period on a portion of that amount. The Company has also agreed with this customer to refund approximately $1,100,000 paid for material that was to have been delivered in later years. There will be no interest charge on this refund. In December 2019, this agreement was modified further allowing the Company to delay the original payments by 3 months and refund an additional $462,258 with no interest charge.

446079

315643

495500

0.01

577

222

799

78075

38755

P4Y9M

0.0675

198091

257383

284631

287108

2886518

4200839

1563909

2636930

2397

3195

2929

14911

2151

12760

1000000

675000

325000

In July 2018, the Plan was amended and restated to increase the number of shares authorized for issuance by an additional 20,000,000. Each of two lenders issued 5,000,000 Class L warrants. Each of the two lenders were granted 7,500,000 additional Class L warrants.

EX-101.SCH 7 inis-20200331.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Reconciliation of Stockholders' (Deficit) Equity link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - The Company and Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Current Developments and Liquidity link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Net Income (Loss) Per Common Share - Basic and Diluted link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Investment and Business Consolidation link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Inventories link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Stockholders' Equity, Options and Warrants link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Debt link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Revenue Recognition link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Segment Information link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - Net Income (Loss) Per Common Share - Basic and Diluted (Tables) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - Inventories (Tables) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Stockholders' Equity, Options and Warrants (Tables) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - Revenue Recognition (Tables) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - Segment Information (Tables) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - The Company and Basis of Presentation (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - Current Developments and Liquidity (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - Net Income (Loss) Per Common Share - Basic and Diluted - Schedule of Common Stock Equivalents (Details) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - Net Income (Loss) Per Common Share - Basic and Diluted (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - Investment and Business Consolidation (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - Inventories - Schedule of Inventory, Current (Details) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - Inventories (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - Shareholders' Equity, Options and Warrants - Schedule of Stock Option Activity (Details) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - Shareholders' Equity, Options and Warrants - Employee Stock Purchase Plan (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - Shareholders' Equity, Options and Warrants - Stock-Based Compensation Plans (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - Debt (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - Commitments and Contingencies (Detail Narrative) link:presentationLink link:calculationLink link:definitionLink 00000038 - Disclosure - Revenue Recognition - Summary of Sales from Contracts with Customers by Business Segment and Geography (Details) link:presentationLink link:calculationLink link:definitionLink 00000039 - Disclosure - Revenue Recognition (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000040 - Disclosure - Leases - Schedule of Lease Expense (Details) link:presentationLink link:calculationLink link:definitionLink 00000041 - Disclosure - Lease Obligations - Schedule of Maturities of Operating and Finance Lease Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 00000042 - Disclosure - Segment Information (Details) link:presentationLink link:calculationLink link:definitionLink 00000043 - Disclosure - Segment Information (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000044 - Disclosure - Subsequent Events (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 inis-20200331_cal.xml XBRL CALCULATION FILE EX-101.DEF 9 inis-20200331_def.xml XBRL DEFINITION FILE EX-101.LAB 10 inis-20200331_lab.xml XBRL LABEL FILE Ownership [Axis] TI Services, LLC RadQual, LLC Class of Stock [Axis] Series B Convertible Redeemable Preferred Stock Series C Redeemable Convertible Preferred Stock Antidilutive Securities [Axis] Stock Options Warrants Related Party Transactions by Related Parties [Axis] Affiliates of the Company Employee Stock Ownership Plan (ESOP) Name [Axis] Employee Stock Purchase Plan Plan Name [Axis] 2015 Incentive Plan Chief Executive Officer 2006 Equity Incentive Plan Class of Warrant or Right [Axis] Class M Warrants Class N Warrants Class O Warrants Long-term Debt, Type [Axis] 2013 Promissory Note Former Chairman of the Board 2018 Promissory Note Chief Executive Officer and Chairman of the Board Loss Contingency Nature [Axis] Contamination Event Business Segments [Axis] Radiochemical Products Geographical [Axis] U.S. Outside U.S. Cobalt Products Nuclear Medicine Products Radiological Services Fluorine Products Consolidation Items [Axis] Operating Segments Nuclear Medicine Standards Corporate Allocation Equity Components [Axis] Common Stock Additional Paid-In Capital Accumulated Deficit Deficit Attributable to Internat'l Isotopes Shareholders Equity Attributable to Noncontrolling Interest Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Note Agreement 2019 Promissory Note Major Shareholders Subsequent Event Type [Axis] Subsequent Event Debt Instrument [Axis] "SBA Loan" Paycheck Protection Program Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Statement of Financial Position [Abstract] Current assets Cash and cash equivalents Accounts receivable Inventories Prepaids and other current assets Total current assets Long-term assets Restricted cash Property, plant and equipment, net Financing lease right-of-use asset Operating lease right-of-use asset Goodwill Patents and other intangibles, net Total long-term assets Total assets Current liabilities Accounts payable Accrued liabilities Current portion of unearned revenue Current portion of operating lease right-of-use liability Current portion of financing lease liability Current installments of notes payable Total current liabilities Long-term liabilities Obligation for lease disposal costs Related party notes payable, net of debt discount Notes payable, net of current portion Financing lease liability, net of current portion Operating lease right-of-use liability, net of current portion Mandatorily redeemable convertible preferred stock, net of discount Total long-term liabilities Total liabilities Commitments and contingencies Stockholders' (Deficit) Equity Common stock Additional paid-in capital Accumulated deficit Deficit attributable to International Isotopes Inc. stockholders Equity attributable to noncontrolling interest Total equity (deficit) Total liabilities and stockholders' equity (deficit) Common stock, par value in dollars Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Income Statement [Abstract] Sale of product Cost of product Gross profit Operating costs and expenses: Salaries and contract labor General, administrative and consulting Research and development Total operating expenses Net operating (loss) income Other income (expense): Other income Interest income Interest expense Total other income (expense) Net (loss) income Less income attributable to non-controlling interest Net loss attributable to International Isotopes Inc. Net income (loss) per common share - basic Net income (loss) per common share - diluted Weighted average common shares outstanding - basic Weighted average common shares outstanding - diluted Statement of Cash Flows [Abstract] Cash flows from operating activities: Net (loss) income Adjustments to reconcile net loss to net cash used in operating activities: Depreciation and amortization Accretion of obligation for lease disposal costs Accretion of beneficial conversion feature and discount Equity based compensation Changes in operating assets and liabilities: EX-101.PRE 11 inis-20200331_pre.xml XBRL PRESENTATION FILE XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 R5.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Cash flows from operating activities:
Net (loss) income	$ (378,037)	$ 56,534
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	103,770	64,985
Accretion of obligation for lease disposal costs	10,100	9,387
Accretion of beneficial conversion feature and discount	92,430	38,788
Equity based compensation	51,522	63,737
Changes in operating assets and liabilities:
Accounts receivable	(148,130)	(536,554)
Inventories	44,047	(320,397)
Prepaids and other current assets	45,268	27,797
Accounts payable and accrued liabilities	117,068	222,378
Unearned revenues	(26,278)	(47,231)
Net cash used in operating activities	(88,240)	(420,576)
Cash flows from investing activities:
Purchase of property, plant and equipment	(1,565)	(5,084)
Net cash used in investing activities	(1,565)	(5,084)
Cash flows from financing activities:
Proceeds from sale of stock	6,666	1,581
Payments on financing lease	(577)
Proceeds from issuance of related party notes payable	325,000
Principal payments on notes payable	(245,728)	(1,939)
Net cash provided by (used in) financing activities	85,361	(358)
Net decrease in cash, cash equivalents, and restricted cash	(4,444)	(426,018)
Cash, cash equivalents, and restricted cash at beginning of period	1,210,920	1,450,467
Cash, cash equivalents, and restricted cash at end of period	1,206,476	1,024,449
Supplemental disclosure of cash flow activities:
Cash paid for interest	60,205	59,127
Supplemental disclosure of noncash financing and investing transactions:
Decrease in accrued interest and increase in equity for conversion of dividends to stock	204,480	205,980
Increase in operating lease right-of-use asset and right-of-use liability for new lease	2,649,070
Decrease in related party notes payable and increase in equity for amounts allocated to warrants and beneficial conversion feature	247,560
Reconciliation of cash, cash equivalents, and restricted cash as shown in the condensed consolidated statements of cash flows is presented in the table below:
Cash and cash equivalents	568,656	398,604
Restricted cash included in long-term assets	637,820	625,845
Total cash, cash equivalents and restricted cash shown in statement of cash flows	$ 1,206,476	$ 1,024,449

XML 14 R19.htm IDEA: XBRL DOCUMENT

Accounting Policies (Policies)	3 Months Ended
Accounting Policies (Policies)	Mar. 31, 2020
Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation – The accompanying unaudited condensed consolidated financial statements are presented in conformity with GAAP and include all operations and balances of INIS and its wholly-owned subsidiaries. The Company also consolidates the accounts of RadQual into the accompanying unaudited condensed consolidated financial statements. See Note 4 “Investment and Business Consolidation” for additional information regarding RadQual. All significant intercompany accounts and transactions have been eliminated in consolidation.
Interim Financial Information	Interim Financial Information – The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with GAAP for interim financial information and pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (SEC). Accordingly, the accompanying unaudited condensed consolidated financial statements do not include all of the information and notes required by GAAP for complete financial statements. In the opinion of management, all adjustments and reclassifications considered necessary in order to make the financial statements not misleading and for a fair and comparable presentation have been included and are of a normal recurring nature. Operating results for the three-month period ended March 31, 2020 are not necessarily indicative of the results that may be expected for the year ending December 31, 2020 or any future periods. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the Company’s Annual Report on Form 10-K for the year ended December 31, 2019 filed with the SEC on March 30, 2020.

XML 15 R1.htm IDEA: XBRL DOCUMENT

Cover - shares	3 Months Ended
Cover - shares	Mar. 31, 2020	May 15, 2020
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2020
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2020
Current Fiscal Year End Date	--12-31
Entity File Number	000-22923
Entity Registrant Name	INTERNATIONAL ISOTOPES INC
Entity Central Index Key	0001038277
Entity Incorporation, State or Country Code	TX
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		423,794,088

XML 16 R9.htm IDEA: XBRL DOCUMENT

Net Income (Loss) Per Common Share - Basic and Diluted

3 Months Ended

Mar. 31, 2020

Earnings Per Share [Abstract]

Net Income (Loss) Per Common Share - Basic and Diluted

(3) Net Income (Loss) Per Common Share - Basic and Diluted

The table below summarizes common stock equivalents outstanding at March 31, 2020:

	March 31,
	2020		2019
Stock options		23,655,000		27,205,000
Warrants		50,090,000		20,090,000
850 Shares of Series B redeemable convertible preferred stock		425,000		425,000
4,213 Shares of Series C redeemable convertible preferred stock		42,130,000		42,130,000
		116,300,000		89,850,000

XML 17 R11.htm IDEA: XBRL DOCUMENT

Inventories

3 Months Ended

Mar. 31, 2020

Inventory Disclosure [Abstract]

Inventories

(5) Inventories

Inventories consisted of the following at March 31, 2020 and December 31, 2019:

	March 31, 2020		December 31, 2019
Raw materials	$	40,648	$	40,648
Work in process		3,334,886		3,379,943
Finished goods		3,839		2,829
	$	3,379,373	$	3,423,420

XML 18 R15.htm IDEA: XBRL DOCUMENT

Revenue Recognition

3 Months Ended

Mar. 31, 2020

Revenue from Contract with Customer [Abstract]

Revenue Recognition

(9) Revenue Recognition

Revenue from Product Sales

The following tables present the Company’s revenue disaggregated by business segment and geography, based on management’s assessment of available data:

	Three Months Ended March 31, 2020									Three Months Ended March 31, 2019
	U.S.		Outside U.S.		Total Revenues		% of Total Revenues			U.S.		Outside U.S.		Total Revenues		% of Total Revenues
Radiochemical Products	$	668,591	$	86,630	$	755,221		32	%	$	459,967	$	3,265	$	463,232		18	%
Cobalt Products		305,620		—		305,620		13	%		336,089		40,000		376,089		15	%
Nuclear Medicine Products		867,604		174,520		1,042,124		45	%		1,080,472		20,450		1,100,922		44	%
Radiological Services		72,321		—		72,321		3	%		587,609		—		587,609		23	%
Fluorine Products		160,500		—		160,500		7	%		—		—		—		0	%
	$	2,074,636	$	261,150	$	2,335,786		100	%	$	2,464,137	$	63,715	$	2,527,852		100	%

Contract Balances

- Definition

The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-URI http://asc.fasb.org/topic&trid=49130388

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130551-203045

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130550-203045

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130558-203045

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045

+ Details

XML 19 R36.htm IDEA: XBRL DOCUMENT

Debt (Details Narrative) - USD ($)

3 Months Ended

12 Months Ended

Apr. 23, 2020

Mar. 31, 2020

Dec. 31, 2019

Dec. 31, 2018

Dec. 31, 2017

Dec. 31, 2016

Dec. 31, 2014

Dec. 31, 2013

Subsequent Event | "SBA Loan" Paycheck Protection Program

Interest rate

1.00%

Maturity date

Apr. 22, 2022

Proceeds from the SBA's Paycheck Protection Program

$ 495,500

Note Agreement

Note payable

$ 2,182,142

Notes payable, payment terms

2013 Promissory Note | Former Chairman of the Board

Maturity date

Dec. 31, 2021

Dec. 31, 2020

Dec. 31, 2017

Jun. 30, 2014

Debt instrument, description

The due date of the $500,000 note was extended to December 31, 2022, with all other terms of the note remaining unchanged.

Note payable, related party

$ 500,000

Accrued interest

189,234

Note payable, related party, interest rate

6.00%

Note payable, related party, maturity date

Dec. 31, 2022

Interest expense

7,500

Warrants issued

15,000,000

^[1]

10,000,000

^[2]

Warrants, exercise price

$ 0.06

Warrants expired

25,000,000

2018 Promissory Note | Chief Executive Officer and Chairman of the Board

Accrued interest

13,970

Note payable, related party, interest rate

6.00%

Note payable, related party, maturity date

Dec. 31, 2021

Mar. 31, 2019

Promissory note

$ 120,000

2019 Promissory Note | Major Shareholders

Available borrowings

$ 1,000,000

Proceeds from borrowings

325,000

$ 675,000

Accrued interest

$ 9,181

Note payable, related party, interest rate

4.00%

Note payable, related party, maturity date

Dec. 31, 2022

Warrants issued

30,000,000

Warrants, exercise price

$ 0.045

Fair value, warrants

$ 446,079

Beneficial conversion feature

$ 315,643

[1]	Each of the two lenders were granted 7,500,000 additional Class L warrants.
[2]	Each of two lenders issued 5,000,000 Class L warrants.

XML 20 R32.htm IDEA: XBRL DOCUMENT

Inventories (Details Narrative) - USD ($)	3 Months Ended
Inventories (Details Narrative) - USD ($)	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019
Inventory, Work in Process and Raw Materials
Inventory, cobalt-60 isotopes, carrying value	$ 201,349		$ 201,349
Approximate revenue from contract with customer	$ 11,000	$ 94,000

- Definition

Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 924
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-URI http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856

+ Details

XML 21 R23.htm IDEA: XBRL DOCUMENT

Revenue Recognition (Tables)

3 Months Ended

Mar. 31, 2020

Revenue from Contract with Customer [Abstract]

Summary of Sales from Contracts with Customers Disaggregated by Business Segment and Geography

	Three Months Ended March 31, 2020									Three Months Ended March 31, 2019
	U.S.		Outside U.S.		Total Revenues		% of Total Revenues			U.S.		Outside U.S.		Total Revenues		% of Total Revenues
Radiochemical Products	$	668,591	$	86,630	$	755,221		32	%	$	459,967	$	3,265	$	463,232		18	%
Cobalt Products		305,620		—		305,620		13	%		336,089		40,000		376,089		15	%
Nuclear Medicine Products		867,604		174,520		1,042,124		45	%		1,080,472		20,450		1,100,922		44	%
Radiological Services		72,321		—		72,321		3	%		587,609		—		587,609		23	%
Fluorine Products		160,500		—		160,500		7	%		—		—		—		0	%
	$	2,074,636	$	261,150	$	2,335,786		100	%	$	2,464,137	$	63,715	$	2,527,852		100	%

XML 22 R27.htm IDEA: XBRL DOCUMENT

Current Developments and Liquidity (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Net (loss) income attributable to International Isotopes Inc.	$ (422,494)	$ (51,958)
Net cash (used in) provided by operating activities	$ (88,240)	$ (420,576)
Operating license term, description	NRC license for the de-conversion facility for a 40 year operating license.

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794

+ Details

XML 23 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.1 html 156 319 1 true 39 0 false 5 false false R1.htm 00000001 - Document - Cover Sheet http://intisoid.com/role/Cover Cover Cover 1 false false R2.htm 00000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited) Sheet http://intisoid.com/role/BalanceSheets Condensed Consolidated Balance Sheets (Unaudited) Statements 2 false false R3.htm 00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://intisoid.com/role/BalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited) Sheet http://intisoid.com/role/StatementsOfOperations Condensed Consolidated Statements of Operations (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://intisoid.com/role/StatementsOfCashFlows Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 5 false false R6.htm 00000006 - Statement - Reconciliation of Stockholders' (Deficit) Equity Sheet http://intisoid.com/role/ReconciliationOfStockholdersDeficitEquity Reconciliation of Stockholders' (Deficit) Equity Statements 6 false false R7.htm 00000007 - Disclosure - The Company and Basis of Presentation Sheet http://intisoid.com/role/CompanyAndBasisOfPresentation The Company and Basis of Presentation Notes 7 false false R8.htm 00000008 - Disclosure - Current Developments and Liquidity Sheet http://intisoid.com/role/CurrentDevelopmentsAndLiquidity Current Developments and Liquidity Notes 8 false false R9.htm 00000009 - Disclosure - Net Income (Loss) Per Common Share - Basic and Diluted Sheet http://intisoid.com/role/NetLossPerCommonShare-BasicAndDiluted Net Income (Loss) Per Common Share - Basic and Diluted Notes 9 false false R10.htm 00000010 - Disclosure - Investment and Business Consolidation Sheet http://intisoid.com/role/Investment Investment and Business Consolidation Notes 10 false false R11.htm 00000011 - Disclosure - Inventories Sheet http://intisoid.com/role/Inventories Inventories Notes 11 false false R12.htm 00000012 - Disclosure - Stockholders' Equity, Options and Warrants Sheet http://intisoid.com/role/StockholdersEquityOptionsAndWarrants Stockholders' Equity, Options and Warrants Notes 12 false false R13.htm 00000013 - Disclosure - Debt Sheet http://intisoid.com/role/Debt Debt Notes 13 false false R14.htm 00000014 - Disclosure - Commitments and Contingencies Sheet http://intisoid.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 14 false false R15.htm 00000015 - Disclosure - Revenue Recognition Sheet http://intisoid.com/role/RevenueRecognition Revenue Recognition Notes 15 false false R16.htm 00000016 - Disclosure - Leases Sheet http://intisoid.com/role/Leases Leases Notes 16 false false R17.htm 00000017 - Disclosure - Segment Information Sheet http://intisoid.com/role/SegmentInformation Segment Information Notes 17 false false R18.htm 00000018 - Disclosure - Subsequent Events Sheet http://intisoid.com/role/SubsequentEvents Subsequent Events Notes 18 false false R19.htm 00000019 - Disclosure - Accounting Policies (Policies) Sheet http://intisoid.com/role/AccountingPoliciesPolicies Accounting Policies (Policies) Policies 19 false false R20.htm 00000020 - Disclosure - Net Income (Loss) Per Common Share - Basic and Diluted (Tables) Sheet http://intisoid.com/role/NetIncomeLossPerCommonShare-BasicAndDilutedTables Net Income (Loss) Per Common Share - Basic and Diluted (Tables) Tables http://intisoid.com/role/NetLossPerCommonShare-BasicAndDiluted 20 false false R21.htm 00000021 - Disclosure - Inventories (Tables) Sheet http://intisoid.com/role/InventoriesTables Inventories (Tables) Tables http://intisoid.com/role/Inventories 21 false false R22.htm 00000022 - Disclosure - Stockholders' Equity, Options and Warrants (Tables) Sheet http://intisoid.com/role/StockholdersEquityOptionsAndWarrantsTables Stockholders' Equity, Options and Warrants (Tables) Tables http://intisoid.com/role/StockholdersEquityOptionsAndWarrants 22 false false R23.htm 00000023 - Disclosure - Revenue Recognition (Tables) Sheet http://intisoid.com/role/RevenueRecognitionTables Revenue Recognition (Tables) Tables http://intisoid.com/role/RevenueRecognition 23 false false R24.htm 00000024 - Disclosure - Leases (Tables) Sheet http://intisoid.com/role/LeasesTables Leases (Tables) Tables http://intisoid.com/role/Leases 24 false false R25.htm 00000025 - Disclosure - Segment Information (Tables) Sheet http://intisoid.com/role/SegmentInformationTables Segment Information (Tables) Tables http://intisoid.com/role/SegmentInformation 25 false false R26.htm 00000026 - Disclosure - The Company and Basis of Presentation (Details Narrative) Sheet http://intisoid.com/role/CompanyAndBasisOfPresentation-JointVentureDetailsNarrative The Company and Basis of Presentation (Details Narrative) Details http://intisoid.com/role/CompanyAndBasisOfPresentation 26 false false R27.htm 00000027 - Disclosure - Current Developments and Liquidity (Details Narrative) Sheet http://intisoid.com/role/CurrentDevelopmentsAndLiquidityDetailsNarrative Current Developments and Liquidity (Details Narrative) Details http://intisoid.com/role/CurrentDevelopmentsAndLiquidity 27 false false R28.htm 00000028 - Disclosure - Net Income (Loss) Per Common Share - Basic and Diluted - Schedule of Common Stock Equivalents (Details) Sheet http://intisoid.com/role/NetLossPerCommonShare-BasicAndDilutedDetailsNarrative Net Income (Loss) Per Common Share - Basic and Diluted - Schedule of Common Stock Equivalents (Details) Details http://intisoid.com/role/NetIncomeLossPerCommonShare-BasicAndDilutedTables 28 false false R29.htm 00000029 - Disclosure - Net Income (Loss) Per Common Share - Basic and Diluted (Details Narrative) Sheet http://intisoid.com/role/NetIncomeLossPerCommonShare-BasicAndDilutedDetailsNarrative Net Income (Loss) Per Common Share - Basic and Diluted (Details Narrative) Details http://intisoid.com/role/NetIncomeLossPerCommonShare-BasicAndDilutedTables 29 false false R30.htm 00000030 - Disclosure - Investment and Business Consolidation (Details Narrative) Sheet http://intisoid.com/role/InvestmentDetailsNarrative Investment and Business Consolidation (Details Narrative) Details http://intisoid.com/role/Investment 30 false false R31.htm 00000031 - Disclosure - Inventories - Schedule of Inventory, Current (Details) Sheet http://intisoid.com/role/InventoriesDetails Inventories - Schedule of Inventory, Current (Details) Details 31 false false R32.htm 00000032 - Disclosure - Inventories (Details Narrative) Sheet http://intisoid.com/role/InventoriesDetailsNarrative Inventories (Details Narrative) Details http://intisoid.com/role/InventoriesTables 32 false false R33.htm 00000033 - Disclosure - Shareholders' Equity, Options and Warrants - Schedule of Stock Option Activity (Details) Sheet http://intisoid.com/role/ShareholdersEquityOptionsAndWarrants-ScheduleOfStockOptionActivityDetails Shareholders' Equity, Options and Warrants - Schedule of Stock Option Activity (Details) Details 33 false false R34.htm 00000034 - Disclosure - Shareholders' Equity, Options and Warrants - Employee Stock Purchase Plan (Details Narrative) Sheet http://intisoid.com/role/ShareholdersEquityOptionsAndWarrants-EmployeeStockPurchasePlanDetailsNarrative Shareholders' Equity, Options and Warrants - Employee Stock Purchase Plan (Details Narrative) Details 34 false false R35.htm 00000035 - Disclosure - Shareholders' Equity, Options and Warrants - Stock-Based Compensation Plans (Details Narrative) Sheet http://intisoid.com/role/ShareholdersEquityOptionsAndWarrants-Stock-basedCompensationPlansDetailsNarrative Shareholders' Equity, Options and Warrants - Stock-Based Compensation Plans (Details Narrative) Details 35 false false R36.htm 00000036 - Disclosure - Debt (Details Narrative) Sheet http://intisoid.com/role/DebtDetailsNarrative Debt (Details Narrative) Details http://intisoid.com/role/Debt 36 false false R37.htm 00000037 - Disclosure - Commitments and Contingencies (Detail Narrative) Sheet http://intisoid.com/role/CommitmentsAndContingenciesDetailNarrative Commitments and Contingencies (Detail Narrative) Details http://intisoid.com/role/CommitmentsAndContingencies 37 false false R38.htm 00000038 - Disclosure - Revenue Recognition - Summary of Sales from Contracts with Customers by Business Segment and Geography (Details) Sheet http://intisoid.com/role/RevenueRecognition-SummaryOfSalesFromContractsWithCustomersByBusinessSegmentAndGeographyDetails Revenue Recognition - Summary of Sales from Contracts with Customers by Business Segment and Geography (Details) Details 38 false false R39.htm 00000039 - Disclosure - Revenue Recognition (Details Narrative) Sheet http://intisoid.com/role/RevenueRecognitionDetailsNarrative Revenue Recognition (Details Narrative) Details http://intisoid.com/role/RevenueRecognitionTables 39 false false R40.htm 00000040 - Disclosure - Leases - Schedule of Lease Expense (Details) Sheet http://intisoid.com/role/Leases-ScheduleOfLeaseExpenseDetails Leases - Schedule of Lease Expense (Details) Details 40 false false R41.htm 00000041 - Disclosure - Lease Obligations - Schedule of Maturities of Operating and Finance Lease Liabilities (Details) Sheet http://intisoid.com/role/LeaseObligations-ScheduleOfMaturitiesOfOperatingAndFinanceLeaseLiabilitiesDetails Lease Obligations - Schedule of Maturities of Operating and Finance Lease Liabilities (Details) Details 41 false false R42.htm 00000042 - Disclosure - Segment Information (Details) Sheet http://intisoid.com/role/SegmentInformationDetails Segment Information (Details) Details http://intisoid.com/role/SegmentInformationTables 42 false false R43.htm 00000043 - Disclosure - Segment Information (Details Narrative) Sheet http://intisoid.com/role/SegmentInformationDetailsNarrative Segment Information (Details Narrative) Details http://intisoid.com/role/SegmentInformationTables 43 false false R44.htm 00000044 - Disclosure - Subsequent Events (Details Narrative) Sheet http://intisoid.com/role/SubsequentEventsDetailsNarrative Subsequent Events (Details Narrative) Details http://intisoid.com/role/SubsequentEvents 44 false false All Reports Book All Reports inis-20200331.xml inis-20200331.xsd inis-20200331_cal.xml inis-20200331_def.xml inis-20200331_lab.xml inis-20200331_pre.xml http://fasb.org/us-gaap/2020-01-31 http://fasb.org/srt/2020-01-31 http://xbrl.sec.gov/country/2020-01-31 http://xbrl.sec.gov/dei/2019-01-31 true true XML 24 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 25 R42.htm IDEA: XBRL DOCUMENT

Segment Information (Details) - USD ($)	3 Months Ended
Segment Information (Details) - USD ($)	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019
Segment Reporting Information [Line Items]
Sale of Product	$ 2,335,786	$ 2,527,852
Depreciation and Amortization	74,617	64,985
Segment Income (Loss)	(422,494)	(51,958)
Expenditures for Segment Assets	1,565	5,084
Segment Assets	17,158,384		$ 15,256,795
Radiochemical Products
Segment Reporting Information [Line Items]
Sale of Product	755,221	463,232
Cobalt Products
Segment Reporting Information [Line Items]
Sale of Product	305,620	376,089
Radiological Services
Segment Reporting Information [Line Items]
Sale of Product	72,321	587,609
Fluorine Products
Segment Reporting Information [Line Items]
Sale of Product	160,500	0
Operating Segments
Segment Reporting Information [Line Items]
Sale of Product	2,335,786	2,527,852
Depreciation and Amortization	69,835	60,248
Segment Income (Loss)	422,657	779,481
Expenditures for Segment Assets	1,565	5,084
Segment Assets	11,591,845		11,576,616
Operating Segments \| Radiochemical Products
Segment Reporting Information [Line Items]
Sale of Product	755,221	463,232
Depreciation and Amortization	10,354	8,817
Segment Income (Loss)	5,619	96,006
Expenditures for Segment Assets	0	0
Segment Assets	536,603		511,381
Operating Segments \| Cobalt Products
Segment Reporting Information [Line Items]
Sale of Product	305,620	376,089
Depreciation and Amortization	8,761	1,080
Segment Income (Loss)	123,796	192,870
Expenditures for Segment Assets	0	3,494
Segment Assets	3,388,527		3,369,828
Operating Segments \| Nuclear Medicine Standards
Segment Reporting Information [Line Items]
Sale of Product	1,042,124	1,100,922
Depreciation and Amortization	15,989	15,619
Segment Income (Loss)	185,301	216,822
Expenditures for Segment Assets	0	0
Segment Assets	2,087,295		2,111,225
Operating Segments \| Radiological Services
Segment Reporting Information [Line Items]
Sale of Product	72,321	587,609
Depreciation and Amortization	8,636	8,636
Segment Income (Loss)	(14,929)	311,279
Expenditures for Segment Assets	0	0
Segment Assets	96,427		106,374
Operating Segments \| Fluorine Products
Segment Reporting Information [Line Items]
Sale of Product	160,500	0
Depreciation and Amortization	26,095	26,095
Segment Income (Loss)	122,870	(37,495)
Expenditures for Segment Assets	1,565	1,590
Segment Assets	5,482,993		5,477,808
Corporate Allocation
Segment Reporting Information [Line Items]
Sale of Product	0	0
Depreciation and Amortization	4,782	4,737
Segment Income (Loss)	(845,151)	(831,439)
Expenditures for Segment Assets	0	$ 0
Segment Assets	$ 5,566,539		$ 3,680,179

XML 26 R22.htm IDEA: XBRL DOCUMENT

Stockholders' Equity, Options and Warrants (Tables)

3 Months Ended

Mar. 31, 2020

Equity [Abstract]

Schedule of Share-Based Compensation Stock Option Activity

Fixed Options	Shares		Weighted Average Exercise Price		Weighted Average Remaining Contractual Life		Aggregate Intrinsic Value
Outstanding at December 31, 2019		23,655,000	$	0.05
Granted		—	$	—
Exercised		—	$	—
Expired		—	$	—
Forfeited		—	$	—
Outstanding at March 31, 2020		23,655,000	$	0.05		6.1	$	235,000
Exerciseable at March 31, 2020		17,936,000	$	0.05		5.6	$	235,000

XML 27 R26.htm IDEA: XBRL DOCUMENT

The Company and Basis of Presentation (Details Narrative)	Mar. 31, 2020	Aug. 31, 2017
TI Services, LLC
Ownership interest, percentage by parent	50.00%
RadQual, LLC
Ownership interest, percentage by parent	24.50%
RadQual, LLC \| Affiliates of the Company
Ownership interest, percentage by parent		75.50%

XML 28 R43.htm IDEA: XBRL DOCUMENT

Segment Information (Details Narrative)	3 Months Ended
Segment Information (Details Narrative)	Mar. 31, 2020 Integer
Segment Reporting [Abstract]
Number of reportable segments	5

ZIP 29 0001515971-20-000065-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001515971-20-000065-xbrl.zip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end XML 30 R10.htm IDEA: XBRL DOCUMENT v3.20.1

Investment and Business Consolidation
3 Months Ended

Mar. 31, 2020

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Investment and Business Consolidation
(4) Investment and Business Consolidation

The Company owns a 24.5% interest in RadQual, with which the Company has an exclusive manufacturing agreement for nuclear medicine products. In August 2017, affiliates of the Company, including the Company’s Chairman of the Board and the Chief Executive Officer, acquired the remaining 75.5% interest in RadQual. The Company’s Chairman of the Board and its Chief Executive Officer also each serve as the managing members of RadQual. As a result of this change in ownership, and other factors, the Company determined that it gained the ability to exercise significant management control over the operations of RadQual. Because of this increased management control, and pursuant to GAAP, the Company has consolidated the accounts of RadQual into its financial statements.

X

- References
No definition available.
+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-URI http://asc.fasb.org/topic&trid=2122149

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-URI http://asc.fasb.org/topic&trid=2197479
+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 31 R8.htm IDEA: XBRL DOCUMENT v3.20.1

Current Developments and Liquidity
3 Months Ended

Mar. 31, 2020

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Current Developments and Liquidity
(2) Current Developments and Liquidity

Business Condition – Since inception, the Company has incurred substantial losses. During the three-months ended March 31, 2020, the Company reported a net loss of $422,494, net of non-controlling interest, and net cash used in operating activities of $88,240.

During the three-months ended March 31, 2019, the Company reported net loss of $51,958, net of non-controlling interest, and net cash used in operating activities of $420,576.

During the three-months ended March 31, 2020, the Company continued its focus on its long-standing core business segments which consist of its radiochemical products, cobalt products, nuclear medicine standards, and radiological services, and in particular, the pursuit of new business opportunities within those segments. During this period the Company received approval from the U.S. Food and Drug Administration (FDA) for a generic sodium iodide I-131 drug product. This product is approved for use in treatment of hyperthyroidism and carcinoma of the thyroid and is the first generic product approved by the FDA in the US.

Additionally, the Company holds a Nuclear Regulatory Commission (NRC) construction and operating license for the depleted uranium facility in, as well as the property agreement with, Lea County, New Mexico, where the plant is intended to be constructed. The NRC license for the de-conversion facility is a forty (40) year operating license and is the first commercial license of this type issued in the United States. There are no other companies with a similar license application under review by the NRC. Therefore, the NRC license represents a significant competitive barrier and the Company considers it a valuable asset.

The Company expects that cash from operations, cash raised through equity or debt financing and its current cash balance will be sufficient to fund operations for the next twelve months. Future liquidity and capital funding requirements will depend on numerous factors, including, contract manufacturing agreements, commercial relationships, technological developments, market factors, available credit, and voluntary warrant redemption by shareholders. There is no assurance that additional capital and financing will be available on acceptable terms to the Company or at all.

X

- References
No definition available.
+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 40
-URI http://asc.fasb.org/subtopic&trid=51888271
+ Details

Name: us-gaap_SubstantialDoubtAboutGoingConcernTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 32 R14.htm IDEA: XBRL DOCUMENT v3.20.1

Commitments and Contingencies
3 Months Ended

Mar. 31, 2020

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies
(8) Commitments and Contingencies

Dependence on Third Parties

The production of High Specific Activity Cobalt is dependent upon the DOE, and its prime operating contractor, which controls the ATR and laboratory operations at the ATR located outside of Idaho Falls, Idaho. In October 2014, the Company signed a ten-year contract with the DOE for the irradiation of cobalt targets for the production of cobalt-60. The Company will be able to purchase cobalt targets for a fixed price per target with an annual 5% escalation in price. The contract term is October 1, 2014, through September 30, 2024, however, the contract may be extended beyond that date. Also, the DOE may end the contract if it determines termination is necessary for the national defense, security or environmental safety of the United States. If this were to occur, all payments made by the Company, for partially irradiated undelivered cobalt material, would be refunded.

Nuclear Medicine Reference and Calibration Standard manufacturing is conducted under an exclusive contract with RadQual, which in turn has an agreement in place with several companies for distributing the products. The radiochemical product sold by the Company is supplied to the Company through agreements with several suppliers. A loss of any of these customers or suppliers could adversely affect operating results by causing a delay in production or a possible loss of sales.

(8) Contingencies

Because all the Company’s business segments involve the handling or use of radioactive material, the Company is required to have an operating license from the NRC and specially trained staff to handle these materials. The Company has amended this operating license numerous times to increase the amount of material permitted within the Company’s facility. Although this license does not currently restrict the volume of business operations performed or projected to be performed in the upcoming year, additional processing capabilities and license amendments could be implemented that would permit processing of other reactor-produced radioisotopes by the Company. The financial assurance required by the NRC to support this license has been provided for with a surety bond held with North American Specialty Insurance Company which is supported by a restricted money market account held with Merrill Lynch in the amount of $637,820.

In August 2011, the Company received land from Lea County, New Mexico, pursuant to a Project Participation Agreement (PPA), whereby the land was deeded to the Company for no monetary consideration. In return, the Company committed to construct a uranium de-conversion and Fluorine Extraction Process facility on the land. In order to retain title to the property, the Company was to begin construction of the de-conversion facility no later than December 31, 2014, and complete Phase I of the project and have hired at least 75 persons to operate the facility no later than December 31, 2015, although commercial operations need not have begun by that date. In 2015, the Company negotiated a modification to the PPA that extended the start of construction date to December 31, 2015, and the hiring milestone to December 31, 2016. Those dates were also not met. The Company is in discussion with commercial companies possibly interested in purchasing rights to this project. Should those discussions come to fruition the Company plans to negotiate a second modification to the PPA agreement to further extend the commitment dates. If the Company is not successful in reaching an amendment to extend the performance dates in the PPA. then it may, at its sole option, either purchase or re-convey the property to Lea County, New Mexico. The purchase price of the property would be $776,078, plus interest at the annual rate of 5.25% from the date of the closing to the date of payment. The Company has not recorded the value of this property as an asset and will not do so until such time that sufficient progress on the project has been made to meet the Company’s obligations under the agreements for permanent transfer of the title.

On May 3, 2019, the Company’s radiological services team was involved in a contamination event involving a breached cesium-137 source at an off-site location in the state of Washington. This work was being performed under a contract with the DOE. The Company supported the initial onsite contamination clean-up operations at that location and completed removal of the cesium source Company equipment. The Company has reviewed the results of the DOE investigation into this event and has implemented appropriate corrective actions. Since August 2019 the DOE has assumed full control of the ongoing cleanup operations and has assumed all of the financial obligations associated with the contractors hired to carry out all of the facility recovery operations. Under the terms of the contract the Company believes it should be indemnified from financial liability for this event by the DOE under the Price Anderson Act (PAA) and the Company has formally requested the DOE to provide indemnification under the PAA. While the DOE’s review of the request is still underway the Company believes that a determination of indemnification under the PAA is probable. Such indemnification would allow the Company to recoup all its costs associated with this contamination event. During 2019, the Company incurred $2,384,255 in expenses related to the contamination and its cleanup. During 2019, the Company received $964,958 in reimbursements from its insurance company for expenses related to the contamination and its cleanup, and the Company has determined that an additional $1,244,744 of its incurred expenses related to the contamination and its cleanup are probable for recovery pursuant to ASC 410-30. The Company believes additional cost recoveries beyond that which is recorded are possible but are not yet deemed probable at this time.

X

- References
No definition available.
+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for commitments and contingencies.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-URI http://asc.fasb.org/topic&trid=2127136

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 440
-URI http://asc.fasb.org/topic&trid=2144648

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 440
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 440
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308
+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 33 R4.htm IDEA: XBRL DOCUMENT v3.20.1

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
3 Months Ended

Mar. 31, 2020

Mar. 31, 2019

Income Statement [Abstract]

Sale of product $ 2,335,786 $ 2,527,852

Cost of product 968,525 1,088,429

Gross profit 1,367,261 1,439,423

Operating costs and expenses:

Salaries and contract labor 741,205 623,699

General, administrative and consulting 788,438 626,863

Research and development 46,928 46,304

Total operating expenses 1,576,571 1,296,866

Net operating (loss) income (209,310) 142,557

Other income (expense):

Other income 23,818 24,632

Interest income 2,335 3,422

Interest expense (194,880) (114,077)

Total other income (expense) (168,727) (86,023)

Net (loss) income (378,037) 56,534

Less income attributable to non-controlling interest 44,457 108,492

Net loss attributable to International Isotopes Inc. $ (422,494) $ (51,958)

Net income (loss) per common share - basic

Net income (loss) per common share - diluted

Weighted average common shares outstanding - basic 420,692,023 413,906,700

Weighted average common shares outstanding - diluted 420,692,023 413,906,700

X

- Definition
The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 924
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-URI http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.2(a),(d))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227
+ Details

Name: us-gaap_CostOfGoodsAndServicesSold

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=120380238&loc=d3e4984-109258

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260
+ Details

Name: us-gaap_EarningsPerShareBasic

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=120380238&loc=d3e4984-109258

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227
+ Details

Name: us-gaap_EarningsPerShareDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.4)
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227
+ Details

Name: us-gaap_GeneralAndAdministrativeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1,2)
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599
+ Details

Name: us-gaap_GrossProfit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_IncomeStatementAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of the cost of borrowed funds accounted for as interest expense.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=119993939&loc=d3e28555-108399

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (210.5-03(11))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04.9)
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260
+ Details

Name: us-gaap_InterestExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.7(b))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599
+ Details

Name: us-gaap_InvestmentIncomeInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(b)(4))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227
+ Details

Name: us-gaap_LaborAndRelatedExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of Net Income (Loss) attributable to noncontrolling interest.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (a)(2)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4J
-URI http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794
+ Details

Name: us-gaap_NetIncomeLossAttributableToNoncontrollingInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.7)
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227
+ Details

Name: us-gaap_NonoperatingIncomeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NonoperatingIncomeExpenseAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.
+ References
No definition available.
+ Details

Name: us-gaap_OperatingExpenses

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OperatingExpensesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The net result for the period of deducting operating expenses from operating revenues.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599
+ Details

Name: us-gaap_OperatingIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of income (expense) related to nonoperating activities, classified as other.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.9)
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227
+ Details

Name: us-gaap_OtherNonoperatingIncomeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 235
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-URI http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884

Reference 8: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 14: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4J
-URI http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3000-108585

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 20: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4K
-URI http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794
+ Details

Name: us-gaap_ProfitLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 985
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373
+ Details

Name: us-gaap_ResearchAndDevelopmentExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 924
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-URI http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856
+ Details

Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 16
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1505-109256
+ Details

Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256
+ Details

Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 34 R18.htm IDEA: XBRL DOCUMENT v3.20.1

Subsequent Events
3 Months Ended

Mar. 31, 2020

Subsequent Events [Abstract]

Subsequent Events
(12) Subsequent Events

As described under Debt above, on April 23, 2020, the Company, through its wholly-owned subsidiary entered into a Loan Agreement and Promissory Note (collectively the “SBA Loan”) with KeyBank National Association pursuant to the Paycheck Protection Program (the “PPP”) under the recently enacted Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”) administered by the U.S. Small Business Administration (the “SBA”). The Company received total proceeds of $495,500 from the SBA Loan. The SBA Loan is scheduled to mature on April 22, 2022 and has a 1.00% interest rate and is subject to the terms and conditions applicable to loans administered by the SBA under the CARES Act. The SBA Loan may be prepaid at any time prior to maturity with no prepayment penalties.

X

- References
No definition available.
+ Details

Name: us-gaap_SubsequentEventsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 855
-URI http://asc.fasb.org/topic&trid=2122774

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 855
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662
+ Details

Name: us-gaap_SubsequentEventsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 35 R37.htm IDEA: XBRL DOCUMENT v3.20.1

Commitments and Contingencies (Detail Narrative) - USD ($)
3 Months Ended 12 Months Ended

Mar. 31, 2020

Dec. 31, 2019

Restricted cash $ 637,820

Other commitments, description In August 2011, the Company received land from Lea County, New Mexico, pursuant to a Project Participation Agreement (PPA), whereby the land was deeded to the Company for no monetary consideration. In return, we committed to construct a uranium de-conversion and Fluorine Extraction Process (FEP) facility on the land. In order to retain title to the property, we were to begin construction of the de-conversion facility no later than December 31, 2014, and complete Phase I of the project and have hired at least 75 persons to operate the facility no later than December 31, 2015, although commercial operations need not have begun by that date. In 2015, the Company negotiated a modification to the PPA agreement that extended the start of construction date to December 31, 2015, and the hiring milestone to December 31, 2016. Those dates were not met and the Company is currently in the process of renegotiating a second modification to the agreement to further extend those dates. If the Company is not successful in extending the performance dates in the agreement then it may, at its sole option, either purchase or re-convey the property to Lea County, New Mexico. The purchase price of the property would be $776,078, plus interest at the annual rate of 5.25% from the date of the closing to the date of payment. The Company has not recorded the value of this property as an asset and will not do so until such time that sufficient progress on the project has been made to meet our obligations under the agreements for permanent transfer of the title.

Contamination Event

Expenses related to contamination $ 2,384,255

Proceeds from insurance claims 964,958

Potential recovery from insurance claims of additional incurred expenses $ 1,244,744

X

- Definition
The amount or range of possible amounts of gain that could be realized upon the resolution of a contingency.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6397426&loc=d3e17499-108355
+ Details

Name: us-gaap_GainContingencyUnrecordedAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Description of the nature and terms of commitment.
+ References
No definition available.
+ Details

Name: us-gaap_OtherCommitmentsDescription

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of expense classified as other.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.4,6)
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04.7)
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263
+ Details

Name: us-gaap_OtherExpenses

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of cash inflow for proceeds from settlement of insurance claim, classified as operating activities. Excludes insurance settlement classified as investing activities.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 16
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3337-108585

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 21B
-URI http://asc.fasb.org/extlink&oid=121586364&loc=SL94080549-108585
+ Details

Name: us-gaap_ProceedsFromInsuranceSettlementOperatingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The noncurrent cash, cash equivalents and investments that is restricted as to withdrawal or usage. Restrictions may include legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or entity statements of intention with regard to particular deposits classified as long-term; that is not expected to be released from such existing restrictions within one year of the balance sheet date or operating cycle, whichever is longer. Excludes compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. Includes noncurrent cash equivalents and investments that are similarly restricted as to withdrawal, usage or disposal.
+ References
No definition available.
+ Details

Name: us-gaap_RestrictedCashAndInvestmentsNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_LossContingenciesByNatureOfContingencyAxis=inis_ContaminationEventMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 36 R33.htm IDEA: XBRL DOCUMENT v3.20.1

Shareholders' Equity, Options and Warrants - Schedule of Stock Option Activity (Details)
3 Months Ended

Mar. 31, 2020

USD ($)

$ / shares

shares

Share-Based Compensation Arrangement By Share-Based Payment Award Options Outstanding

Stock options outstanding, beginning of period | shares 23,655,000

Stock options, granted | shares

Stock options, exercised | shares

Stock options, expired | shares

Stock options, forfeited | shares

Stock options outstanding, end of period | shares 23,655,000

Stock options exercisable, end of period | shares 17,936,000

Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price

Weighted average exercise price outstanding, beginning of period | $ / shares $ 0.05

Weighted average exercise price, granted | $ / shares

Weighted average exercise price, exercised | $ / shares

Weighted average exercise priced, expired | $ / shares

Weighted average exercise priced, forfeited | $ / shares

Weighted average exercise price outstanding, end of period | $ / shares 0.05

Weighted average exercise price exercisable, end of period | $ / shares $ 0.05

Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures

Weighted average remaining contractual life outstanding, end of period 6 years 1 month

Weighted average remaining contractual life exercisable, end of period 5 years 7 months

Average intrinsic value outstanding, end of period | $ $ 235,000

Average intrinsic value, exercisable, end of period | $ $ 235,000

X

- References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iii)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iii)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(4)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(3)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Gross number of share options (or share units) granted during the period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Number of options outstanding, including both vested and non-vested options.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)-(ii)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average price at which option holders acquired shares when converting their stock options into shares.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of share options (or share units) exercised during the current period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(2)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 37 R28.htm IDEA: XBRL DOCUMENT v3.20.1

Net Income (Loss) Per Common Share - Basic and Diluted - Schedule of Common Stock Equivalents (Details) - shares
3 Months Ended

Mar. 31, 2020

Mar. 31, 2019

Dec. 31, 2019

Stock options, outstanding 23,655,000 27,205,000 23,655,000

Warrants, outstanding 50,090,000 20,090,000

Series B Convertible Redeemable Preferred Stock

Redeemable convertible preferred stock, outstanding 850 850

Weighted average shares, outstanding 425,000 425,000

Series C Redeemable Convertible Preferred Stock

Redeemable convertible preferred stock, outstanding 4,213 4,213

Weighted average shares, outstanding 42,130,000 42,130,000

X

- Definition
Number of warrants or rights outstanding.
+ References
No definition available.
+ Details

Name: us-gaap_ClassOfWarrantOrRightOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of options outstanding, including both vested and non-vested options.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)-(ii)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).
+ References
No definition available.
+ Details

Name: us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 38 R20.htm IDEA: XBRL DOCUMENT v3.20.1

Net Income (Loss) Per Common Share - Basic and Diluted (Tables)
3 Months Ended

Mar. 31, 2020

Earnings Per Share [Abstract]

Schedule of Common Stock Equivalents

March 31,

2020 2019

Stock options 23,655,000 27,205,000

Warrants 50,090,000 20,090,000

850 Shares of Series B redeemable convertible preferred stock 425,000 425,000

4,213 Shares of Series C redeemable convertible preferred stock 42,130,000 42,130,000

116,300,000 89,850,000

X

- Definition
Schedule of common stock equivalents outstanding.
+ References
No definition available.
+ Details

Name: inis_ScheduleOfCommonStockEquivalentsTableTextBlock

Namespace Prefix: inis_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 39 R24.htm IDEA: XBRL DOCUMENT v3.20.1

Leases (Tables)
3 Months Ended

Mar. 31, 2020

Leases [Abstract]

Schedule of Lease Expense

Three Months Ended March 31,

2020 2019

Operating lease costs $ 68,400 $ 36,853

Short-term operating lease costs 8,876 1,902

Financing lease expense:

Amortization of right-of-use assets 577 —

Interest on lease liabilities 222 —

Total financing lease expense 799

Total lease expense $ 78,075 $ 38,755

Right-of-use assets obtained in exchange for new operating lease liabilities $ 2,649,070 $ 810,367

Right-of-use assets obtained in exchange for new financing lease liabilities $ — $ —

Weighted-average remaining lease term (years) - operating leases 14.8 7.0

Weighted-average remaining lease term (years) - financing leases 4.7

Weighted-average discount rate - operating leases 6.75 % 6.75 %

Weighted-average discount rate - financing leases 6.75 %

Schedule of Maturities of Operating and Finance Lease Liabilities

Operating Financing

2020 (excluding the three months ended March 31, 2020) $ 198,091 $ 2,397

2021 257,383 3,195

2022 284,631 3,195

2023 287,108 3,195

2024 287,108 2,929

Thereafter 2,886,518 —

Total minimum operating lease obligations 4,200,839 14,911

Less-amounts representing interest (1,563,909 ) (2,151 )

Present value of minimum operating lease obligations 2,636,930 12,760

Current maturities (87,158 ) (2,407 )

Lease obligations, net of current maturities $ 2,549,772 $ 10,353

X

- Definition
Tabular disclosure of undiscounted cash flows of lessee's operating and financing lease liabilities. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating and financing lease liabilities recognized in statement of financial position.
+ References
No definition available.
+ Details

Name: inis_ScheduleOfMaturitiesOfOperatingAndFinanceLeaseLiabilitiesTableTextBlock

Namespace Prefix: inis_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980
+ Details

Name: us-gaap_LeaseCostTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_LeasesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 40 R41.htm IDEA: XBRL DOCUMENT v3.20.1

Lease Obligations - Schedule of Maturities of Operating and Finance Lease Liabilities (Details) - USD ($)

Mar. 31, 2020

Dec. 31, 2019

Operating Leases Liability, Payment Due, Rolling Maturity

Year ending December 31, 2020 (excluding the three-months ended March 31, 2020) $ 198,091

Year ending December 31, 2021 257,383

Year ending December 31, 2022 284,631

Year ending December 31, 2023 287,108

Year ending December 31, 2024 287,108

Thereafter 2,886,518

Total minimum operating lease obligations 4,200,839

Less-amount representing interest (1,563,909)

Present value of minimum operating lease obligations 2,636,930

Current maturities (87,158) $ (100,777)

Lease obligations, net of current maturities 2,549,772 609,106

Finance Leases, Liability, Payment, Due, Rolling Maturity

Year ending December 31, 2020 (excluding the three-months ended March 31, 2020) 2,397

Year ending December 31, 2021 3,195

Year ending December 31, 2022 3,195

Year ending December 31, 2023 3,195

Year ending December 31, 2024 2,929

Thereafter

Total minimum finance lease obligations 14,911

Less-amount representing interest (2,151)

Present value of minimum finance lease obligations 12,760

Current maturities (2,407) (2,367)

Lease obligations, net of current maturities $ 10,353 $ 10,970

X

- Definition
Amount of interest expense on finance lease liability.
+ References
No definition available.
+ Details

Name: inis_LessamountRepresentingFinanceLeaseInterest

Namespace Prefix: inis_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of interest expense on operating lease liability.
+ References
No definition available.
+ Details

Name: inis_LessamountRepresentingOperatingLeaseInterest

Namespace Prefix: inis_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_FinanceLeaseLiabilitiesPaymentsRollingMaturityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Present value of lessee's discounted obligation for lease payments from finance lease.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977
+ Details

Name: us-gaap_FinanceLeaseLiability

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977
+ Details

Name: us-gaap_FinanceLeaseLiabilityCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977
+ Details

Name: us-gaap_FinanceLeaseLiabilityNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's undiscounted obligation for lease payments for finance lease.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980
+ Details

Name: us-gaap_FinanceLeaseLiabilityPaymentsDue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's undiscounted obligation for lease payments for finance lease, due after fifth fiscal year following latest statement of financial position date. For interim and annual periods when interim periods are reported on rolling approach, from latest statement of financial position date.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980
+ Details

Name: us-gaap_FinanceLeaseLiabilityPaymentsDueInNextRollingTwelveMonths

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's undiscounted obligation for lease payments for finance lease, due after fifth rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on rolling approach, from latest statement of financial position date.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980
+ Details

Name: us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingAfterYearFive

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's undiscounted obligation for lease payments for finance lease, due in fifth rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on rolling approach, from latest statement of financial position date.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980
+ Details

Name: us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearFive

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's undiscounted obligation for lease payments for finance lease, due in fourth rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on rolling approach, from latest statement of financial position date.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980
+ Details

Name: us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearFour

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's undiscounted obligation for lease payments for finance lease, due in third rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on rolling approach, from latest statement of financial position date.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980
+ Details

Name: us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearThree

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's undiscounted obligation for lease payments for finance lease, due in second rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on rolling approach, from latest statement of financial position date.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980
+ Details

Name: us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearTwo

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's undiscounted obligation for lease payment for operating lease.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980
+ Details

Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's undiscounted obligation for lease payments for operating lease, due after fifth rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on rolling approach, from latest statement of financial position date.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980
+ Details

Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fifth rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980
+ Details

Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980
+ Details

Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980
+ Details

Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980
+ Details

Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's undiscounted obligation for lease payments for operating lease, due in next rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980
+ Details

Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_OperatingLeaseLiabilitiesPaymentsDueRollingMaturityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Present value of lessee's discounted obligation for lease payments from operating lease.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977
+ Details

Name: us-gaap_OperatingLeaseLiability

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977
+ Details

Name: us-gaap_OperatingLeaseLiabilityCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977
+ Details

Name: us-gaap_OperatingLeaseLiabilityNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 41 R35.htm IDEA: XBRL DOCUMENT v3.20.1

Shareholders' Equity, Options and Warrants - Stock-Based Compensation Plans (Details Narrative) - USD ($)
3 Months Ended

Mar. 31, 2020

Mar. 31, 2019

Dec. 31, 2019

Compensation expense $ 51,522 $ 63,737

Warrants outstanding 50,090,000 20,090,000

Mandatorily redeemable convertible preferred stock $ 4,817,170 $ 4,785,086

Unrecognized compensation expense $ 59,808

Period for recognition 1 year 9 months

Intrinsic value, per share $ 0.06

Series B Convertible Redeemable Preferred Stock

Preferred stock outstanding 850 850

Redemption date May 31, 2022

Redemption price per share $ 1,000

Mandatorily redeemable convertible preferred stock $ 850,000

Convertible preferred stock convertible into common stock 425,000

Conversion price per share $ 2.00

Series C Redeemable Convertible Preferred Stock

Preferred stock outstanding 4,213 4,213

Redemption date Feb. 28, 2022

Redemption price per share $ 1,000

Preferred stock dividend rate 6.00%

Conversion price per share $ 0.10

Dividends paid $ 251,280 $ 252,780

Value of shares issued in lieu of dividend payment 204,480 $ 205,980

Preferred stock dividend, settlement in cash $ 46,800

Common stock issued in lieu of dividend 3,408,000 3,433,000

Class M Warrants

Warrants outstanding 17,165,000 17,165,000

Exercise price of warrants $ 0.12 $ 0.12

Maturity date of warrants Feb. 17, 2022 Feb. 17, 2022

Class N Warrants

Warrants outstanding 2,925,000 2,925,000

Exercise price of warrants $ 0.10 $ 0.10

Maturity date of warrants May 12, 2022 May 12, 2022

Class O Warrants

Warrants outstanding 30,000,000

Exercise price of warrants $ 0.045

Maturity date of warrants Dec. 30, 2024

2015 Incentive Plan

Number of shares authorized ^[1] 80,000,000

Shares available for issuance 34,135,593

2015 Incentive Plan | Chief Executive Officer

Shares issued 500,000

Shares issued, value $ 28,000

Net shares issued 302,125

Shares issued, price per share $ 0.056

Share price $ 0.06

Shares withheld to satisfy payroll tax liabilities 197,875

Compensation expense $ 18,128

2006 Equity Incentive Plan

Additional shares authorized 11,089,967

[1] In July 2018, the Plan was amended and restated to increase the number of shares authorized for issuance by an additional 20,000,000.

X

- Definition
Conversion price per share for preferred stock convertible into shares of common stock.
+ References
No definition available.
+ Details

Name: inis_ConversionPricePerShare

Namespace Prefix: inis_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of shares that are convertible into the company's common stock.
+ References
No definition available.
+ Details

Name: inis_ConvertiblePreferredStockConvertibleIntoCommonStock

Namespace Prefix: inis_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The combined weighted average of the accumulated differences between the fair values on underlying shares and exercises prices to acquire such shares as of the grant date on options that are outstanding and exercisable.
+ References
No definition available.
+ Details

Name: inis_IntrinsicValuePerShare

Namespace Prefix: inis_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Date the warrants or rights expire, in CCYY-MM-DD format.
+ References
No definition available.
+ Details

Name: inis_MaturityDateOfWarrants

Namespace Prefix: inis_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 14.F)
-URI http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (h)(1)(i)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_AllocatedShareBasedCompensationExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Exercise price per share or per unit of warrants or rights outstanding.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644
+ Details

Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of warrants or rights outstanding.
+ References
No definition available.
+ Details

Name: us-gaap_ClassOfWarrantOrRightOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of shares of common stock issued as dividends during the period. Excludes stock splits.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644
+ Details

Name: us-gaap_CommonStockDividendsShares

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 405
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817
+ Details

Name: us-gaap_Dividends

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 405
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817
+ Details

Name: us-gaap_DividendsPreferredStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 405
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770
+ Details

Name: us-gaap_DividendsPreferredStockCash

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of cost not yet recognized for nonvested award under share-based payment arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
The percentage rate used to calculate dividend payments on preferred stock.
+ References
No definition available.
+ Details

Name: us-gaap_PreferredStockDividendRatePercentage

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Date the preferred stock has been redeemed, in CCYY-MM-DD format.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21564-112644

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644
+ Details

Name: us-gaap_PreferredStockRedemptionDate

Namespace Prefix: us-gaap_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition
The price per share at which the preferred stock of an entity that has priority over common stock in the distribution of dividends and in the event of liquidation of the entity is redeemed or may be called at. The redemption features of this preferred stock are solely within the control of the issuer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21488-112644

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21564-112644
+ Details

Name: us-gaap_PreferredStockRedemptionPricePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of additional shares authorized for issuance under share-based payment arrangement.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of shares authorized for issuance under share-based payment arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Price of a single share of a number of saleable stocks of a company.
+ References
No definition available.
+ Details

Name: us-gaap_SharePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Per share or per unit amount of equity securities issued.
+ References
No definition available.
+ Details

Name: us-gaap_SharesIssuedPricePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.
+ References
No definition available.
+ Details

Name: us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount that is required to be paid, determined under the conditions specified in the contract, if as of the reporting date, the holder of the share has exercised the right to or the shares are mandatorily redeemable after one year from the reporting date or operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 480
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109262807&loc=d3e22047-110879
+ Details

Name: us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmountNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).
+ References
No definition available.
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Value, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).
+ References
No definition available.
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ClassOfWarrantOrRightAxis=inis_ClassmWarrantsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ClassOfWarrantOrRightAxis=inis_ClassnWarrantsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ClassOfWarrantOrRightAxis=inis_ClassoWarrantsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PlanNameAxis=inis_TwoThousandFifteenIncentivePlanMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_ChiefExecutiveOfficerMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PlanNameAxis=inis_EquityIncentivePlanMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 42 R31.htm IDEA: XBRL DOCUMENT v3.20.1

Inventories - Schedule of Inventory, Current (Details) - USD ($)

Mar. 31, 2020

Dec. 31, 2019

Inventory, Net, Items Net of Reserve

Raw materials $ 40,648 $ 40,648

Work in process 3,334,886 3,379,943

Finished goods 3,839 2,829

Total inventory $ 3,379,373 $ 3,423,420

X

- Definition
Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 5.BB)
-URI http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(6)(a)(1))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_InventoryFinishedGoodsNetOfReserves

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.6(a))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_InventoryNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 5.BB)
-URI http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(6)(a)(4))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_InventoryRawMaterialsNetOfReserves

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 5.BB)
-URI http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(6)(a)(3))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_InventoryWorkInProcessNetOfReserves

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

XML 43 R39.htm IDEA: XBRL DOCUMENT v3.20.1

Revenue Recognition (Details Narrative) - USD ($)

Mar. 31, 2020

Dec. 31, 2019

Unearned revenue, current $ 1,213,927 $ 1,240,205

Accounts receivable 1,024,044 875,914

Cobalt Products

Unearned revenue, current $ 1,213,927 $ 1,240,705

X

- Definition
Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=121593590&loc=d3e4428-111522

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(3))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section 45
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=121593590&loc=d3e4531-111522
+ Details

Name: us-gaap_AccountsReceivableNetCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(5))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_DeferredRevenueCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_StatementBusinessSegmentsAxis=inis_CobaltProductsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 44 R12.htm IDEA: XBRL DOCUMENT v3.20.1

Stockholders' Equity, Options and Warrants
3 Months Ended

Mar. 31, 2020

Equity [Abstract]

Stockholders' Equity, Options and Warrants
(6) Stockholders’ Equity, Options, and Warrants

Employee Stock Purchase Plan

The Company has an employee stock purchase plan pursuant to which employees of the Company may participate to purchase shares of common stock at a discount. During the three-months ended March 31, 2020 and 2019, the Company issued 156,845 and 31,618 shares of common stock, respectively, to employees under the employee stock purchase plan for proceeds of $6,666 and $1,581, respectively. As of March 31, 2020, 318,316 shares of common stock remain available for issuance under the employee stock purchase plan.

Stock-Based Compensation Plans

2015 Incentive Plan - In April 2015, the Company’s Board of Directors approved the International Isotopes Inc. 2015 Incentive Plan (as amended, the 2015 Plan), which was subsequently approved by the Company’s shareholders in July 2015. The 2015 Plan was amended and restated in July 2018 to increase the number of shares authorized for issuance under the 2015 Plan by an additional 20,000,000 shares. The 2015 Plan provides for the grant of incentive and non-qualified stock options, stock appreciation rights, restricted stock, restricted stock units, performance shares and units, and other stock or cash-based awards. The 2015 Plan amended and restated the Company’s Amended and Restated 2006 Equity Incentive Plan (2006 Plan). The 2015 Plan authorizes the issuance of up to 80,000,000 shares of common stock, plus 11,089,967 shares authorized, but not issued under the 2006 Plan. At March 31, 2020, there were 34,135,593 shares available for issuance under the 2015 Plan.

Employee/Director Grants - The Company accounts for issuances of stock-based compensation to employees by recognizing, as compensation expense, the cost of employee services received in exchange for equity awards. The compensation expense is based on the grant date fair value of the award. Stock option compensation expense is recognized over the period during which an employee is required to provide service in exchange for the award (the vesting period).

Non-Employee Grants - The Company accounts for its issuances of stock-based compensation to non-employees by measuring the value of any awards that were vested and non-forfeitable at their date of issuance based on the grant date fair value of the award. The non-vested portion of awards that are subject to the future performance of the counterparty are adjusted at each reporting date to their fair values based upon the then current market value of the Company’s stock and other assumptions that management believes are reasonable.

Option awards outstanding as of March 31, 2020, and changes during the three-months ended March 31, 2020, were as follows:

Fixed Options Shares
Weighted

Average

Exercise Price

Weighted

Average

Remaining

Contractual Life

Aggregate

Intrinsic Value

Outstanding at December 31, 2019 23,655,000 $ 0.05

Granted — $ —

Exercised — $ —

Expired — $ —

Forfeited — $ —

Outstanding at March 31, 2020 23,655,000 $ 0.05 6.1 $ 235,000

Exerciseable at March 31, 2020 17,936,000 $ 0.05 5.6 $ 235,000

The intrinsic value of outstanding and exercisable shares is based on the closing price of the Company’s common stock on the OTCQB of $0.06 per share on March 31, 2020, the last trading day of the quarter.

As of March 31, 2020, there was $59,808 of unrecognized compensation expense related to stock options that will be recognized over a weighted-average period of 1.76 years.

Total stock-based compensation expense for the three-months ended March 31, 2020 and 2019 was $51,522 and $63,737 respectively.

Pursuant to an employment agreement with its Chief Executive Officer, the Company awarded 500,000 fully vested shares of common stock to its Chief Executive Officer in February 2020 under the 2015 Plan. The number of shares awarded was based on a $28,000 stock award using a price of $0.056 per share. The employment agreement provides that the number of shares issued will be based on the average closing price of common stock for the 20 trading days prior to issue date but not less than $0.05 per share. Compensation expense recorded pursuant to this stock grant was $18,128, which was determined by multiplying the number of shares awarded by the closing price of the common stock on February 28, 2020, which was $0.06 per share. The Company withheld 197,875 shares of common stock to satisfy the employee’s payroll tax obligations in connection with this issuance. The net shares issued on February 28, 2020 totaled 302,125.

Warrants

Warrants outstanding at March 31, 2020, included 17,165,000 Class M Warrants which are immediately exercisable at an exercise price of $0.12 per share and expire on February 17, 2022; 2,925,000 Class N Warrants which are immediately exercisable at an exercise price of $0.10 per share and expire on May 12, 2022; and 30,000,000 Class O Warrants which are immediately exercisable at an exercise price of $0.045 per share and expire December 30, 2024.

Warrants outstanding at March 31, 2019, included 17,165,000 Class M Warrants which are immediately exercisable at an exercise price of $0.12 per share and expire on February 17, 2022 and 2,925,000 Class N Warrants which are immediately exercisable at an exercise price of $0.10 per share and expire on May 12, 2022.

Preferred Stock

At March 31, 2020, there were 850 shares of the Series B Preferred Stock outstanding with a mandatory redemption date of May 2022 at $1,000 per share or $850,000. The shares of Series B Preferred Stock are also convertible into 425,000 shares of the Company’s common stock at a conversion price of $2.00 per share. These shares of Series B Preferred Stock do not carry any dividend preferences. Due to the mandatory redemption provision, the Series B Preferred Stock has been classified as a liability in the accompanying condensed consolidated balance sheets.

At March 31, 2020, there were 4,213 shares of the Series C Preferred Stock outstanding with a mandatory redemption date of February 2022 at $1,000 per share in either cash or shares of common stock, at the option of the holder. Holders of the Series C Preferred Stock do not have any voting rights except as required by law and in connection with certain events as set forth in the Statement of Designation of the Series C Preferred Stock. The Series C Preferred Stock accrues dividends at a rate of 6% per annum, payable annually on February 17th of each year. The Series C Preferred Stock are convertible at the option of the holders at any time into shares of the Company's common stock at an initial conversion price equal to $0.10 per share, subject to adjustment. If the volume-weighted average closing price of the Company’s common stock over a period of 90 consecutive trading days is greater than $0.25 per share, the Company may redeem all or any portion of the outstanding Series C Preferred Stock at the original purchase price per share plus any accrued and unpaid dividends, payable in shares of common stock.

During the three-months ended March 31, 2020 and 2019 dividends paid to holders of the Series C Preferred Stock totaled $251,280 and $252,780, respectively. Some holders of the Series C Preferred Stock elected to settle their dividend payments with shares of the Company’s common stock in lieu of cash. For the three-months March 31, 2020 and 2019 the Company issued 3,408,000 and 3,433,000 shares of common stock, respectively, in lieu of a dividend payment of $204,480 and $205,980, respectively. The remaining $46,800 of dividend payable was settled with cash.

X

- References
No definition available.
+ Details

Name: us-gaap_EquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e)(1))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-URI http://asc.fasb.org/topic&trid=2208762
+ Details

Name: us-gaap_StockholdersEquityNoteDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 45 R16.htm IDEA: XBRL DOCUMENT v3.20.1

Leases
3 Months Ended

Mar. 31, 2020

Leases [Abstract]

Leases
(10) Leases

The Company leases office and warehouse space under operating leases. Right-of-use assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent its obligation to make lease payments under the lease. Operating lease, right-of-use assets, and liabilities are recognized at the lease commencement date based on the present value of lease payments over the reasonably certain lease term. The implicit rates with the Company’s operating leases are generally not determinable and the Company uses its incremental borrowing rate at the lease commencement date to determine the present value of its lease payments. The determination of the Company’s incremental borrowing rate requires judgement. The company determines its incremental borrowing rate for each lease using its then-current borrowing rate. Certain of the Company’s leases include options to extend or terminate the lease. The Company establishes the number of renewal options periods used in determining the operating lease term based upon its assessment at the inception of the operating lease. The option to renew the lease may be automatic, at the option of the Company, or mutually agreed to between the landlord and the Company. Once the facility lease term has begun, the present value of the aggregate future minimum lease payments is recorded as a right-of-use asset. Lease expense is recognized on a straight-line basis over the term of the lease.

Three Months Ended March 31,

2020 2019

Operating lease costs $ 68,400 $ 36,853

Short-term operating lease costs 8,876 1,902

Financing lease expense:

Amortization of right-of-use assets 577 —

Interest on lease liabilities 222 —

Total financing lease expense 799

Total lease expense $ 78,075 $ 38,755

Right-of-use assets obtained in exchange for new operating lease liabilities $ 2,649,070 $ 810,367

Right-of-use assets obtained in exchange for new financing lease liabilities $ — $ —

Weighted-average remaining lease term (years) - operating leases 14.8 7.0

Weighted-average remaining lease term (years) - financing leases 4.7

Weighted-average discount rate - operating leases 6.75 % 6.75 %

Weighted-average discount rate - financing leases 6.75 %

The future minimum payments under these operating lease agreements are as follows:

Operating Financing

2020 (excluding the three months ended March 31, 2020) $ 198,091 $ 2,397

2021 257,383 3,195

2022 284,631 3,195

2023 287,108 3,195

2024 287,108 2,929

Thereafter 2,886,518 —

Total minimum operating lease obligations 4,200,839 14,911

Less-amounts representing interest (1,563,909 ) (2,151 )

Present value of minimum operating lease obligations 2,636,930 12,760

Current maturities (87,158 ) (2,407 )

Lease obligations, net of current maturities $ 2,549,772 $ 10,353

X

- References
No definition available.
+ Details

Name: us-gaap_LeasesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-URI http://asc.fasb.org/subtopic&trid=77888251
+ Details

Name: us-gaap_LesseeOperatingLeasesTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 46 R6.htm IDEA: XBRL DOCUMENT v3.20.1

Reconciliation of Stockholders' (Deficit) Equity - USD ($)

Common Stock

Additional Paid-In Capital

Accumulated Deficit

Deficit Attributable to Internat'l Isotopes Shareholders

Equity Attributable to Noncontrolling Interest

Total

Beginning balance, value at Dec. 31, 2018 $ 4,131,683 $ 120,805,997 $ (126,541,421) $ (1,603,741) $ 1,757,875 $ 154,134

Beginning balance, shares at Dec. 31, 2018 413,168,301

Shares issued under employee stock purchase plan, value $ 316 1,265 1,581 1,581

Shares issued under employee stock purchase plan, shares 31,618

Stock grant, value $ 2,798 (2,798)

Stock grant, shares 279,767

Stock in lieu of dividends on convertible preferred C shares, value $ 34,330 171,650 205,980 205,980

Stock in lieu of dividends on convertible preferred C shares, shares 3,433,000

Stock based compensation 63,737 63,737 63,737

Net (loss) income (51,958) (51,958) 108,492 56,534

Ending balance, value at Mar. 31, 2019 $ 4,169,127 121,039,851 (126,593,379) (1,384,401) 1,866,367 481,966

Ending balance, shares at Mar. 31, 2019 416,912,686

Beginning balance, value at Dec. 31, 2019 $ 4,198,423 121,680,163 (128,064,385) (2,185,799) 2,073,649 (112,150)

Beginning balance, shares at Dec. 31, 2019 419,842,256

Shares issued under employee stock purchase plan, value $ 1,568 5,098 6,666 6,666

Shares issued under employee stock purchase plan, shares 156,845

Stock grant, value $ 3,021 (3,021)

Stock grant, shares 302,125

Stock in lieu of dividends on convertible preferred C shares, value $ 34,080 170,400 204,480 204,480

Stock in lieu of dividends on convertible preferred C shares, shares 3,408,000

Convertible debenture beneficial conversion feature 102,584 102,584 102,584

Warrants issued with convertible debentures 144,976 144,976 144,976

Stock based compensation 51,522 51,522 51,522

Net (loss) income (422,494) (422,494) 44,457 (378,037)

Ending balance, value at Mar. 31, 2020 $ 4,237,092 $ 122,151,722 $ (128,486,879) $ (2,098,065) $ 2,118,106 $ 20,041

Ending balance, shares at Mar. 31, 2020 423,709,226

X

- Definition
Amount of increase (decrease) in additional paid in capital (APIC) resulting from recognition of deferred taxes for convertible debt with a beneficial conversion feature.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 55
-Paragraph 51
-URI http://asc.fasb.org/extlink&oid=121610041&loc=d3e34017-109320
+ Details

Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 20
-Section 55
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=120383193&loc=d3e11149-113907

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 20
-Section 55
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=120383193&loc=d3e11178-113907

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 35
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899
+ Details

Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 25
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109126253&loc=d3e4724-112606

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770
+ Details

Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Number of shares of preferred stock issued as dividends during the period. Excludes stock splits.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644
+ Details

Name: us-gaap_PreferredStockDividendsShares

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 235
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-URI http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884

Reference 8: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 14: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4J
-URI http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3000-108585

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 20: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4K
-URI http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794
+ Details

Name: us-gaap_ProfitLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Number of shares issued which are neither cancelled nor held in the treasury.
+ References
No definition available.
+ Details

Name: us-gaap_SharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Value, after forfeiture, of shares granted under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 30
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=121321822&loc=d3e3913-113898

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 30
-Section 35
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=121323062&loc=d3e15009-113911
+ Details

Name: us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Number of shares issued during the period as a result of an employee stock purchase plan.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Value of stock issued to shareholders as a dividend during the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueStockDividend

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 45
-Paragraph 17
-URI http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 45
-Paragraph 23
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 10
-Section 65
-Paragraph 4
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (f)(2)
-URI http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 16
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4568740-111683

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 65
-Paragraph 15
-Subparagraph (f)(2)
-URI http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4I
-URI http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (f)(1)
-URI http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641

Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 45
-Paragraph 20
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 45
-Paragraph 5
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793

Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4568447-111683

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 65
-Paragraph 15
-Subparagraph (f)(1)
-URI http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333

Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(3)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794

Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 65
-Paragraph 15
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 65
-Paragraph 8
-Subparagraph (d)(2)

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 65
-Paragraph 8
-Subparagraph (d)(3)
+ Details

Name: us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 47 R2.htm IDEA: XBRL DOCUMENT v3.20.1

Condensed Consolidated Balance Sheets (Unaudited) - USD ($)

Mar. 31, 2020

Dec. 31, 2019

Current assets

Cash and cash equivalents $ 568,656 $ 575,422

Accounts receivable 1,024,044 875,914

Inventories 3,379,373 3,423,420

Prepaids and other current assets 1,399,325 1,444,593

Total current assets 6,371,398 6,319,349

Long-term assets

Restricted cash 637,820 635,498

Property, plant and equipment, net 1,970,872 2,003,887

Financing lease right-of-use asset 12,625 13,302

Operating lease right-of-use asset 2,630,830 709,883

Goodwill 1,384,255 1,384,255

Patents and other intangibles, net 4,150,584 4,190,621

Total long-term assets 10,786,986 8,937,446

Total assets 17,158,384 15,256,795

Current liabilities

Accounts payable 4,292,161 4,229,128

Accrued liabilities 968,021 1,096,090

Current portion of unearned revenue 1,213,927 1,240,205

Current portion of operating lease right-of-use liability 87,158 100,777

Current portion of financing lease liability 2,407 2,367

Current installments of notes payable 1,738,845 1,519,496

Total current liabilities 8,302,519 8,188,063

Long-term liabilities

Obligation for lease disposal costs 556,670 546,570

Related party notes payable, net of debt discount 891,802 1,216,874

Notes payable, net of current portion 10,057 12,276

Financing lease liability, net of current portion 10,353 10,970

Operating lease right-of-use liability, net of current portion 2,549,772 609,106

Mandatorily redeemable convertible preferred stock, net of discount 4,817,170 4,785,086

Total long-term liabilities 8,835,824 7,180,882

Total liabilities 17,138,343 15,368,945

Commitments and contingencies

Stockholders' (Deficit) Equity

Common stock 4,237,092 4,198,423

Additional paid-in capital 122,151,722 121,680,163

Accumulated deficit (128,486,879) (128,064,385)

Deficit attributable to International Isotopes Inc. stockholders (2,098,065) (2,185,799)

Equity attributable to noncontrolling interest 2,118,106 2,073,649

Total equity (deficit) 20,041 (112,150)

Total liabilities and stockholders' equity (deficit) $ 17,158,384 $ 15,256,795

X

- Definition
Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19(a))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_AccountsPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=121593590&loc=d3e4428-111522

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(3))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section 45
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=121593590&loc=d3e4531-111522
+ Details

Name: us-gaap_AccountsReceivableNetCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_AccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 65
-Paragraph 15
-Subparagraph (g)(2)
-URI http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30)(a)(1))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_AdditionalPaidInCapital

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Noncurrent portion of the carrying amount of a liability for an asset retirement obligation. An asset retirement obligation is a legal obligation associated with the disposal or retirement of a tangible long-lived asset that results from the acquisition, construction or development, or the normal operations of a long-lived asset, except for certain obligations of lessees.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 410
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6392692&loc=d3e7535-110849
+ Details

Name: us-gaap_AssetRetirementObligationsNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(11))
-URI http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (bb)
-URI http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(12))
-URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599
+ Details

Name: us-gaap_Assets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (bb)
-URI http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.9)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765
+ Details

Name: us-gaap_AssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_AssetsCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(11))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(12))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(15))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(17))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(13))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(16))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(14))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(10))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (bb)
-URI http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685
+ Details

Name: us-gaap_AssetsNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_AssetsNoncurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.1)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.25)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03.(a),19)
-URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03.17)
-URI http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349
+ Details

Name: us-gaap_CommitmentsAndContingencies

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(5))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_DeferredRevenueCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Portion of the carrying amount as of the balance sheet date of obligations due all related parties that is payable after one year or beyond the normal operating cycle if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(k)(1))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.23)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_DueToRelatedPartiesNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977
+ Details

Name: us-gaap_FinanceLeaseLiabilityCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977
+ Details

Name: us-gaap_FinanceLeaseLiabilityNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount, after accumulated amortization, of right-of-use asset from finance lease.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977
+ Details

Name: us-gaap_FinanceLeaseRightOfUseAsset

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 926
-SubTopic 20
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(10)(1))
-URI http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 45
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266
+ Details

Name: us-gaap_Goodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.6(a))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_InventoryNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (bb)
-URI http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19-26)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690
+ Details

Name: us-gaap_Liabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(23))
-URI http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(25))
-URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(32))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612
+ Details

Name: us-gaap_LiabilitiesAndStockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (bb)
-URI http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.21)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571
+ Details

Name: us-gaap_LiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_LiabilitiesCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of obligation due after one year or beyond the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 201.5-02(25))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(23))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 201.5-02(26))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (bb)
-URI http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 201.5-02(24))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988
+ Details

Name: us-gaap_LiabilitiesNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_LiabilitiesNoncurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19,20)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_LongTermDebtCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_LongTermNotesPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(24))
-URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.31)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(22))
-URI http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690
+ Details

Name: us-gaap_MinorityInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977
+ Details

Name: us-gaap_OperatingLeaseLiabilityCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977
+ Details

Name: us-gaap_OperatingLeaseLiabilityNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's right to use underlying asset under operating lease.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977
+ Details

Name: us-gaap_OperatingLeaseRightOfUseAsset

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 340
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (g)
-URI http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=121566466&loc=d3e6787-107765
+ Details

Name: us-gaap_OtherPrepaidExpenseCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(14))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(8))
-URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(13))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121566466&loc=d3e6812-107765

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(17))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 954
-SubTopic 210
-Section 45
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580
+ Details

Name: us-gaap_RestrictedCashNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The cumulative amount of the reporting entity's undistributed earnings or deficit.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30)(a)(3))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 65
-Paragraph 15
-Subparagraph (g)(2)
-URI http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(23)(a)(4))
-URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (h)(2)
-URI http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(i)
-URI http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641
+ Details

Name: us-gaap_RetainedEarningsAccumulatedDeficit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The amount that is required to be paid, determined under the conditions specified in the contract, if as of the reporting date, the holder of the share has exercised the right to or the shares are mandatorily redeemable after one year from the reporting date or operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 480
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109262807&loc=d3e22047-110879
+ Details

Name: us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmountNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571
+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 45
-Paragraph 17
-URI http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 45
-Paragraph 23
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 10
-Section 65
-Paragraph 4
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (f)(2)
-URI http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 16
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4568740-111683

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 65
-Paragraph 15
-Subparagraph (f)(2)
-URI http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4I
-URI http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (f)(1)
-URI http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641

Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 45
-Paragraph 20
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 45
-Paragraph 5
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793

Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4568447-111683

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 65
-Paragraph 15
-Subparagraph (f)(1)
-URI http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333

Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(3)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794

Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 65
-Paragraph 15
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 65
-Paragraph 8
-Subparagraph (d)(2)

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 65
-Paragraph 8
-Subparagraph (d)(3)
+ Details

Name: us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 48 R38.htm IDEA: XBRL DOCUMENT v3.20.1

Revenue Recognition - Summary of Sales from Contracts with Customers by Business Segment and Geography (Details) - USD ($)
3 Months Ended

Mar. 31, 2020

Mar. 31, 2019

Disaggregation of Revenue [Line Items]

Total revenues $ 2,335,786 $ 2,527,852

Percent of total revenues 100.00% 100.00%

U.S.

Disaggregation of Revenue [Line Items]

Total revenues $ 2,074,636 $ 2,464,137

Outside U.S.

Disaggregation of Revenue [Line Items]

Total revenues 261,150 63,715

Radiochemical Products

Disaggregation of Revenue [Line Items]

Total revenues $ 755,221 $ 463,232

Percent of total revenues 32.00% 18.00%

Radiochemical Products | U.S.

Disaggregation of Revenue [Line Items]

Total revenues $ 668,591 $ 459,967

Radiochemical Products | Outside U.S.

Disaggregation of Revenue [Line Items]

Total revenues 86,630 3,265

Cobalt Products

Disaggregation of Revenue [Line Items]

Total revenues $ 305,620 $ 376,089

Percent of total revenues 13.00% 15.00%

Cobalt Products | U.S.

Disaggregation of Revenue [Line Items]

Total revenues $ 305,620 $ 336,089

Cobalt Products | Outside U.S.

Disaggregation of Revenue [Line Items]

Total revenues 40,000

Nuclear Medicine Products

Disaggregation of Revenue [Line Items]

Total revenues $ 1,042,124 $ 1,100,922

Percent of total revenues 45.00% 44.00%

Nuclear Medicine Products | U.S.

Disaggregation of Revenue [Line Items]

Total revenues $ 867,604 $ 1,080,472

Nuclear Medicine Products | Outside U.S.

Disaggregation of Revenue [Line Items]

Total revenues 174,520 20,450

Radiological Services

Disaggregation of Revenue [Line Items]

Total revenues $ 72,321 $ 587,609

Percent of total revenues 3.00% 23.00%

Radiological Services | U.S.

Disaggregation of Revenue [Line Items]

Total revenues $ 72,321 $ 587,609

Radiological Services | Outside U.S.

Disaggregation of Revenue [Line Items]

Total revenues 0 0

Fluorine Products

Disaggregation of Revenue [Line Items]

Total revenues $ 160,500 $ 0

Percent of total revenues 7.00% 0.00%

Fluorine Products | U.S.

Disaggregation of Revenue [Line Items]

Total revenues $ 160,500 $ 0

Fluorine Products | Outside U.S.

Disaggregation of Revenue [Line Items]

Total revenues $ 0 $ 0

X

- Definition
Percent of Total Revenues
+ References
No definition available.
+ Details

Name: inis_PercentOfTotalRevenues

Namespace Prefix: inis_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_DisaggregationOfRevenueLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 924
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-URI http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856
+ Details

Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: srt_StatementGeographicalAxis=country_US

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_StatementGeographicalAxis=us-gaap_NonUsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementBusinessSegmentsAxis=inis_RadiochemicalProductsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementBusinessSegmentsAxis=inis_CobaltProductsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementBusinessSegmentsAxis=inis_NuclearMedicineProductsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementBusinessSegmentsAxis=inis_RadiologicalServicesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementBusinessSegmentsAxis=inis_FluorineProductsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 49 R34.htm IDEA: XBRL DOCUMENT v3.20.1

Shareholders' Equity, Options and Warrants - Employee Stock Purchase Plan (Details Narrative) - Employee Stock Purchase Plan - USD ($)
3 Months Ended

Mar. 31, 2020

Mar. 31, 2019

Employee Stock Ownership Plan (ESOP) Disclosures [Line Items]

Number of shares available for issuance 318,316

Shares issued during period 156,845 31,618

Proceeds from issuance of shares during the period $ 6,666 $ 1,581

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The cash inflow associated with the amount received from the stock plan during the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromStockPlans

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of shares issued during the period as a result of an employee stock purchase plan.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=inis_EmployeeStockOwnershipMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 50 R30.htm IDEA: XBRL DOCUMENT v3.20.1

Investment and Business Consolidation (Details Narrative) - RadQual, LLC

Mar. 31, 2020

Aug. 31, 2017

Ownership interest, percentage by parent 24.50%

Affiliates of the Company

Ownership interest, percentage by parent 75.50%

X

- Definition
The parent entity's interest in net assets of the subsidiary, expressed as a percentage.
+ References
No definition available.
+ Details

Name: us-gaap_MinorityInterestOwnershipPercentageByParent

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Details

Name: srt_OwnershipAxis=inis_RadqualLlcMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 51 R7.htm IDEA: XBRL DOCUMENT v3.20.1

The Company and Basis of Presentation
3 Months Ended

Mar. 31, 2020

Organization, Consolidation and Presentation of Financial Statements [Abstract]

The Company and Basis of Presentation
(1) The Company and Basis of Presentation

International Isotopes Inc. (INIS) was incorporated in Texas in November 1995. The accompanying unaudited condensed consolidated financial statements are presented in conformity with accounting principles generally accepted in the United States of America (GAAP) and include all operations and balances of INIS and its wholly owned subsidiaries. The unaudited condensed consolidated financial statements also include the accounts of INIS’s 50% owned joint venture, TI Services, LLC (TI Services), and the accounts of INIS’s 24.5% interest in RadQual, LLC (RadQual). TI Services is headquartered in Youngstown, Ohio and was formed with RadQual in December 2010 to distribute products and services for nuclear medicine, nuclear cardiology and Positron Emission Tomography (PET) imaging. RadQual is a global supplier of molecular imaging quality control and calibration devices, and is headquartered in Idaho Falls, Idaho. In August 2017, affiliates of INIS purchased 75.5% of RadQual and at the time INIS was named as one of the two managing members of RadQual. As a result of this ownership change, INIS has significant influence in management decisions with regard to RadQual’s business operations. INIS, its wholly owned subsidiaries, TI Services, and RadQual are collectively referred to herein as the “Company,” “we,” “our” or “us.”

Nature of Operations – INIS and its subsidiaries, TI Services and RadQual, manufacture a full range of nuclear medicine calibration and reference standards, generic sodium iodide I-131 drug product, cobalt teletherapy sources, and a varied selection of radiochemicals for medical research, and clinical applications. The Company also offers contract manufacturing services for certain pharmaceutical products. The Company’s business consists of five business segments: Nuclear Medicine Standards, Cobalt Products, Radiochemical Products, Fluorine Products, and Radiological Services. The Company’s headquarters and all operations, with the exception of TI Services, are located in Idaho Falls, Idaho.

With the exception of certain unique products, the Company’s normal operating cycle is considered to be one year. Due to the time required to produce some cobalt products, the Company’s operating cycle for those products is considered to be two to three years. Accordingly, preliminary payments received on cobalt contracts, where shipment will not take place for greater than one year, have been recorded as unearned revenue and, depending upon estimated ship dates, classified under either current or long-term liabilities on the Company’s consolidated balance sheets. These unearned revenues are being recognized as revenue in the periods during which the cobalt shipments take place. All assets expected to be realized in cash or sold during the normal operating cycle of business are classified as current assets.

Principles of Consolidation – The accompanying unaudited condensed consolidated financial statements are presented in conformity with GAAP and include all operations and balances of INIS and its wholly-owned subsidiaries. The Company also consolidates the accounts of RadQual into the accompanying unaudited condensed consolidated financial statements. See Note 4 “Investment and Business Consolidation” for additional information regarding RadQual. All significant intercompany accounts and transactions have been eliminated in consolidation.

Interim Financial Information – The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with GAAP for interim financial information and pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (SEC). Accordingly, the accompanying unaudited condensed consolidated financial statements do not include all of the information and notes required by GAAP for complete financial statements. In the opinion of management, all adjustments and reclassifications considered necessary in order to make the financial statements not misleading and for a fair and comparable presentation have been included and are of a normal recurring nature. Operating results for the three-month period ended March 31, 2020 are not necessarily indicative of the results that may be expected for the year ending December 31, 2020 or any future periods. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the Company’s Annual Report on Form 10-K for the year ended December 31, 2019 filed with the SEC on March 30, 2020.

X

- Definition
The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-URI http://asc.fasb.org/topic&trid=2122369

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-URI http://asc.fasb.org/topic&trid=2122149

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-URI http://asc.fasb.org/topic&trid=2134479
+ Details

Name: us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 52 R3.htm IDEA: XBRL DOCUMENT v3.20.1

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares

Mar. 31, 2020

Dec. 31, 2019

Statement of Financial Position [Abstract]

Common stock, par value in dollars $ 0.01 $ 0.01

Common stock, shares authorized 750,000,000 750,000,000

Common stock, shares issued 423,709,226 419,842,256

Common stock, shares outstanding 423,709,226 419,842,256

X

- Definition
Face amount or stated value per share of common stock.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of common shares permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_StatementOfFinancialPositionAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 53 R13.htm IDEA: XBRL DOCUMENT v3.20.1

Debt
3 Months Ended

Mar. 31, 2020

Debt Disclosure [Abstract]

Debt
(7) Debt

In December 2013, we entered into a promissory note agreement with our then Chairman of the Board and one of our major shareholders, pursuant to which we borrowed $500,000 (the 2013 Promissory Note). The 2013 Promissory Note is secured and bears interest at 6% per annum and was originally due June 30, 2014. According to the terms of the 2013 Promissory Note, at any time, the lenders may settle any or all of the principal and accrued interest with shares of our common stock. In connection with the 2013 Promissory Note, each of the two lenders was issued 5,000,000 Class L warrants to purchase shares of our common stock at an exercise price of $0.06 per share. The warrants were immediately exercisable. In June 2014, we renegotiated the terms of the 2013 Promissory Note. Pursuant to the modification, the maturity date was extended to December 31, 2017 and each lender was granted an additional 7,500,000 Class L warrants to purchases shares of our common stock at an exercise price of $0.06 per share. The warrants were immediately exercisable. In February 2017, the 2013 Promissory Note was further modified to extend the maturity date to December 31, 2020, with all remaining terms unchanged. On December 23, 2018, all 25,000,000 Class L warrants expired. In December 2019, the 2013 Promissory Note was further modified to extend the maturity date to December 31, 2021, with all remaining terms unchanged.

At March 31, 2020, the principal balance of the 2013 Promissory Note was $500,000 and accrued interest payable on the 2013 Promissory Note was $189,234. Interest expense recorded for the three-months ended March 31, 2020, was $7,500.

In April 2018, we borrowed $120,000 from our Chief Executive Officer and Chairman of the Board pursuant to a promissory note (the 2018 Promissory Note). The 2018 Promissory Note accrues interest at 6% per annum, which is payable upon maturity of the 2018 Promissory Note. The 2018 Promissory Note was originally unsecured and originally matured on August 1, 2018. At any time, the holder of the 2018 Promissory Note may elect to have any or all of the principal and accrued interest settled with shares of our common stock based on the average price of the shares over the previous 20 trading days. Pursuant to an amendment to the 2018 Promissory Note in June 2018, the maturity date was extended to March 31, 2019 with all other provisions remaining unchanged. Pursuant to a second amendment to the 2018 Promissory Note in February 2019, the maturity date was extended to July 31, 2019 with all other provisions remaining unchanged. Pursuant to a third amendment to the 2018 Promissory Note in July 2019, the maturity date was extended to January 31, 2020 with all other provisions remaining unchanged. Pursuant to a fourth amendment to the 2018 Promissory Note in December 2019, the maturity date was extended to December 31, 2021, the note was modified to become secured by company assets, with all other provisions remaining unchanged.

At March 31, 2020, accrued interest on the 2018 Promissory Note totaled $13,970.

In April 2019, one of the prepaid revenue customers requested a refund of the amounts paid. The Company entered into a note agreement to repay $2,182,142 over the next 12 months. The modification was necessary to address the delays to cobalt delivery in 2019 caused by changes to the ATR operating schedule and also to accommodate this customer’s request to reduce their cobalt purchase obligations in future years. The modifications require that the Company refund approximately $1,050,000, of payments received for prior year undelivered material, plus interest at 12% per year, payable over a one-year period on a portion of that amount. The Company has also agreed with this customer to refund approximately $1,100,000 paid for material that was to have been delivered in later years. There will be no interest charge on this refund. In December 2019, this agreement was modified further allowing the Company to delay the original payments by 3 months and refund an additional $462,258 with no interest charge.

On December 20, 2019, the Company entered into a promissory note agreement with four of the Company’s major shareholders (the 2019 Promissory Note). The 2019 Promissory Note authorizes the Company to borrow up to $1,000,000. As of December 31, 2019, the Company had borrowed $675,000 under the 2019 promissory note. In February 2020, the Company borrowed an additional $325,000. The 2019 Promissory Note bears an interest rate of 4% annually and is due December 31, 2022. According to the terms of the 2019 Promissory Note, at any time, the lenders may settle any or all of the principal and accrued interest with shares of the Company’s common stock based on the average closing price of the Company’s common stock for the 20 days preceding the payment. In connection with the 2019 Promissory Note, the lenders were issued warrants totaling 30,000,000 warrants to purchase shares of the Company’s common stock at $0.045 per share. The fair value of these warrants issued totaled $446,079 and was recorded as a debt discount and will be amortized over the life of the 2019 Promissory Note. The Company calculated a beneficial conversion feature of $315,643 which will be accreted to interest expense over the life of the 2019 Promissory Note. At March 31, 2020 accrued interest on the 2019 Promissory Note totaled $9,181.

On April 23, 2020, the Company, through its wholly-owned subsidiary entered into a Loan Agreement and Promissory Note (collectively the “SBA Loan”) with KeyBank National Association pursuant to the Paycheck Protection Program (the “PPP”) under the recently enacted Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”) administered by the U.S. Small Business Administration (the “SBA”). The Company received total proceeds of $495,500 from the SBA Loan. The SBA Loan is scheduled to mature on April 22, 2022 and has a 1.00% interest rate and is subject to the terms and conditions applicable to loans administered by the SBA under the CARES Act. The SBA Loan may be prepaid at any time prior to maturity with no prepayment penalties.

The SBA Loan contains customary events of default relating to, among other things, payment defaults and breaches of representations and warranties. Subject to certain conditions, the SBA Loan may be forgiven in whole or in part by applying for forgiveness pursuant to the CARES Act and the PPP. The amount of loan proceeds eligible for forgiveness is based on a formula based on a number of factors, including the amount of loan proceeds used by the Company during the eight-week period after the loan origination for certain purposes, including payroll costs, interest on certain mortgage obligations, rent payments on certain leases, and certain qualified utility payments, provided that, among other things, at least 75% of the loan amount is used for eligible payroll costs, the employer maintaining or rehiring employees and maintaining salaries at certain level. In accordance with the requirements of the CARES Act and the PPP, the Company intends to use the proceeds from the SBA Loan primarily for payroll costs. No assurance can be given that the Company will be granted forgiveness of the SBA Loan in whole or in part.

X

- References
No definition available.
+ Details

Name: us-gaap_DebtDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-URI http://asc.fasb.org/topic&trid=2208564
+ Details

Name: us-gaap_DebtDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 54 R17.htm IDEA: XBRL DOCUMENT v3.20.1

Segment Information
3 Months Ended

Mar. 31, 2020

Segment Reporting [Abstract]

Segment Information
(11) Segment Information

The Company has five reportable segments which include: Nuclear Medicine Standards, Cobalt Products, Radiochemical Products, Fluorine Products, and Radiological Services. Information regarding the operations and assets of these reportable business segments is contained in the following table:

Three months ended March 31,

Sale of Product 2020 2019

Radiochemical Products $ 755,221 $ 463,232

Cobalt Products 305,620 376,089

Nuclear Medicine Standards 1,042,124 1,100,922

Radiological Services 72,321 587,609

Fluorine Products 160,500 —

Total Segments 2,335,786 2,527,852

Corporate revenue — —

Total consolidated $ 2,335,786 $ 2,527,852

Three months ended March 31,

Depreciation and Amortization 2020 2019

Radiochemical Products $ 10,354 $ 8,817

Cobalt Products 8,761 1,080

Nuclear Medicine Standards 15,989 15,619

Radiological Services 8,636 8,636

Fluorine Products 26,095 26,095

Total Segments 69,835 60,248

Corporate depreciation and amortization 4,782 4,737

Total Consolidated $ 74,617 $ 64,985

Three months ended March 31,

Segment Income (Loss) 2020 2019

Radiochemical Products $ 5,619 $ 96,006

Cobalt Products 123,796 192,870

Nuclear Medicine Standards 185,301 216,822

Radiological Services (14,929 ) 311,279

Fluorine Products 122,870 (37,495 )

Total Segments 422,657 779,481

Corporate loss (845,151 ) (831,439 )

Net Income (Loss) $ (422,494 ) $ (51,958 )

Three months ended March 31,

Expenditures for Segment Assets 2020 2019

Radiochemical Products $ — $ —

Cobalt Products — 3,494

Nuclear Medicine Standards — —

Radiological Services — —

Fluorine Products 1,565 1,590

Total Segments 1,565 5,084

Corporate purchases — —

Total Consolidated $ 1,565 $ 5,084



Segment Assets
March 31,

2020

December 31,

2019

Radiochemical Products $ 536,603 $ 511,381

Cobalt Products 3,388,527 3,369,828

Nuclear Medicine Standards 2,087,295 2,111,225

Radiological Services 96,427 106,374

Fluorine Products 5,482,993 5,477,808

Total Segments 11,591,845 11,576,616

Corporate assets 5,566,539 3,680,179

Total Consolidated $ 17,158,384 $ 15,256,795

X

- References
No definition available.
+ Details

Name: us-gaap_SegmentReportingAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8981-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8657-108599

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-URI http://asc.fasb.org/topic&trid=2134510
+ Details

Name: us-gaap_SegmentReportingDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 55 R21.htm IDEA: XBRL DOCUMENT v3.20.1

Inventories (Tables)
3 Months Ended

Mar. 31, 2020

Inventory Disclosure [Abstract]

Schedule of Inventory, Current

March 31,

2020

December 31,

2019

Raw materials $ 40,648 $ 40,648

Work in process 3,334,886 3,379,943

Finished goods 3,839 2,829

$ 3,379,373 $ 3,423,420

X

- References
No definition available.
+ Details

Name: us-gaap_InventoryDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(6)(c))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(6)(b))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(6)(a))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766
+ Details

Name: us-gaap_ScheduleOfInventoryCurrentTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 56 R25.htm IDEA: XBRL DOCUMENT v3.20.1

Segment Information (Tables)
3 Months Ended

Mar. 31, 2020

Segment Reporting [Abstract]

Schedule of Segment Reporting Information by Segment

Three months ended March 31,

Sale of Product 2020 2019

Radiochemical Products $ 755,221 $ 463,232

Cobalt Products 305,620 376,089

Nuclear Medicine Standards 1,042,124 1,100,922

Radiological Services 72,321 587,609

Fluorine Products 160,500 —

Total Segments 2,335,786 2,527,852

Corporate revenue — —

Total consolidated $ 2,335,786 $ 2,527,852

Three months ended March 31,

Depreciation and Amortization 2020 2019

Radiochemical Products $ 10,354 $ 8,817

Cobalt Products 8,761 1,080

Nuclear Medicine Standards 15,989 15,619

Radiological Services 8,636 8,636

Fluorine Products 26,095 26,095

Total Segments 69,835 60,248

Corporate depreciation and amortization 4,782 4,737

Total Consolidated $ 74,617 $ 64,985

Three months ended March 31,

Segment Income (Loss) 2020 2019

Radiochemical Products $ 5,619 $ 96,006

Cobalt Products 123,796 192,870

Nuclear Medicine Standards 185,301 216,822

Radiological Services (14,929 ) 311,279

Fluorine Products 122,870 (37,495 )

Total Segments 422,657 779,481

Corporate loss (845,151 ) (831,439 )

Net Income (Loss) $ (422,494 ) $ (51,958 )

Three months ended March 31,

Expenditures for Segment Assets 2020 2019

Radiochemical Products $ — $ —

Cobalt Products — 3,494

Nuclear Medicine Standards — —

Radiological Services — —

Fluorine Products 1,565 1,590

Total Segments 1,565 5,084

Corporate purchases — —

Total Consolidated $ 1,565 $ 5,084



Segment Assets
March 31,

2020

December 31,

2019

Radiochemical Products $ 536,603 $ 511,381

Cobalt Products 3,388,527 3,369,828

Nuclear Medicine Standards 2,087,295 2,111,225

Radiological Services 96,427 106,374

Fluorine Products 5,482,993 5,477,808

Total Segments 11,591,845 11,576,616

Corporate assets 5,566,539 3,680,179

Total Consolidated $ 17,158,384 $ 15,256,795

X

- Definition
Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 25
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599
+ Details

Name: us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_SegmentReportingAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 57 R29.htm IDEA: XBRL DOCUMENT v3.20.1

Net Income (Loss) Per Common Share - Basic and Diluted (Details Narrative) - shares
3 Months Ended

Mar. 31, 2020

Mar. 31, 2019

Series B Convertible Redeemable Preferred Stock

Stock equivalents excluded from the computation of diluted net loss per common share 850 850

Series C Redeemable Convertible Preferred Stock

Stock equivalents excluded from the computation of diluted net loss per common share 4,213 4,213

Stock Options

Stock equivalents excluded from the computation of diluted net loss per common share 23,655,000 27,205,000

Warrants

Stock equivalents excluded from the computation of diluted net loss per common share 50,090,000 20,090,000

X

- Definition
Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

EXCEL 58 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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
&PO=V]R:W-H965T&UL4$L! A0#% @ ;6:T4+*.1.*Z 0 )P0 !D M ( !'WP 'AL+W=O&PO M&PO7[0, (0= / " 5^^ !X;"]W;W)K8F]O:RYX M;6Q02P$"% ,4 " !M9K10>+),+;H! I&P &@ @ %Y MP@ >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4 " !M9K10 M$Z1#MK4! !2&P $P @ %KQ 6T-O;G1E;G1?5'EP97-= :+GAM;%!+!08 -0 U &4. !1Q@ ! end XML 60 R44.htm IDEA: XBRL DOCUMENT v3.20.1

Subsequent Events (Details Narrative) - Subsequent Event - "SBA Loan" Paycheck Protection Program

Apr. 23, 2020

USD ($)

Subsequent Event [Line Items]

Proceeds from the SBA's Paycheck Protection Program $ 495,500

Interest rate 1.00%

Maturity date Apr. 22, 2022

X

- Definition
Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 6
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120520924&loc=SL6036836-161870

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22(a)(1))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_DebtInstrumentInterestRateEffectivePercentage

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Date when the debt instrument is scheduled to be fully repaid, in CCYY-MM-DD format.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22(a)(2))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (bbb)(2)
-URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258
+ Details

Name: us-gaap_DebtInstrumentMaturityDate

Namespace Prefix: us-gaap_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition
The cash inflow from bank borrowing during the year.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromBankDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.
+ References
No definition available.
+ Details

Name: us-gaap_SubsequentEventLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=inis_SbaPaycheckProtectionProgramMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 61 R40.htm IDEA: XBRL DOCUMENT v3.20.1

Leases - Schedule of Lease Expense (Details) - USD ($)
3 Months Ended

Mar. 31, 2020

Mar. 31, 2019

Leases [Abstract]

Operating lease costs $ 68,400 $ 36,853

Short-term operating lease costs 8,876 1,902

Finance lease expense:

Amortization of right-of-use assets 577

Interest on lease liabilities 222

Total financing lease expense 799

Total lease expense 78,075 38,755

Right-of-use assets obtained in exchange for new operating lease liabilities 2,649,070 810,367

Right-of-use assets obtained in exchange for new financing lease liabilities

Weighted-average remaining lease term (years) - operating leases 14 years 10 months 7 years

Weighted-average remaining lease term (years) - financing leases 4 years 9 months

Weighted-average discount rate - operating leases 6.75% 6.75%

Weighted-average discount rate - financing leases 6.75%

X

- References
No definition available.
+ Details

Name: inis_FinanceLeaseExpenseAbstract

Namespace Prefix: inis_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Total financing lease expense.
+ References
No definition available.
+ Details

Name: inis_TotalFinancingLeaseExpense

Namespace Prefix: inis_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of interest expense on finance lease liability.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121603541&loc=SL77918638-209977

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 55
-Paragraph 53
-URI http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971
+ Details

Name: us-gaap_FinanceLeaseInterestExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of amortization expense attributable to right-of-use asset from finance lease.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121603541&loc=SL77918638-209977

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 55
-Paragraph 53
-URI http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971
+ Details

Name: us-gaap_FinanceLeaseRightOfUseAssetAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Weighted average discount rate for finance lease calculated at point in time.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (g)(4)
-URI http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 55
-Paragraph 53
-URI http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971
+ Details

Name: us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (g)(3)
-URI http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 55
-Paragraph 53
-URI http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971
+ Details

Name: us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: instant

X

- Definition
Amount of lease cost recognized by lessee for lease contract.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 55
-Paragraph 53
-URI http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971
+ Details

Name: us-gaap_LeaseCost

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_LeasesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 55
-Paragraph 53
-URI http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980
+ Details

Name: us-gaap_OperatingLeaseCost

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Weighted average discount rate for operating lease calculated at point in time.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (g)(4)
-URI http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 55
-Paragraph 53
-URI http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971
+ Details

Name: us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 55
-Paragraph 53
-URI http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (g)(3)
-URI http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980
+ Details

Name: us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: instant

X

- Definition
Amount of increase in right-of-use asset obtained in exchange for finance lease liability.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 55
-Paragraph 53
-URI http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (g)(2)
-URI http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980
+ Details

Name: us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of increase in right-of-use asset obtained in exchange for operating lease liability.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 55
-Paragraph 53
-URI http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (g)(2)
-URI http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980
+ Details

Name: us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of short-term lease cost, excluding expense for lease with term of one month or less.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 55
-Paragraph 53
-URI http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971
+ Details

Name: us-gaap_ShortTermLeaseCost

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Income Statement [Abstract]
Sale of product	$ 2,335,786	$ 2,527,852
Cost of product	968,525	1,088,429
Gross profit	1,367,261	1,439,423
Operating costs and expenses:
Salaries and contract labor	741,205	623,699
General, administrative and consulting	788,438	626,863
Research and development	46,928	46,304
Total operating expenses	1,576,571	1,296,866
Net operating (loss) income	(209,310)	142,557
Other income (expense):
Other income	23,818	24,632
Interest income	2,335	3,422
Interest expense	(194,880)	(114,077)
Total other income (expense)	(168,727)	(86,023)
Net (loss) income	(378,037)	56,534
Less income attributable to non-controlling interest	44,457	108,492
Net loss attributable to International Isotopes Inc.	$ (422,494)	$ (51,958)
Net income (loss) per common share - basic
Net income (loss) per common share - diluted
Weighted average common shares outstanding - basic	420,692,023	413,906,700
Weighted average common shares outstanding - diluted	420,692,023	413,906,700

Shareholders' Equity, Options and Warrants - Schedule of Stock Option Activity (Details)	3 Months Ended
	Mar. 31, 2020 USD ($) $ / shares shares
Share-Based Compensation Arrangement By Share-Based Payment Award Options Outstanding
Stock options outstanding, beginning of period \| shares	23,655,000
Stock options, granted \| shares
Stock options, exercised \| shares
Stock options, expired \| shares
Stock options, forfeited \| shares
Stock options outstanding, end of period \| shares	23,655,000
Stock options exercisable, end of period \| shares	17,936,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price
Weighted average exercise price outstanding, beginning of period \| $ / shares	$ 0.05
Weighted average exercise price, granted \| $ / shares
Weighted average exercise price, exercised \| $ / shares
Weighted average exercise priced, expired \| $ / shares
Weighted average exercise priced, forfeited \| $ / shares
Weighted average exercise price outstanding, end of period \| $ / shares	0.05
Weighted average exercise price exercisable, end of period \| $ / shares	$ 0.05
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures
Weighted average remaining contractual life outstanding, end of period	6 years 1 month
Weighted average remaining contractual life exercisable, end of period	5 years 7 months
Average intrinsic value outstanding, end of period \| $	$ 235,000
Average intrinsic value, exercisable, end of period \| $	$ 235,000

Lease Obligations - Schedule of Maturities of Operating and Finance Lease Liabilities (Details) - USD ($)	Mar. 31, 2020	Dec. 31, 2019
Operating Leases Liability, Payment Due, Rolling Maturity
Year ending December 31, 2020 (excluding the three-months ended March 31, 2020)	$ 198,091
Year ending December 31, 2021	257,383
Year ending December 31, 2022	284,631
Year ending December 31, 2023	287,108
Year ending December 31, 2024	287,108
Thereafter	2,886,518
Total minimum operating lease obligations	4,200,839
Less-amount representing interest	(1,563,909)
Present value of minimum operating lease obligations	2,636,930
Current maturities	(87,158)	$ (100,777)
Lease obligations, net of current maturities	2,549,772	609,106
Finance Leases, Liability, Payment, Due, Rolling Maturity
Year ending December 31, 2020 (excluding the three-months ended March 31, 2020)	2,397
Year ending December 31, 2021	3,195
Year ending December 31, 2022	3,195
Year ending December 31, 2023	3,195
Year ending December 31, 2024	2,929
Thereafter
Total minimum finance lease obligations	14,911
Less-amount representing interest	(2,151)
Present value of minimum finance lease obligations	12,760
Current maturities	(2,407)	(2,367)
Lease obligations, net of current maturities	$ 10,353	$ 10,970

Inventories - Schedule of Inventory, Current (Details) - USD ($)	Mar. 31, 2020	Dec. 31, 2019
Inventory, Net, Items Net of Reserve
Raw materials	$ 40,648	$ 40,648
Work in process	3,334,886	3,379,943
Finished goods	3,839	2,829
Total inventory	$ 3,379,373	$ 3,423,420

Revenue Recognition (Details Narrative) - USD ($)	Mar. 31, 2020	Dec. 31, 2019
Unearned revenue, current	$ 1,213,927	$ 1,240,205
Accounts receivable	1,024,044	875,914
Cobalt Products
Unearned revenue, current	$ 1,213,927	$ 1,240,705

Reconciliation of Stockholders' (Deficit) Equity - USD ($)	Common Stock	Additional Paid-In Capital	Accumulated Deficit	Deficit Attributable to Internat'l Isotopes Shareholders	Equity Attributable to Noncontrolling Interest	Total
Beginning balance, value at Dec. 31, 2018	$ 4,131,683	$ 120,805,997	$ (126,541,421)	$ (1,603,741)	$ 1,757,875	$ 154,134
Beginning balance, shares at Dec. 31, 2018	413,168,301
Shares issued under employee stock purchase plan, value	$ 316	1,265		1,581		1,581
Shares issued under employee stock purchase plan, shares	31,618
Stock grant, value	$ 2,798	(2,798)
Stock grant, shares	279,767
Stock in lieu of dividends on convertible preferred C shares, value	$ 34,330	171,650		205,980		205,980
Stock in lieu of dividends on convertible preferred C shares, shares	3,433,000
Stock based compensation		63,737		63,737		63,737
Net (loss) income			(51,958)	(51,958)	108,492	56,534
Ending balance, value at Mar. 31, 2019	$ 4,169,127	121,039,851	(126,593,379)	(1,384,401)	1,866,367	481,966
Ending balance, shares at Mar. 31, 2019	416,912,686
Beginning balance, value at Dec. 31, 2019	$ 4,198,423	121,680,163	(128,064,385)	(2,185,799)	2,073,649	(112,150)
Beginning balance, shares at Dec. 31, 2019	419,842,256
Shares issued under employee stock purchase plan, value	$ 1,568	5,098		6,666		6,666
Shares issued under employee stock purchase plan, shares	156,845
Stock grant, value	$ 3,021	(3,021)
Stock grant, shares	302,125
Stock in lieu of dividends on convertible preferred C shares, value	$ 34,080	170,400		204,480		204,480
Stock in lieu of dividends on convertible preferred C shares, shares	3,408,000
Convertible debenture beneficial conversion feature		102,584		102,584		102,584
Warrants issued with convertible debentures		144,976		144,976		144,976
Stock based compensation		51,522		51,522		51,522
Net (loss) income			(422,494)	(422,494)	44,457	(378,037)
Ending balance, value at Mar. 31, 2020	$ 4,237,092	$ 122,151,722	$ (128,486,879)	$ (2,098,065)	$ 2,118,106	$ 20,041
Ending balance, shares at Mar. 31, 2020	423,709,226

Condensed Consolidated Balance Sheets (Unaudited) - USD ($)	Mar. 31, 2020	Dec. 31, 2019
Current assets
Cash and cash equivalents	$ 568,656	$ 575,422
Accounts receivable	1,024,044	875,914
Inventories	3,379,373	3,423,420
Prepaids and other current assets	1,399,325	1,444,593
Total current assets	6,371,398	6,319,349
Long-term assets
Restricted cash	637,820	635,498
Property, plant and equipment, net	1,970,872	2,003,887
Financing lease right-of-use asset	12,625	13,302
Operating lease right-of-use asset	2,630,830	709,883
Goodwill	1,384,255	1,384,255
Patents and other intangibles, net	4,150,584	4,190,621
Total long-term assets	10,786,986	8,937,446
Total assets	17,158,384	15,256,795
Current liabilities
Accounts payable	4,292,161	4,229,128
Accrued liabilities	968,021	1,096,090
Current portion of unearned revenue	1,213,927	1,240,205
Current portion of operating lease right-of-use liability	87,158	100,777
Current portion of financing lease liability	2,407	2,367
Current installments of notes payable	1,738,845	1,519,496
Total current liabilities	8,302,519	8,188,063
Long-term liabilities
Obligation for lease disposal costs	556,670	546,570
Related party notes payable, net of debt discount	891,802	1,216,874
Notes payable, net of current portion	10,057	12,276
Financing lease liability, net of current portion	10,353	10,970
Operating lease right-of-use liability, net of current portion	2,549,772	609,106
Mandatorily redeemable convertible preferred stock, net of discount	4,817,170	4,785,086
Total long-term liabilities	8,835,824	7,180,882
Total liabilities	17,138,343	15,368,945
Commitments and contingencies
Stockholders' (Deficit) Equity
Common stock	4,237,092	4,198,423
Additional paid-in capital	122,151,722	121,680,163
Accumulated deficit	(128,486,879)	(128,064,385)
Deficit attributable to International Isotopes Inc. stockholders	(2,098,065)	(2,185,799)
Equity attributable to noncontrolling interest	2,118,106	2,073,649
Total equity (deficit)	20,041	(112,150)
Total liabilities and stockholders' equity (deficit)	$ 17,158,384	$ 15,256,795

Revenue Recognition - Summary of Sales from Contracts with Customers by Business Segment and Geography (Details) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Disaggregation of Revenue [Line Items]
Total revenues	$ 2,335,786	$ 2,527,852
Percent of total revenues	100.00%	100.00%
U.S.
Disaggregation of Revenue [Line Items]
Total revenues	$ 2,074,636	$ 2,464,137
Outside U.S.
Disaggregation of Revenue [Line Items]
Total revenues	261,150	63,715
Radiochemical Products
Disaggregation of Revenue [Line Items]
Total revenues	$ 755,221	$ 463,232
Percent of total revenues	32.00%	18.00%
Radiochemical Products \| U.S.
Disaggregation of Revenue [Line Items]
Total revenues	$ 668,591	$ 459,967
Radiochemical Products \| Outside U.S.
Disaggregation of Revenue [Line Items]
Total revenues	86,630	3,265
Cobalt Products
Disaggregation of Revenue [Line Items]
Total revenues	$ 305,620	$ 376,089
Percent of total revenues	13.00%	15.00%
Cobalt Products \| U.S.
Disaggregation of Revenue [Line Items]
Total revenues	$ 305,620	$ 336,089
Cobalt Products \| Outside U.S.
Disaggregation of Revenue [Line Items]
Total revenues		40,000
Nuclear Medicine Products
Disaggregation of Revenue [Line Items]
Total revenues	$ 1,042,124	$ 1,100,922
Percent of total revenues	45.00%	44.00%
Nuclear Medicine Products \| U.S.
Disaggregation of Revenue [Line Items]
Total revenues	$ 867,604	$ 1,080,472
Nuclear Medicine Products \| Outside U.S.
Disaggregation of Revenue [Line Items]
Total revenues	174,520	20,450
Radiological Services
Disaggregation of Revenue [Line Items]
Total revenues	$ 72,321	$ 587,609
Percent of total revenues	3.00%	23.00%
Radiological Services \| U.S.
Disaggregation of Revenue [Line Items]
Total revenues	$ 72,321	$ 587,609
Radiological Services \| Outside U.S.
Disaggregation of Revenue [Line Items]
Total revenues	0	0
Fluorine Products
Disaggregation of Revenue [Line Items]
Total revenues	$ 160,500	$ 0
Percent of total revenues	7.00%	0.00%
Fluorine Products \| U.S.
Disaggregation of Revenue [Line Items]
Total revenues	$ 160,500	$ 0
Fluorine Products \| Outside U.S.
Disaggregation of Revenue [Line Items]
Total revenues	$ 0	$ 0

Shareholders' Equity, Options and Warrants - Employee Stock Purchase Plan (Details Narrative) - Employee Stock Purchase Plan - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Employee Stock Ownership Plan (ESOP) Disclosures [Line Items]
Number of shares available for issuance	318,316
Shares issued during period	156,845	31,618
Proceeds from issuance of shares during the period	$ 6,666	$ 1,581

Investment and Business Consolidation (Details Narrative) - RadQual, LLC	Mar. 31, 2020	Aug. 31, 2017
Ownership interest, percentage by parent	24.50%
Affiliates of the Company
Ownership interest, percentage by parent		75.50%

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2020	Dec. 31, 2019
Statement of Financial Position [Abstract]
Common stock, par value in dollars	$ 0.01	$ 0.01
Common stock, shares authorized	750,000,000	750,000,000
Common stock, shares issued	423,709,226	419,842,256
Common stock, shares outstanding	423,709,226	419,842,256

Net Income (Loss) Per Common Share - Basic and Diluted (Details Narrative) - shares	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Series B Convertible Redeemable Preferred Stock
Stock equivalents excluded from the computation of diluted net loss per common share	850	850
Series C Redeemable Convertible Preferred Stock
Stock equivalents excluded from the computation of diluted net loss per common share	4,213	4,213
Stock Options
Stock equivalents excluded from the computation of diluted net loss per common share	23,655,000	27,205,000
Warrants
Stock equivalents excluded from the computation of diluted net loss per common share	50,090,000	20,090,000

Subsequent Events (Details Narrative) - Subsequent Event - "SBA Loan" Paycheck Protection Program	Apr. 23, 2020 USD ($)
Subsequent Event [Line Items]
Proceeds from the SBA's Paycheck Protection Program	$ 495,500
Interest rate	1.00%
Maturity date	Apr. 22, 2022

Leases - Schedule of Lease Expense (Details) - USD ($)	3 Months Ended
Leases - Schedule of Lease Expense (Details) - USD ($)	Mar. 31, 2020	Mar. 31, 2019
Leases [Abstract]
Operating lease costs	$ 68,400	$ 36,853
Short-term operating lease costs	8,876	1,902
Finance lease expense:
Amortization of right-of-use assets	577
Interest on lease liabilities	222
Total financing lease expense	799
Total lease expense	78,075	38,755
Right-of-use assets obtained in exchange for new operating lease liabilities	2,649,070	810,367
Right-of-use assets obtained in exchange for new financing lease liabilities
Weighted-average remaining lease term (years) - operating leases	14 years 10 months	7 years
Weighted-average remaining lease term (years) - financing leases	4 years 9 months
Weighted-average discount rate - operating leases	6.75%	6.75%
Weighted-average discount rate - financing leases	6.75%